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ABSTRACT 
Treatments for Candida albicans systemic infections are limited to three classes 
of antifungals, some of which have harmful side effects or increasing instances of 
antifungal resistance. These shortcomings illustrate a need for new antifungals. 
The phosphatidylserine (PS) synthase, Cho1p, represents a potential drug target 
that can address this need. Cho1p is involved in a major phospholipid 
biosynthesis pathway and represents a novel drug target for three key reasons: 
1) It is required for virulence, indicating that inhibitors of Cho1p would render the 
organism incapable of causing infection; 2) it is absent in mammals, so inhibitors 
potentially have no toxic side effects; and 3) the enzyme appears to be well 
conserved across fungi, indicating that inhibitors could be broadly effective 
against many fungal pathogens. In order to take full advantage of Cho1p as a 
drug target, we performed several screens of small molecules for ones that 
inhibit Cho1p. In one screen we identified SB-224289 that seems to act by 
inducing large scale endocytosis. A second screen identified the compound Lee-
3664 which demonstrates selective toxicity against C. albicans. Further, we 
performed a detailed biochemical characterization of Cho1p where we identified 
substrate binding sites as well as the Km [subscript M] and apparent Vmax 
[subscript max] for each substrate. Computational modeling has produced a 
useful model of what Cho1p might look like and has further increased interest in 
crystallizing the protein in future work. The results of this dissertation will lead to 
more direct approaches for finding Cho1p inhibitors, leading ultimately to more 
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effective antifungals, as well as a greater understanding of enzymes involved in 
phospholipid biosynthesis, which is necessary for virulence in this pathogen. 
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Understanding the roles for lipids in the virulence of microbial pathogens has 
long been an area of interest. Virulence is a broad area of study, encompassing 
both host and microbe factors, however, within the last decade the role of 
microbial physiology in virulence has become more appreciated. Many microbes 
have complex life cycles or reside in a variety of locations and must sense their 
environment in order to survive and reproduce. This adjustment to environmental 
stimuli (e.g. nutrient availability, temperature, pH) plays a large role in the 
metabolism and virulence of microbes (Finlay and Falkow 1989, Finlay and 
Falkow 1997, Mahan, et al. 2000). 
 Lipids are one of the four main macromolecules (along with nucleic acids, 
proteins, and carbohydrates) essential for cells to function. Depending on their 
properties, lipids can have many roles in the cell including control of membrane 
structure and fluidity (Cronan 2003, Dowhan 1997), signaling (Shea and Del 
Poeta 2006), facilitating membrane-associated functions (Bogdanov and Dowhan 
1999, Cronan 2003), virulence (Bhatt, et al. 2007, Jain, et al. 2007, Mirucki, et al. 
2014, Upreti, et al. 1984, Wessel, et al. 2006) and drug resistance (Anderes, et 
al. 1971, Cronan 2003, Rakotomanga, et al. 2005). A great deal of research has 
been conducted to help better understand the role that lipids play in virulence 
across species, and even within strains of the same species (Cox and Best 1972, 
Disalvo and Denton 1963, Nielsen 1965). Some of the first studies into the 
importance of lipids within fungal pathogens compared lipid composition of 
different strains of Blastomyces dermatitidis (Disalvo and Denton 1963). 
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Differences in total lipid content were observed, revealing that the more virulent 
strains had higher levels of total lipids. However, no correlation was seen 
between virulence and increased phospholipids in particular. In contrast, a similar 
study on Histoplasma capsulatum revealed no direct correlation between 
virulence and lipid content (Nielsen 1965). A later study on the impact of lipid 
composition on virulence in Cryptococcus neoformans found that lower virulence 
correlated with decreased levels of total lipids and phospholipids, but no major 
association between virulence and specific lipids was identified (Upreti, et al. 
1984). Over the past few decades, a great deal of research has led to a deeper 
understanding of lipids and their roles in virulence. 
 Within the broad category of lipids are many different subtypes, including 
sphingolipids, phospholipids, and sterols. Nearly all of these have been 
implicated in virulence across a wide range of pathogens (Davis, et al. 2014a, 
Geiger 2010, Goren, et al. 1974, Rella, et al. 2016, Tilney, et al. 2001, Wessel, et 
al. 2006). Furthermore, some microbes have been shown to have the ability to 
take up host fatty acids which alters the microbe’s membrane, allowing them to 
resist antibiotics and other stressors (Giles, et al. 2011, Harp, et al. 2016, Saito, 
et al. 2014, Yao and Rock 2017). While there are many reviews describing the 
general role of lipids in microbial pathogenesis (Geiger 2010, Mishra, et al. 1992, 
Ramakrishnan, et al. 2013, Rella, et al. 2016, Sant, et al. 2016), this review will 
focus on a specific subset of aminophospholipids, phosphatidylserine (PS) and 
phosphatidylethanolamine (PE), and their role in microbial pathogenesis. PS and 
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PE have been subject to fewer studies than some other classes regarding their 
roles in virulence, but a number of more recent reports reveal interesting roles for 
PS and PE in a variety of fungal, protozoan, and prokaryotic pathogens, 
indicating that these phospholipids and their biosynthetic enzymes should be 
considered more carefully.  This introduction will briefly review PS and PE 
synthesis, and then cover the role of PS and PE in particular cellular pathogens 
as regulators of virulence and the role of host PS/PE as facilitators of virulence. 
 
Phosphatidylserine and phosphatidylethanolamine synthesis in microbes 
Phosphatidylserine 
PS is a negatively charged phospholipid with a glycerol backbone and two fatty 
acid tails (Fig. I.1A). In bacteria and fungi, PS is produced from two substrates: 
cytidine diphosphate diacylglycerol (CDP-DAG) and serine (Fig. I.2). Although 
the enzymes responsible for this reaction can differ greatly in sequence between 
fungi and many prokaryotic microbes (excepting some bacteria like B. subtillis or 
Sinorhizobium meliloti whose PS synthase is similar to S. cerevisiae) the 
mechanism by which they produce PS is similar (Carman and Han 2011, Carman 
and Zeimetz 1996, Cronan 2003, Henry, et al. 2012, Raetz and Dowhan 1990, 
Sohlenkamp, et al. 2004, Vance 2015, Vance and Steenbergen 2005a). In 
mammals and many parasites like Trypanosoma brucei, PS is produced through 
a base-exchange reaction. In mammals, head groups of existing 
phosphatidylcholine (PC) and PE are cleaved off by two different enzymes, PSS2  
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Figure I. 1 The Structure of Two Amino Phospholipids 
(A) phosphatidylserine and (B) phosphatidylethanolamine 
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and PSS1 respectively, and replaced with serine to produce PS (Kuge and 
Nishijima 1997, Signorell, et al. 2008, Tasseva, et al. 2013, Vance 2015) (Fig. 
I.3). 
 
Phosphatidylethanolamine 
Phosphatidylethanolamine (PE) is considered a major phospholipid in many 
eukaryotic organisms and some prokaryotes. It is an uncharged, non-bilayer 
forming phospholipid due to its small head group, which causes a cone-like 
shape for its structure (Fig. I.1B). In eukaryotes and most prokaryotes that 
contain it, PE is produced by the decarboxylation of PS (Carman and Han 2011, 
Cassilly, et al. 2017, Cronan 2003, Dowhan 1997, Kanfer and Kennedy 1964).  
However, in many eukaryotes PE can alternatively be made from ethanolamine 
via a scavenging pathway known as the Kennedy Pathway (Fig. I.2 and I.3) 
(Kennedy and Weiss 1956). In the Kennedy pathway, ethanolamine is taken up 
by the cells and phosphorylated to produce phosphoethanolamine, which is then 
condensed with CTP to produce CDP-ethanolamine. The third and final step is 
condensation of CDP-ethanolamine with diacylglycerol (DAG) to generate PE 
and CMP (Gibellini and Smith 2010). 
 Although the CDP-DAG and Kennedy pathways are the most common 
methods employed to generate PE in mammals and fungi, there are alternative 
mechanisms that produce PE or its precursors in other microbes. In the bacterial 
plant pathogen Xanthomonas campestris, a bifunctional cardiolipin/PE synthase 
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Figure I. 2 Phospholipid Biosynthesis Pathways in C. albicans 
C. albicans acquires phospholipids via both an endogenous pathway, the de 
novo pathway, and an exogenous pathway, the Kennedy pathway.  The 
precursors for producing the most common phospholipids are PA and CDP-DAG.  
CDP-DAG is then converted to PI, PS, or PG.  The endogenously produced PS 
can be decarboxylated into PE and then further methylated into PC.  In the 
Kennedy pathway, exogenous ethanolamine (Etn) and/or choline (Cho) are 
brought into the cell and converted into PE and PC. Abbreviations: PA – 
phosphatidic acid; CDP-DAG – cytidine diphosphate diacylglycerol; PI – 
phosphatidylinositol; PS – phosphatidylserine; PG – phosphatidylglycerol; PE – 
phosphatidylethanolamine; CL – cardiolipin; PC – phosphatidylcholine; Etn – 
ethanolamine; Cho – choline, Etn-P-phosphoethanolamine, Cho-P-
phosphocholine, CDP-Etn-cytidyldiphosphate-ethanolamine, CDP-Cho-
cytidyldiphosphate-choline, Ser-serine  
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Figure I. 3 Phospholipid Biosynthesis Pathways in 
Mammals and Parasites  
Mammals acquire phospholipids via both an endogenous 
pathway, the de novo pathway, and a scavenging pathway, 
the Kennedy pathway. Headgroups of existing PE and PC 
can be cleaved and replaced with serine to produce PS. PS 
can be decarboxylated to produce PE. PE can then be 
methylated three times to produce PC. In the Kennedy 
pathway, exogenous ethanolamine (Etn) and/or choline 
(Cho) are brought into the cell and converted into PE and 
PC. Abbreviations: PS – phosphatidylserine; PE – 
phosphatidylethanolamine; PC – phosphatidylcholine; Etn – 
ethanolamine; Cho – choline (Figure adapted from Chen et 
al., 2010)  
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 was identified. X. campestris produces PE by the decarboxylation of PS; 
however, upon the deletion of PS decarboxylase, growth of the organism was 
partially restored when exogenous ethanolamine was supplemented. 
Researchers identified a putative cardiolipin synthase gene that, in addition to 
making CL from CDP-DAG and phosphatidylglycerol-phosphate, could produce 
PE from CDP-DAG and ethanolamine. This process, which may be important in 
certain conditions, seems to be restricted to Xanthomonadales and 
Pseudomonadales orders based on phylogenetic analysis (Moser, et al. 2014). 
 In the kinetoplast parasites such as Trypanomes and Leishmania, the 
Kennedy pathway appears to be the key method of synthesizing PE.  In 
Trypanosoma brucei, PE is maintained within the cell in two distinct pools 
(Signorell, et al. 2008).  For Leishmania most of the ethanolamine used to 
produce PE is not taken up from the environment, but rather produced within the 
organism by cleaving sphingosine-1-phosphate to form long chain fatty 
aldehydes and phosphoethanolamine. The phosphoethanolamine can be 
funneled directly into the second step of the Kennedy pathway where 
phosphoethanolamine is converted to CDP-ethanolamine which leads in another 
step to PE (Fig. I.3) (Pulido, et al. 2017, Zhang, et al. 2007).  This cleavage is 
carried out by the enzyme sphinosine-1-phosphate lyase, which is also found in 
other microbes such as S. cerevisiae (Dpl1).  In yeast, Dpl1 can support growth 
of yeast in the absence of PS decarboxylase (psd1∆ psd2∆) and exogenous 
ethanolamine, indicating that it can support PE synthesis by the Kennedy 
10 
 
pathway in yeast as well. However, under normal conditions, Dpl1 is not a major 
source for PE synthesis in this organism (Birner, et al. 2001, Mao, et al. 1997, 
Saba, et al. 1997). Yeast also have the ability to take up and acylate lyso-PE to 
produce PE or remodel existing PE species (Burgermeister, et al. 2004, Deng, et 
al. 2010, Flis and Daum 2013, Riekhof and Voelker 2006, Riekhof, et al. 2007a, 
Riekhof, et al. 2007b). 
 The apicomplexan parasites also have unusual characteristics regarding 
PS and PE.   The malaria parasite Plasmodium falciparum can acquire 
ethanolamine for the Kennedy pathway by directly decarboxylating serine into 
ethanolamine, by means of the serine decarboxylase (SDC) enzyme, an 
enzymatic activity shared with plants but not animals or fungi (Fig 3) (Elabbadi, et 
al. 1997). 
Toxoplasma gondii is an intracellular apicomplexan parasite that 
reproduces within a parasitophorous vacuole. In T. gondii, PE is produced via the 
Kennedy pathway and via the decarboxylation of PS in the mitochondria 
(Hartmann, et al. 2014) as is seen in fungi or mammals.  However, T. gondii also 
has unusual versions of the canonical base-exchanging PS synthase and PS 
decarboxylase enzymes.  First, in addition to an internal, membrane-bound PS 
decarboxylase, it has a second, soluble PS decarboxylase enzyme (TgPSD1) 
that is secreted extracellularly from T. gondii cells and appears to decarboxylate 
PS to PE in the parasitophorous vacuole (Hartmann, et al. 2014). This is highly 
unusual because both PS decarboxylase and PS synthase are typically 
11 
 
membrane bound enzymes with multiple transmembrane domains.  There have 
been other reports of hyperexpressed PS decarboxylase enzymes dissociating 
from the cytoplasmic membrane in bacteria (Tyhach, et al. 1979) and in 
Plasmodium falciparum (Baunaure, et al. 2004, Choi, et al. 2016), but TgPSD1 is 
the first example of a secreted PS decarboxylase with the enzymatic ability to 
convert PS to PE. TgPSD1 has also been detected within the parasitophorous 
vacuole. Although its function within this compartment is not entirely clear, it 
could potentially help damage the host cell membrane to allow T. gondii to 
escape the parasitophorous vacuole when it lyses the cell. Furthermore, the 
secreted enzyme may bind liposomes and host membranes to allow for 
membrane biogenesis and parasite replication. Thirdly, the secreted enzyme 
may suppress PS exposure on the apoptotic host cell, thereby avoiding 
phagocytosis, and allowing the parasite to replicate and avoid the immune 
system. While these possibilities are likely, the exact reasons for its unique 
function still remain to be elucidated (Gupta, et al. 2012).  T. gondii also appears 
to have the ability to take up host PE (possibly via a permease) when production 
of PE is inhibited intracellularly, further increasing the survival and fitness of this 
organism (Hartmann, et al. 2014).  
In addition to an unusual PS decarboxylase that could affect host PE, T. 
gondii also been shown to make an unusual phospholipid that is closely related 
to PS called phosphatidylthreonine (PT).  PT is found in small amounts in 
mammals and some bacteria (Heikinheimo and Somerharju 2002, Ivanova, et al. 
12 
 
2010, Mitoma, et al. 1998, Muller, et al. 2011), but in T. gondii PT is found in 
more substantial amounts than PS.  PT is synthesized in T. gondii by an enzyme 
with close homology to the mammalian PSS base-exchange enzymes (Fig 3), 
but it exchanges threonine or serine instead of serine alone (Arroyo-Olarte, et al. 
2015, Arroyo-Olarte and Gupta 2016). The PT synthase is predicted to be found 
in a few other protozoa including Neospora, Eimeria, Phytophtora, and Perkinsus 
(Arroyo-Olarte, et al. 2015, Arroyo-Olarte and Gupta 2016). 
 
PS and PE as Modulators of Virulence 
Candida albicans 
Candida albicans is a commensal fungus that normally inhabits the gut and skin 
of healthy people. However, immunocompromised individuals are at a high risk of 
developing bloodstream infections where C. albicans can infect the deep organs 
leading to sepsis. C. albicans is known to produce several virulence factors 
including hyphae, adhesins, lipases, proteases, and the more recently described 
Candidalysin (Moyes, et al. 2016).  It is also able to hide itself to a limited extent 
from the innate immune system by a process called masking. Yeast cell walls 
contain four main components: chitin, mannosylated proteins (mannan), β(1-6)-
glucan and β(1-3)-glucan. Mannan makes up the majority of the surface layer of 
the cell wall, while β-glucans, and chitin are “hidden” beneath.  β-(1,3)-glucan is a 
pathogen associate molecular pattern (PAMP) that can be detected by the innate 
immune receptor Dectin-1 as a signal that the host is infected by a fungal 
pathogen (Brown and Gordon 2001) .  Dectin-1 is found on macrophages, 
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dendritic cells, neutrophils, and some other immune cells. The proposed layered 
topology, where mannan masks the immunogenic molecule β(1-3)-glucan is a 
method of innate immune system evasion by this yeast (Davis, et al. 2014a). 
Disruption of this layering (i.e. unmasking) makes it easier for the host to detect 
the fungus (Hasim, et al. 2017, Wheeler and Fink 2006, Wheeler, et al. 2008). 
 It has been shown that the fungal phosphatidylserine (PS) synthase, 
Cho1p, is absolutely required for virulence of C. albicans. In a mouse model of 
systemic infection, the cho1∆∆ deletion mutant was unable to cause infection, 
while mice infected with wild-type or cho1∆/∆::CHO1 reintegrant strains died 
within two weeks (Chen, et al. 2010). In addition, cho1∆∆ shows significant 
reduction in kidney colonization and is completely cleared from the mice, even 
when they are made neutropenic with cyclophosphamide (Y. L. Chen and T. B. 
Reynolds, unpublished data). In contrast, mice infected with wild-type C. albicans 
showed high kidney burden before succumbing to infection (Chen, et al. 2010). 
 In addition to a complete loss of PS, the cho1∆∆ mutation also causes a 
loss of PE synthesized from PS (Fig 2) (Cassilly, et al. 2017).  This suggested 
that the avirulence could be caused by loss of PE as well as PS.  A 
psd1∆∆ psd2∆∆ double mutation, which eliminates all PS decarboxylase activity, 
also causes severe avirulence; however, there is a significantly greater loss of C. 
albicans colonization from the kidneys in cho1∆∆ than in psd1∆∆ psd2∆∆ (Davis, 
et al., data unpublished).  The major difference between cho1∆∆ and psd1∆∆ 
psd2∆∆ is that only cho1∆∆ has increased β(1-3)-glucan unmasking in its cell 
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wall, increasing host immune recognition of this microbe (Davis, et al. 2014a).  
Thus, other underlying factors related to loss of PE play a role in the loss of 
virulence, but cell wall unmasking driven by the loss of PS correlates with even 
faster clearance.  The mechanism responsible for cell wall unmasking in the 
cho1∆∆ mutant are currently under investigation. 
 These defects in virulence in the cho1∆∆ and psd1∆∆ psd2∆∆ mutants are 
manifest despite the presence of an alternative Kennedy pathway for PE 
synthesis (Fig. 2).  This brings up questions as to whether Kennedy pathway 
synthesized PE is able to compensate for PS-derived PE or if cells are unable to 
make sufficient PE by the Kennedy pathway. Furthermore, this also opens the 
question of how much of a role the loss of PS alone plays in virulence, in addition 
to its effects on cell wall unmasking.   
 Due to these virulence defects, Cho1p represents a good drug target in C. 
albicans (Cassilly, et al. 2016, Chen, et al. 2010). First, as loss of Cho1p renders 
C. albicans avirulent, inhibition of Cho1p should render C. albicans 
nonpathogenic to the host. Secondly, since the mammalian PS synthase 
enzymes are not orthologous with the fungal PS synthase, an inhibitor of Cho1p 
should be very specific for fungi without affecting mammalian Pss1p and Pss2p 
(Compare Figs I.2 and I.3). Identification of small molecule inhibitors of Cho1p as 
potential therapeutics is a priority (Cassilly, et al. 2016).  Finally, Cho1p is 
conserved throughout pathogenic fungi, so an inhibitor could be broad spectrum 
(Braun, et al. 2005). 
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Brucella abortus 
Brucella abortus is the causative agent of brucellosis which can be a severe and 
chronic infection within humans. This organism is a facultative, intracellular 
pathogen that typically resides within a specific compartment in the host cell 
called the Brucella-containing vacuole (BCV). From this location, B. abortus can 
control the host cell machinery and replicate. Several factors contribute to B. 
abortus virulence including immune modulators, smooth lipopolysaccharide 
(LPS), and cyclic β-glucans. However, recent studies have shown that the 
membrane phospholipid composition is crucial for interaction of the microbe with 
the host cells (Bukata, et al. 2008, Comerci, et al. 2006). For example, 
phosphatidylcholine (PC)—one of the main phospholipids produced in this 
microbe—is necessary for the organism to set up a chronic infection in a murine 
model (Comerci, et al. 2006, Conde-Alvarez, et al. 2006). Further studies showed 
that PS and PE play significant roles in virulence.  A mutant of the 
phosphatidylserine synthase (pssA), was produced.  PS is not considered a 
major phospholipid within B. abortus, but this enzyme is crucial for production of 
PE (Fig 2) (Bukata, et al. 2008, Thiele and Kehr 1969). The pssA mutant had a 
loss of PE and showed increased sensitivity to membrane-perturbing agents like 
SDS. The pssA mutant also showed decreased survival intracellularly in tissue 
culture cells and showed a marked decrease in maturation of the BCV that 
protects the bacteria intracellularly. Finally, a marked decrease in virulence was 
found in the pssA mutant as compared to the wild-type within a mouse model of 
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infection (Bukata, et al. 2008). Although the exact impact on virulence is not 
known, it is thought that PE contributes to BCV formation and thus is necessary 
for virulence. Further, by disrupting the structure of the membrane, it is possible 
that important protein complexes or virulence determinants are also disrupted 
which negatively affects the organism’s ability to survive within host cells.   
 The pssA gene is important for growth in Escherichia coli, but it has only 
been examined for its role in growth in non-pathogenic laboratory strains.  As in 
B. abortus deletion of pssA causes not only a decrease in PS and PE, but it also 
causes a growth defect unless the media is supplemented with divalent cations 
like Ca2+ or Mn2+ (Nakajima, et al. 1991). Further investigations into the role for 
PS/PE synthesis in the pathogenesis of Gram negative organisms is warranted 
as it may be important for virulence in a variety of these often-drug-resistant 
pathogens.   
 
Plasmodium 
Plasmodium parasites are the causative agents of malaria, which is one of the 
most important health problems in the developing world. Finding new treatments 
with novel modes of actions to better combat this pathogen is a major area of 
current research because of the rising resistance to existing anti-malarial 
therapies. Enzymes involved in the production of important malarial lipids, like 
the PS decarboxylase (PSD) enzyme, have been suggested as a drug target 
since PE is an essential phospholipid within Plasmodium membranes. Indeed, 
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inhibition of PSD results in growth arrest of the parasite (Ben Mamoun, et al. 
2010, Choi, et al. 2016, Serran-Aguilera, et al. 2016). Recent findings have 
shown that the PSD enzyme from Plasmodium falciparum, though both soluble 
and membrane-bound in this organism, can complement yeast psd mutants 
(Choi, et al. 2016). Furthermore, screening a library of known malaria inhibitors 
identified a particular compound, 7-chloro-N-(4-ethoxyphenyl)-4-quinolinamine 
(MMV007285), with potent activity against Plasmodium, and the ability to inhibit 
the catalytic function of PSD (Choi, et al. 2016). 
 In addition to PSD, the choline kinase (CK) is crucial for PE synthesis in 
Plasmodium, and has been suggested as another drug target (Serran-Aguilera, 
et al. 2016). This enzyme is involved in the Kennedy Pathway where choline and 
ethanolamine are taken up from the environment and used to produce PC and 
PE, respectively (Fig 3). Recent work has found that known anti-cancer 
compounds BR23 and BR25 that inhibit human choline kinase cause a dramatic 
drop in the levels of PE within P. falciparum but not PC, as these compounds 
influence PE synthesis more than PC synthesis in this parasite (Serran-Aguilera, 
et al. 2016).  The CK of P. falciparum is involved in both choline and 
ethanolamine phosphorylation, but the drugs seem to primarily impact 
ethanolamine phosphorylation, rather than choline phosphorylation, explaining 
the differential effects on PE and PC synthesis. Treatment with either drug led to 
arrested development of the parasite, likely as a result of the loss of membrane 
PE, and ultimately were lethal (Serran-Aguilera, et al. 2016). These findings 
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demonstrate the importance of PE biosynthesis in survival and pathogenicity of 
microbes, and are some of the first studies where small molecule inhibition of an 
ethanolamine kinase in a pathogen has led to promising lead inhibitory 
compounds.   
 Finally, although P. falciparum has two different pathways to make PE, 
(both CDP-DAG and Kennedy, Fig 2-3), loss of either pathway appears to be 
sufficient to compromise its growth.  This is surprising, and indicates several 
possible explanations: 1) the molecular species of PE made from the two 
pathway differ and each is crucial for virulence, 2) localization of PE synthesis for 
each pathway differs (PSD is in the mitochondria while the Kennedy pathway 
synthesizes PE in the ER) and PE made in one location is not sufficient to make 
up for the other, 3) the volume of PE made by either pathway alone is not 
sufficient to support virulence (Choi, et al. 2016, Serran-Aguilera, et al. 2016). 
 
Trypanosomes 
Trypanosoma brucei is a neglected tropical pathogen that affects both humans 
and livestock within specific regions of Africa. Current therapies are inadequate 
due to rising drug resistance and high toxicity, creating a need for new drugs. 
Like in Plasmodium, phospholipid biosynthetic pathways have been suggested 
as excellent targets for therapy in T. brucei. PE represents a good target for 
several reasons including its importance in providing the phophoethanolamine 
moiety that links GPI anchors to membrane proteins, including variant surface 
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glycoprotein (VSG) (Menon, et al. 1993, Menon and Stevens 1992). VSG is a 
crucial aspect of T. brucei virulence as it is key in allowing the organism to evade 
the immune system and set up chronic infections within the host. Thus, disruption 
of proper VSG production and localization represents an excellent drug target in 
this organism. Indeed, a conditional knockout of the ethanolamine-phosphate 
cytidyltransferase (EPT) in T. brucei revealed that this gene is essential for 
growth and crucial in the synthesis of both PE and GPI-anchors (Gibellini, et al. 
2009). In addition, ethanolamine analogues are being explored as inhibitors of 
the ethanolamine kinase enzyme (Gibellini, et al. 2008). 
 
Toxoplasma gondii  
Phosphatidylthreonine (PT) has been shown to be naturally abundant in T. gondii 
and play a role in virulences. In a Δtgpts PT synthase mutant, replication of the 
parasite was normal, but a marked decrease in plaques and plaque size was 
seen upon infection, when compared with a wild-type control. Further, the Δtgpts 
mutant showed a decrease in motility, which is a major contributor to virulence 
within this organism. As expected, the Δtgpts mutant demonstrated decreased 
virulence in a mouse model of infection. These findings implicate PT in the lysis 
of host cells, as well as possible egression into new host cells for propagation of 
infection, indicating that the parasite has evolved PT specifically for use in its lytic 
cycle of infection. Although the exact mechanism of PT in disease is still 
unknown, it is likely that PT may affect calcium flux at the plasma membrane and 
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calcium homeostasis, which could in turn control motility (Arroyo-Olarte, et al. 
2015, Arroyo-Olarte and Gupta 2016). 
 
Host PS and PE are utilized by pathogens for virulence 
Host membranes serve as a barrier to microbes, either by preventing entry into 
tissues or limiting access to necessary nutrients. It is a common trait for microbes 
to manipulate and alter host membranes in order to establish infection and 
persist within the host (Ham, et al. 2011, Sarantis and Grinstein 2012). PS is an 
important phospholipid in a variety of processes. In mammalian systems, 
redistribution of PS is a key indicator that a cell is undergoing apoptosis. Cells 
typically maintain an asymmetrical distribution of PS in the plasma membrane, 
where most PS faces the cytoplasm (localized to the inner leaflet of the 
membrane). Upon receipt of “death signals” for apoptosis from the cell, PS is 
flipped to the outer leaflet as a signal to macrophages that a cell is dying.  
Macrophages use PS as the “eat me” signal to then engulf the apoptotic cells. 
Exposed PS (or even PE) on the host cell, either naturally or as a result of 
promoted PS externalization via activity of the microbe (Fujimoto, et al. 1998, 
Gao and Abu Kwaik 1999, Goth and Stephens 2001, Murata-Kamiya, et al. 2010, 
Semiramoth, et al. 2010, Wandler, et al. 2010), can be recognized and exploited 
by microbes. Some microbes, like Chlamydia trachomatis or the influenza virus 
enter cells and promote PS-externalization and apoptosis, likely to ensure exit 
from the infected cell and further dissemination (Fujimoto, et al. 1998, Goth and 
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Stephens 2001). In Helicobacter pylori, the virulence determinant CagA was 
shown to bind tightly to PS exposed on host cells via a specific motif. Once 
bound, CagA is thought to promote its own uptake into the host cell where it 
remains tethered to the membrane via PS and modulates several signaling 
pathways (Backert, et al. 2011, Murata-Kamiya, et al. 2010, Wandler, et al. 
2010). 
 In addition, enterohemorrhagic Escherichia coli (EHEC) has been shown 
to induce apoptosis and expose both PS and PE on host cell surfaces. EHEC 
can then bind to the exposed PE, establishing a tight connection with the host, 
followed by subsequent internalization of the microbe, nutrient acquisition, or 
delivery of toxins deep into host tissues (Barnett Foster, et al. 2000, Barnett 
Foster, et al. 1999). Exposed host PS can also be used as a tool for microbial 
dissemination. 
 Listeria monocytogenes exploits efferocytosis, or the removal of dead cells 
and debris via phagocytosis, to facilitate spread from cell to cell. These bacteria 
are phagocytosed, but can escape from the phagosome through the activity of 
their pore-forming toxin listeriolysin O (LLO). LLO then can promote the release 
of bacteria-containing vesicles with exposed PS on the surface which are then 
phagocytosed by macrophages, continuing the cycle of dissemination 
(Czuczman, et al. 2014). 
 Similarly, Mycobacterium tuberculosis also has the ability to escape the 
phagosome and can produce the secreted protein EspB which, when processed, 
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has been shown to bind phosphatidic acid (PA) and PS. Although the exact 
function of this binding is still unknown, it is hypothesized that EspB may interfere 
with PA- and PS-mediated signaling in the host (Chen, et al. 2013, Korotkova, et 
al. 2015). Based on these examples, it is clear that interaction with host 
phospholipids is crucial in many aspects of infection. However, in addition to this 
face of virulence, microbial phospholipids have also been shown to be important 
in virulence. 
 
PS-Exposure and Apoptotic Mimicry 
Many obligate- or facultative-intracellular pathogens employ various methods of 
invading host cells. In addition to other various surface determinants, like sugars 
(van Zandbergen, et al. 2007), the lipid composition in the microbe’s plasma 
membrane can play a role in promoting their uptake by host cells (e.g. 
phagocytosis by host macrophages).  Phospholipids like PS can play a major 
role in this process. 
 
Leishmania 
L. braziliensis is known to have multiple virulence factors associated with its 
disease and includes cell surface molecules like lipophosphoglycan (LPG) and 
carbohydrates. In addition, PS also serves as a ligand for mononuclear 
macrophages. L. tropica promastigote forms expose higher levels of PS on their 
surface during the infective growth phases (Tripathi and Gupta 2003). 
Furthermore, amastigotes of L. amazonensis with higher levels of PS on the cell 
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surface had increased infectivity in vivo and in vitro (Wanderley, et al. 2006). 
These findings indicate that a higher concentration of PS on the surface of these 
organisms increases the chances of being internalized by the host macrophages 
(Wanderley, et al. 2006). 
 The PS exposed on the membrane of the parasite is thought to play a role 
in apoptotic mimicry, allowing L. brasiliensis to establish an infection within the 
host (de Freitas Balanco, et al. 2001, van Zandbergen, et al. 2007). When PS 
exposed on the surface of L. brasiliensis, L. tropica or L. amazonensis is blocked 
with annexin V, the infectivity of the parasite in murine peritoneal macrophages is 
decreased (de Freitas Balanco, et al. 2001, Farias, et al. 2013, Tripathi and 
Gupta 2003, Wanderley, et al. 2006, Wanderley, et al. 2009).  
 Interestingly, PS exposure seems to have importance even beyond the 
initial entry into host macrophages.  L. amazonensis and L. major, 
subpopulations of PS-positive and PS-negative promastigotes cooperate to 
produce a sustained and successful infection of host macrophages (van 
Zandbergen, et al. 2006, Wanderley, et al. 2009). L. amazonensis amastigotes 
with high levels of PS exposed on their cell surfaces are able to induce cytokine 
production as well as inhibit NO production (Wanderley, et al. 2006). These 
findings implicate PS production and exposure as an excellent drug target within 
Leishmania. 
 Similar instances of apoptotic mimicry have also been reported for 
Trypanosoma cruzi (Damatta, et al. 2007, Freire-de-Lima, et al. 2000), 
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Toxoplasma gondii (Seabra, et al. 2004), and even enveloped viruses (Jemielity, 
et al. 2013, Moller-Tank, et al. 2013, Soares, et al. 2008, Vanlandschoot and 
Leroux-Roels 2003), demonstrating the prevalence of PS exposure in regulating 
infection. Targeting proteins responsible for this PS exposure (Araujo-Santos, et 
al. 2003, dos Santos, et al. 2013) or enzymes involved in PS synthesis, could be 
a viable option for future therapies across a wide variety of pathogens. 
 
Cryptococcus neoformans 
Cryptococcus neoformans is a facultative intracellular fungal pathogen. Recent 
studies have demonstrated that beyond secreted virulence factors, there are also 
other important proteins within the organism that play a role in virulence. One 
such example is Cdc50, which is a lipid flippase responsible for maintaining 
asymmetry in the phospholipid bilayer (Huang, et al. 2016). Upon deletion of 
Cdc50, C. neoformans becomes more sensitive to fluconazole, caspofungin, and 
SDS likely due to a change in membrane integrity. In mice, the cdc50∆ mutant 
was unable to cause a robust infection and was cleared from the lungs, further 
implicating this protein as a virulence factor. Though the exact mechanism 
behind this loss of virulence is currently still under scrutiny, the cdc50∆ mutant 
had increased levels of PS exposed to the outer membrane, further supporting 
the importance of proper PS localization and membrane integrity for the virulence 
of this fungus. These results indicate that loss of Cdc50, and likely a change in 
PS localization, can massively disrupt virulence, and fitness of the organism, thus 
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representing a drug target within Cryptococcus. In addition, since the cdc50∆ 
mutant showed greater susceptibility to caspofungin, a common antifungal drug 
that Cryptococcus is naturally resistant to, further exploration of phospholipid 
flippases or membrane symmetry could improve the effectiveness of 
echinocandins against the fungus. 
 
PS and PE in Extracellular Vesicles 
A potential contributor to virulence in microbes is the use of extracellular vesicles 
as delivery systems for virulence factors. This characteristic can be found in C. 
albicans, Candida parapsilosis, Sporothrix schenckii, Saccharomyces cerevisiae 
(Albuquerque, et al. 2008), Cryptococcus neoformans (Oliveira, et al. 2010, 
Rodrigues, et al. 2008), and Paracoccidioides brasiliensis (Manocha, et al. 1980), 
and even Gram negative bacteria like E. coli (Hoekstra, et al. 1976, Horstman 
and Kuehn 2000), Pseudomonas aeurginosa (Tashiro, et al. 2011), Legionella 
pneumophila (Fernandez-Moreira, et al. 2006, Wessel, et al. 2006) and 
Haemophilus influenzae (Kulkarni and Jagannadham 2014, Kulp and Kuehn 
2010, Roier, et al. 2015, Sharpe, et al. 2011). 
 A recent study found that the cho1∆∆ mutant of C. albicans displayed 
decreased ability to secrete proteases and phospholipases via extracellular 
vesicles (Wolf, et al. 2015), indicating the importance of proper phospholipid 
balance in this process. 
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 Lipid profiles from 4 different strains of P. brasiliensis (Manocha, et al. 
1980) revealed that the concentration of PC was higher in virulent strains than in 
the avirulent strain. Further studies into the lipid composition of fungal 
extracellular vesicles, known to harbor various virulence factors, showed some 
differences in the lipid composition, which is theorized to play a role in the 
virulence of different strains of P. brasiliensis (Vallejo, et al. 2012). 
 Histoplasma capsulatum is a pathogenic fungus that can cause life-
threatening systemic disease. This organism has many different characteristics 
that allow it to grow well within the host environment, including survival in a wide 
pH range and nutrient starvation. H. capsulatum also produces various virulence 
factors like heat-shock proteins and the cell wall protein YPS3p. Analysis of the 
composition of extracellular vesicles reveals that the vesicles were made up of 
common plasma membrane phospholipids including PE, PS, and PC 
(Albuquerque, et al. 2008). This composition is similar to what is found in 
mammalian exosomes which are known to transport important molecules like 
bioactive lipids and lipid-degrading enzymes. The biogenesis of exosomes in 
mammals is a specific process that requires certain lipids with a characteristic 
membrane organization (Laulagnier, et al. 2004, Subra, et al. 2007). Although the 
importance of this phospholipid composition has not been studied in H. 
capsulatum, it is likely that the specific phospholipids making up the extracellular 
vesicles are important in virulence and proper function. 
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Significance 
Because of this clear significance of aminophospholipids within microbial 
virulence, we were interested in focusing on PS synthesis in Candida albicans as 
a possible drug target. C. albicans is an opportunistic fungal pathogen that, along 
with several other species in the Candida genus, represents the most common 
fungal pathogen of humans and has even been shown to cause problems to 
astronauts on the international space station (Crabbe, et al. 2013). In most 
people, this organism occupies the skin, gut, and vagina as a commensal (Hube 
2004); however, it can be a severe threat to immunocompromised individuals 
(rendered so by HIV-AIDS, chemotherapy, etc.). In these patients, C. albicans 
causes oral thrush, infects skin wounds, and causes life-threatening invasive 
bloodstream infections and fungal endocarditis (FE) (Mishra, et al. 2007, Pierrotti 
and Baddour 2002). Invasive bloodstream infections and FE—which can arise 
from implanted medical devices like long-dwelling intravascular catheters or 
prosthetic heart valves (Mishra, et al. 2007, Sun, et al. 2013)—have high 
mortality rates, around 30% and 50%, respectively (Baddley, et al. 2008, 
Maccallum, et al. 2013, Pierrotti and Baddour 2002). There are three main 
classes of antifungals used to treat C. albicans invasive bloodstream infections: 
azoles (i.e. fluconazole, itraconazole) which inhibit ergosterol synthesis; polyenes 
(i.e. amphotericin B) which target existing ergosterol in the plasma membrane 
(Anderson, et al. 2014, Ghannoum and Rice 1999); and echinocandins (i.e. 
caspofungin) which target the fungal cell wall (Alem and Douglas 2004, 
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Bachmann, et al. 2002, Baddley, et al. 2008, Lyons and White 2000). However, 
because of rising drug resistance (azoles, echinocandins), high toxicity 
(amphotericin B), and poor oral availability (polyenes, echinocandins) of these 
drugs, they are not always effective at safely eliminating the infection (Anderson 
2005, Ghannoum and Rice 1999). Lack of effective treatment contributes to high 
mortality in individuals with FE or invasive bloodstream infections (Sun, et al. 
2013), which creates the need for novel drug targets in the organism as well as 
new antifungal compounds (Maccallum, et al. 2013). 
 Despite this pressing need, little progress has been made in recent 
decades to identify new antifungal compounds. The process of drug development 
is notoriously slow, but rendered slower in fungi. One main reason for this delay 
is the amount of similarity between fungi and humans. Saccharomyces 
cerevisiae has long been used as a model organism for understanding eukaryotic 
organisms and mammalian processes. Because of this, finding drugs that are 
selectively toxic to fungi, while having no side effects on mammalian host cells, is 
a monumental hurdle. Even the currently used Amphotericin B suffers from toxic 
side effects due to the similarities between fungal ergosterol and mammalian 
cholesterol. Thus, it is of utmost importance to identify new or better targets for 
antifungal therapies. 
 Several recent reviews have highlighted the potential of the fungal cell 
membrane as an excellent drug target (Rella, et al. 2016, Sant, et al. 2016). 
While those reviews aim to provide a general overview of fungal membranes and 
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lipids as antifungal targets, the aim of this work was to fully understand PS 
synthesis as a drug target within C. albicans. 
 
Screening Approaches for Identifying PS Synthase Inhibitors 
Because of the promise of using Cho1p as a drug target, we developed several 
approaches for identifying small molecule inhibitors. These approaches largely 
hinge on using phenotypic traits of cho1∆∆ as indicators that Cho1p is being 
inhibited. Our first method, described in Chapter 2 was based on the anti-fungal 
activity of a marine depsipeptide Papuamide A (Pap-A). This compound has 
been shown to bind specifically to PS in membranes of liposomes (Andjelic, et al. 
2008). Although the exact mechanism of action has not been demonstrated, it is 
thought that Pap-A binds PS by inserting a lipophilic tail into cell membranes, 
causing a disruption in membrane integrity and subsequent lysis. Indeed, the 
cho1∆∆ mutant is completely resistant to Pap-A (Cassilly, et al. 2016, Chen, et al. 
2010). As a result, we used Pap-A as an indicator of functional PS synthesis, 
hypothesizing that if a small molecule inhibited Cho1p, it would cause the 
organism to become resistant to Pap-A. The screening approach and results 
from this study can be found in Chapters 2 and 3 and Appendix 3. 
 A second phenotypic trait that we wished to exploit for our screening was 
ethanolamine auxotrophy. Because phosphatidylethanolamine is an essential 
phospholipid, the cho1∆∆ cannot survive without ethanolamine provided in the 
growth medium. This exogenous ethanolamine can be taken up by the cells and 
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used in the Kennedy pathway to circumvent the organism’s requirement for PS 
(as a precursor for PE). Thus, cho1∆∆ has a very distinct characteristic of growth 
inhibition in minimal medium deplete of ethanolamine, but showing a return of 
growth when ethanolamine is supplemented back into the medium. We 
hypothesized that small molecules that inhibit Cho1p would cause ethanolamine 
auxotrophy in wild-type C. albicans that we could detect based on a lack of 
growth in minimal medium. The screening approach and results from this study 
can be found in Appendix 1. 
 
Characterization of PS Synthase and PS Trafficking 
Although our screening approaches have been beneficial in certain ways, they 
have not yet yielded PS synthase inhibitors as we expected. Thus, in addition to 
our screening, we were also interested in characterizing the PS synthase 
enzyme to provide information that could aid in a more rational drug design 
approach. We hypothesized that identifying specific regions on Cho1p that were 
crucial for enzyme function could help provide a framework by which we could 
design inhibitors to competitively or allosterically inhibit the enzyme. In order to 
perform these studies, we began by characterizing Cho1p both in vivo and in 
vitro. The results of these studies are described in Chapter 1. Further, we began 
biochemical characterization where we mapped the substrate binding sites in 
Cho1p. This study is described in Chapter 4. 
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 In addition to these biochemical characterizations, we were interested in 
describing PS dynamics within yeast. Although we wished to perform these 
studies in C. albicans, the model yeast S. cerevisiae was more amendable to use 
of genetic tools and thus characterization of PS trafficking and dynamics at the 
membrane was performed in yeast. The findings from this study can be found in 
Appendix 2. 
 Last, we wished to complete our biochemical characterization by solving 
the 3D crystal structure of Cho1p. Although we were unable to complete this 
project due to time constraints, we developed several strains of S. cerevisiae 
containing Cho1p tagged with 3X FLAG and 6X His which will ultimately allow 
purification of the protein via affinity chromatography. These strains will be useful 
in future studies to determine the structure of Cho1p. These preliminary 
experiments can be found in Appendix 4. 
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ROLE OF PHOSPHATIDYLSERINE SYNTHASE IN SHAPING THE 
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Abstract  
  
Phosphatidylserine (PS) synthase (Cho1p) and the PS decarboxylase enzymes 
(Psd1p and Psd2p), which synthesize PS and phosphatidylethanolamine (PE), 
respectively, are crucial for Candida albicans virulence. Mutations that disrupt 
these enzymes, which are part of the cytidyldiphosphate-diacylglycerol (CDP-
DAG) pathway (i.e. de novo pathway), utilized for phospholipid synthesis, 
compromise virulence. Understanding how losses of PS and/or PE synthesis 
54 
 
pathways affect the phospholipidome of Candida is important for fully 
understanding how these enzymes impact virulence. The cho1Δ/Δ and psd1Δ/Δ 
psd2Δ/Δ mutations cause similar changes in levels of phosphatidic acid (PA), 
phosphatidylglycerol (PG), phosphatidylinositol (PI), and PS. However, only slight 
changes were seen in PE and phosphatidylcholine (PC). This finding suggests 
that the alternative mechanism for making PE and PC, the Kennedy Pathway, 
can compensate for loss of the de novo synthesis pathway. C. albicans Cho1p, 
the lipid biosynthetic enzyme with the most potential as a drug target, has been 
biochemically characterized, and analysis of its substrate specificity and kinetics 
reveal that these are similar to those previously published for Saccharomyces 
cerevisiae Cho1p. 
 
Introduction 
Fungi of the genus Candida are opportunistic pathogens known to cause 
vulvovaginal, oral, and invasive bloodstream infections in humans. Invasive 
infections are the most serious, with a mortality rate around 30% (Morrell, et al. 
2005, Wisplinghoff, et al. 2004).  Currently, there are three main antifungal 
classes used to treat bloodstream infections of C. albicans, the species that 
causes the majority of these infections (Pfaller, et al. 2012).  These therapies 
include azoles (e.g. fluconazole), echinocandins (e.g. caspofungin), and 
polyenes (amphotericin B).  Unfortunately, these drugs have limited effectiveness 
due to documented cases of azole and echinocandin resistance (Mishra, et al. 
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2007), the nephrotoxicity of amphotericin B (Ghannoum and Rice 1999, Holeman 
and Einstein 1963), and the requirement for intravenous administration of both 
amphotericin B and caspofungin.  Furthermore, the recent rise in patients that 
are immunocompromised puts more people at risk every year (Low and Rotstein 
2011), while also dramatically increasing healthcare costs (Mishra, et al. 2007).  
As a result, it is of utmost importance to find novel antifungals to treat C. albicans 
potently and effectively. 
 Phospholipids are crucial components of biological membranes in both 
prokaryotes and eukaryotes.  The phospholipidome of C. albicans is made up 
mostly of phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG), 
and cardiolipin (CL) (Singh, et al. 2012).  C. albicans has a de novo method for 
producing phospholipids, which involves the conversion of cytidine diphosphate-
diacylglycerol (CDP-DAG) into PI, PG, and PS (Fig. 1.1).  Although PI, PG, and 
PS can be end products; PG and PS can be further modified to form CL and PE, 
respectively, and PE can subsequently be methylated to produce PC.  C. 
albicans also utilizes exogenously provided ethanolamine and choline to produce 
PE and PC via the Kennedy pathway (Chen, et al. 2010, Gibellini and Smith 
2010, Henry, et al. 2012). 
 Previous studies have identified the PS synthase (Cho1p) as a potential 
drug target in Candida albicans (Braun, et al. 2005, Chen, et al. 2010). Studies 
have been done on the enzymology and lipid profiles associated with PS 
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 Figure 1. 1 Phospholipid Biosynthesis Pathways in C. albicans. 
Canidida albicans phospholipid biosynthesis occurs via both an endogenous 
pathway, the de novo pathway and an exogenous pathway, the Kennedy 
pathway. The precursors for producing the most common phospholipids are PA 
and CDP-DAG. CDP-DAG is then converted into PI, PS or PG. The 
endogenously produced PS can then be decarboxylated via Psd1 or Psd2 
(Psd1/2) into PE and then further methylated into PC. In the Kennedy pathway, 
exogenous ethanolamine (Etn) and/or choline (Cho) are brought into the cell and 
converted into PE and PC. PG and CDP-DAG can be combined to generate CL. 
Abbreviations: PA, phosphatidic acid; CDP-DAG, cytidine diphosphate-
diacylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; PG, 
phosphatidylglycerol; PE, phosphatidylethanolamine; CL, cardiolipin; PC, 
phosphatidylcholine. 
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synthase in S. cerevisiae (Bae-Lee and Carman 1984), but little characterization 
of the orthologous enzyme or its effects on lipid profiles in C. albicans has been 
performed.  Here we report the phospholipidome of the Candida albicans 
cho1Δ/Δ and psd1Δ/Δ psd2Δ/Δ strains, as well as the enzyme kinetics of C. 
albicans Cho1p, finding both the Km and Vmax to be in close agreement with those 
values reported for S. cerevisiae Cho1p (Bae-Lee and Carman 1984). The 
studies described in this report set the stage for further characterization of these 
enzymes as drug targets. 
 
Materials and Methods 
Strains used 
The SC5314 (wild-type) strain of C. albicans and mutants used in this study have 
been previously described in (Chen, et al. 2010).  These include cho1Δ/Δ 
(YLC337), cho1Δ/Δ::CHO1 (YLC344 ), psd1Δ/Δ (YLC280), psd1Δ/Δ::PSD1 
(YLC294), psd2Δ/Δ (YLC271), psd2Δ/Δ::PSD2 (YLC290), psd1Δ/Δ psd2Δ/Δ 
(YLC375). The media used to culture strains was YPD (1% yeast extract, 2% 
peptone, and 2% dextrose). 
 
Lipid Isolation for Mass Spectrometry Analysis 
Lipid isolations were adapted from the protocol of (Singh, et al. 2010).  Cultures 
were grown overnight, shaking at 30° C in 5 mL of YPD.  Cultures were then 
diluted to 0.4 OD600 in 25 mL of YPD and grown for 6 hours, shaking at 30° C.  
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After the 6 hours, cultures were pelleted and washed twice with PBS.  The final 
pellets were incubated for at least 1 hour at -80° C, then lyophilized overnight.  
Dry mass was then recorded for normalization and pellets were suspended in 
500 μL to 1 mL of PBS.  The resulting thick suspension was then transferred to 
Teflon-capped glass tubes (Pyrex) and 1.5 mL of methanol was added.  Two 
scoops of 150-212 μm sized glass beads (Sigma-Aldrich, St. Louis, MO) were 
added to each tube.  Cells were lysed by vigorous vortexing for 30 seconds 
punctuated by 30 second incubations on ice.  3 mL of chloroform was added and 
the solution was vortexed briefly before being transferred to 15 mL glass funnel 
filtration system (Millipore, Billerica, MA, USA) with 24 mm glass microfibre filters 
(Whatman).  Liquid collected was then poured into a separating funnel and 
washed with 900 μL of sterile 0.9% NaCl.  The mixture was allowed to sit and 
separate for at least 5 minutes, or until adequate separation of the organic and 
aqueous layers was observed.  The lower organic layer only was collected 
carefully into fresh Teflon-capped glass tubes.  The organic layer was then dried 
under nitrogen gas until completely dry and stored at -20°C. Immediately before 
mass spectrometric analysis, the lipid extracts were resuspended in 300uL of 9:1 
methanol:chloroform (v/v). 
 
Mass Spectrometry Lipidomics 
Lipid extracts were separated on a Kinetex HILIC column (150 mm x 2.1 mm, 2.6 
μm: (Phenomenex, Torrance, CA, USA) connected to a Ultimate 3000 UltraHigh 
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Performance Liquid Chromatograph (UHPLC) with autosampler and an Exactive 
benchtop Orbitrap mass spectrometer (MS) (Thermo Fisher Scientific, San Jose, 
CA) equipped with a electrospray ionization (ESI) probe. The column oven 
temperature was maintained at 25°C, and the temperature of the autosampler 
was set to 4°C. For each analysis, 10 PL was injected onto the column. 
Separations ran for 35 minutes at a UHPLC flow rate of 0.2 mL/min with mobile 
phase A and B consisting of 10 mM aqueous ammonium formate pH 3 and 10 
mM ammonium formate pH 3 in 93% ACN (v/v), respectively. The gradient 
started at 100% B and was altered based on the following profile: t = 0 minutes, 
100% B; t = 1 minute, 100% B; t = 15 minutes, 81% B, 29% A; t = 15.1 minutes, 
48% B, 52% A; t = 25 in, 48% B, 52% A; t = 25.1 minutes, 100% B, t = 35 
minutes, 100% B. The same LC conditions and buffers were used for all MS 
experiments described below. 
 The MS spray voltage was set to 4 kV, and the heated capillary 
temperature was set at 350°C. The sheath and auxiliary gas flow rates were set 
to 25 units and 10 units, respectively. These conditions were held constant for 
both positive and negative ionization mode acquisitions, which were both 
performed for every sample. External mass calibration was accomplished using 
the standard calibration mixture and protocol from the manufacturer 
approximately every 2 days. For full scan profiling experiments, the MS was run 
with resolution of 140,000 with a scan range of 113-1700 m/z. For lipid 
identification studies, HCD fragmentation experiments were run. These 
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experiments were performed by alternating between full scan acquisitions and all 
ion fragmentation HCD scans. Samples were analyzed in both positive and 
negative mode, and full scan settings were the same as listed above. For the all 
ion fragmentation scans, the resolution was 140,000 with a scan range of 113-
1700 m/z. The normalized collision energy was 30eV, and a stepped collision 
energy algorithm of 50% was used. Full scan MS data was evaluated using 
Maven software (Melamud, et al. 2010), and lipid classes were identified by their 
fragments using the Xcalibur software package (Thermo Fisher Scientific, San 
Jose, CA) and information from the LIPID MAPS initiative (Fahy, et al. 2007). 
 Lipid species were verified using retention times, high mass accuracy, and 
fragmentation data. Internal standards were not used in this study; therefore, the 
relative amounts of each phospholipid species are presented. Inter-class 
comparisons are possible, although some approximation of the relative 
intensities is inherent due to differing ionization efficiencies among lipids with 
different acyl chain lengths. Adequate separation of phospholipids was seen 
(data not shown) (Cassilly et al., 2017). 
 
Phosphatidylserine Synthase Assay 
This procedure was done as previously described with minor alterations (Bae-
Lee and Carman 1984, Cassilly, et al. 2016, Matsuo, et al. 2007).  Cultures were 
grown over night and then diluted into 1 L YPD, to approximately 0.1 OD600/mL.  
These cultures were shaken at 30°C for 6 to 10 hours.  Cells were then 
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harvested by centrifugation at 6,000 xg for 20 minutes.  Pellets were then 
transferred to 50 mL conical tubes and washed with water and re-pelleted.  
Supernatant was removed and the wet weight of the samples was taken.  Cell 
pellets were stored overnight in -80°C.  The following day, a cold mixture of 0.1 M 
Tris-Cl pH 7.5, 5 mM β-mercaptoethanol (BME), 10% glycerol, and protease 
inhibitors (phenylmethylsuphonylfluoride (PMSF), leupeptin, and pepstatin) was 
added to the frozen pellets (1mL/g [wet weight]) and allowed to thaw on ice.  
Cells were lysed using a either a French Press (three passes at approximately 
13,000 lb/in2) or using osmotic lysis (Graham, et al. 1994).  The homogenate was 
centrifuged at 4°C for 5 minutes at 3,000 rpm to clear unbroken cells and heavy 
material.  Supernatant was then spun again at 27,000 g for 10 minutes at 4°C.  
For some experiments, the resulting supernatant was then spun at 100,000 g to 
collect the lower density membranes.  Pellets were resuspended in 500 μL to 1 
mL of 0.1 M Tris-Cl pH 7.5, 5 mM β-mercaptoethanol (BME), 10% glycerol, and 
protease inhibitors.  This mixture was aliquoted into microcentrifuge tubes and 
homogenized to break apart clumps, keeping on ice as much as possible. Total 
crude protein concentration was determined using a Bradford Assay.  The 
optimal assay mixture contained 50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 0.5 
mM MnCl2, 0.1 mM CDP-DAG (Avanti Polar Lipids, Alabaster, AL) added as a 
suspension in 1% to 20% Triton X-100 and 0.4-0.5 mg protein in a total volume 
of 0.1 mL. The PS synthase assay was performed by monitoring the 
incorporation of 0.5 mM L-serine spiked with 5% by volume [3H]-L-serine (~20 
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Ci/mmol) into the chloroform-soluble product at 37°C for a predetermined amount 
of time. The reaction was terminated by the addition of 1 mL chloroform: 
methanol (2:1).  Following a low-speed spin, 800 to 1000 μL of the supernatant 
was removed to a fresh tube and washed with 200 μL 0.9% NaCl.  Following a 
second low-speed spin, 400-500 μL of the chloroform phase was removed to a 
new tube and washed with 500 μL of chloroform: methanol: 0.9% NaCl (3:48:47).  
Following a third low-speed spin, 200-300 μL was transferred into scintillation 
vials (Thermo Fisher Scientific, San Jose, CA).  Tubes were left open in the hood 
until dried fully.  The next day, 2.5 mL scintillation fluid was added to each tube 
and run through the scintillation counter. 
 
Statistical analysis 
Graphs were made using GraphPad Prism version 6.04.  Unpaired t-tests were 
used to determine significance between results.  The lipidomics data were 
normalized by dry weight prior to statistical analyses.  
  
Results 
Phospholipids synthesized in the de novo pathway are dominated by 34:n 
species  
Phospholipid profiles have previously been generated for the cho1Δ/Δ, psd1Δ/Δ, 
and psd1Δ/Δ psd2Δ/Δ mutants using [32P]-labeled phospholipids and thin layer 
chromatography (TLC) (Chen, et al. 2010).  However, TLC only reveals levels of 
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different lipid classes (polar head groups).  We wanted to also determine the 
differences among the individual species (fatty acid composition) within each 
class.  Thus, profiles of the major phospholipid classes were generated via 
lipidomics from lipids extracted from wild-type, cho1Δ/Δ, cho1Δ/Δ::CHO1, 
psd1Δ/Δ, psd1Δ/Δ::PSD1, psd2Δ/Δ, psd2Δ/Δ::PSD2, psd1Δ/Δ psd2Δ/Δ strains of 
C. albicans.  The lipids were analyzed by UHPLC-ESI-MS using the protocol 
described in methods and materials and adequate separation of standard 
phospholipids was seen (data not shown).  Profiles of PA, CDP-DAG, PI, PG, 
CL, PS, PE, and PC from three biological replicates were generated and are 
shown in Figure 1.2. Statistically significant differences for particular species 
within each class compared to wild-type were seen (data not shown). 
 In the cho1Δ/Δ mutant, which lacks PS synthase (the initial step in the de 
novo pathway, Fig. 1), PS is essentially absent, as expected (Fig. 1.2).   The 
cho1Δ/Δ::CHO1 reintegrant strain exhibited a modest return of PS levels as 
compared with the cho1Δ/Δ and wild-type strains.  The reintegrant strain has only 
one copy of CHO1, so haploinsufficiency is a possible explanation of this result.  
However, since the level of PS in the reintegrant is only about 37% of the 
wildtype, one allele may be dominant over the other.  C. albicans has well-
documented heterozygosity, which could account for this result (Eckert and 
Muhlschlegel 2009). 
 The distribution of PS species in the wild-type consists predominantly of 
34:n species, with 34:2 being the most prevalent (Fig. 1.2). The psd1Δ/Δ mutant,  
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Figure 1. 2. The Phospholipid Species Profiles for the Major Classes of 
Phospholipids in C. albicans Phospholipid Synthesis Mutants 
(A) The phospholipid species profiles are shown for the major phospholipid 
classes of phosphatidylserine (PS), phosphatidylethanolamine (PE), 
phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylinositol (PI) 
and cardiolipin (CL). (B) The species profiles detected are shown for the 
precursor lipids phosphatidic acid (PA) and cytidyldiphosphate-diacylglycerol 
(CDP-DAG). For each lipid class, a stacked bar graph is used and the species 
associated with each color is shown in the legend based on the combined carbon 
content and number of unsaturated bonds within the fatty acid component of the 
phospholipid. The Y-axis of the graph is the area under the peak for each 
species based on spectral profiles. The X-axis is the strains, which are as 
follows: wild-type (WT), cho1 (cho1Δ/Δ), psd1 (psd1Δ/Δ), psd1, 2 (psd1Δ/Δ 
psd2Δ/Δ), psd2 (psd2Δ/Δ), psd2R (psd2Δ/Δ::PSD2), psd1R (psd1Δ/Δ::PSD1). 
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which lacks the dominant PS decarboxylase (predicted to be localized to the 
mitochondria) that converts PS to PE, exhibits an overall increase in PS, but 
especially of the 34:2 species. A slight increase in PS is seen in the psd2Δ/Δ 
mutant, which lacks the alternative PS decarboxylase (predicted to localize to the 
Golgi/endosome).  The reintegrant strains psd1Δ/Δ::PSD1 and psd2Δ/Δ::PSD2 
also show slight increases in levels of PS. The psd1Δ/Δ psd2Δ/Δ mutant, which 
lacks all PS decarboxylase activity, has over a 3-fold increase in PS species 
overall, but individual species are over-represented by 2 to 5 fold.  The 34:n 
species, which were the most abundant in wild-type, are also the most abundant 
in psd1Δ/Δ psd2Δ/Δ and are over-represented by ~5 fold compared to wild-type. 
However, it appears that all species are decarboxylated to some extent, given 
that they build up as well. 
 PE is the direct downstream product of PS decarboxylation (Fig. 1), and 
loss of PS was expected to result in a sizeable decrease in PE, but surprisingly 
we saw increases in PE levels in most of our mutants (Fig. 1.2).  Most of these 
changes are not statistically significant in the majority of mutants, including 
cho1Δ/Δ (data not shown), although they are for psd1Δ/Δ psd2Δ/Δ. The 
maintenance of PE levels by the cho1Δ/Δ and psd1Δ/Δ psd2Δ/Δ mutants is likely 
due to growing these cultures in YPD, a rich medium containing ethanolamine 
and choline.  Since the cho1Δ/Δ and psd1Δ/Δ psd2Δ/Δ mutants have no 
production of PE via the CDP-DAG pathway, it is likely that these mutants 
compensate through activity from the Kennedy Pathway in order to synthesize 
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PE. The psd1Δ/Δ mutant, which is missing the mitochondrial PS decarboxylase 
activity, showed wild-type levels of PE, suggesting that the loss of Psd1p was 
rescued by the redundant function of Psd2p.  The psd2Δ/Δ strain exhibited an 
increase in PE, but this was again not statistically significant.  The 
psd2Δ/Δ::PSD2 strain did have significant increases in many phospholipids, 
which was unexpected. The psd1Δ/Δ::PSD1 did not show many significant 
differences from wild-type. Overall, the majority of PE species in wild-type are of 
36:n or 34:n, and even in the psd1Δ/Δ psd2Δ/Δ where the changes were 
significant, this only shifted slightly compared to wild-type.  
 Since the majority of PS is 34:n in wild-type cells, the Kennedy pathway 
may account for half of the PE population (34:n) or significant acyl remodeling of 
PS-derived PE is used to create other species after, or just prior to, 
decarboxylation.  However, since a similar distribution of PE is found in wild-type, 
cho1Δ/Δ (totally lacks PS), and psd1Δ/Δ psd2Δ/Δ strains (cannot convert PS to 
PE), this suggests that most of the 36:n PE is derived from the Kennedy 
pathway, and the Kennedy pathway also synthesizes 34:n PE efficiently or 
converts 36:n by acyl remodeling. 
 Previous studies with S. cerevisiae showed an accumulation of PC in the 
Sccho1∆ mutant based upon TLC analysis (Atkinson, et al. 1980b). Indeed, our 
data show an approximately 1.5 fold increase in the level of PC in both the 
cho1Δ/Δ and psd1Δ/Δ psd2Δ/Δ mutants when compared to the wild-type (Fig 
1.2). The most obvious common relationship between cho1Δ/Δ and 
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psd1Δ/Δ psd2Δ/Δ is that both have a complete loss of de novo PE synthesis, 
which may indicate that this metabolic alteration causes an increase in PC 
synthesis via the Kennedy pathway. In the psd1Δ/Δ psd2Δ/Δ or cho1Δ/Δ 
mutants, PC can be synthesized directly from choline and DAG via the Kennedy 
pathway or by methylation of Kennedy-pathway-derived PE via the de novo 
pathway (Fig. 1.1). However, from this data it is not possible to determine the 
level of PC coming directly from Kennedy pathway versus the methylation of 
Kennedy pathway derived PE to PC. Interestingly, the cho1Δ/Δ::CHO1 strain, 
which has only one allele of CHO1, has wild-type levels of PC. Loss of PS 
decarboxylase activity in psd1Δ/Δ or psd2Δ/Δ mutants also has little effect on PC 
levels when compared with that of wild-type. Although there is a slight decrease 
in PC in the psd2Δ/Δ mutant, it does not appear to be statistically significant.  
These findings suggest that the organism strictly controls the production of PC to 
at least maintain wild-type levels. The majority of PC species are 36:n and 38:n. 
It is possible that the 36:n PC is formed through the de novo methylation of 36:n 
PE. The 38:n species are probably produced from the importation of exogenous 
choline. However, there are no striking changes within lipid species across 
mutant strains to confirm or deny these hypotheses. 
 Increases in other CDP-DAG derived phospholipids may be caused by an 
abundance of substrate in the PS synthase and PS decarboxylase mutants 
Phosphatidic acid (PA) is the precursor for CDP-DAG (Gibellini, et al., 2010) that 
is used to produce PS, PG, and PI (Fig. 1.1).  The cho1Δ/Δ mutant showed a 
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nearly 3 fold increase in PA levels when compared to wild-type (Fig 1.2). These 
results were expected because the loss of PS synthesis causes a major 
blockage in de novo phospholipid synthesis, which would in turn lead to a build-
up of the precursor molecule PA (substrate for CDP-DAG). This is further 
supported by the intermediate level of PA in cho1Δ/Δ::CHO1, which correlates 
with the partial return of PS production, and thus increased usage of PA.  Varying 
increases are shown in PA levels within psd1Δ/Δ and psd2Δ/Δ mutants and their 
reintegrant strains, again potentially relating back to the build-up of PS in these 
strains, which translates into a build-up of PA. This is supported by the large 
increase in PA seen in psd1Δ/Δ psd2Δ/Δ, which has no de novo PE production, 
and thus represents a blockage in this biosynthetic pathway. 
 We also aimed to analyze the levels of CDP-DAG within our mutants and 
found that we could only detect 32:0 species and that the overall levels of this 
precursor lipid were extremely low (Fig. 1.2B). This suggests that there is a high 
turnover of CDP-DAG and that it is rapidly used to produce PS, PI, or PG. 
Although there was some variability within the CDP-DAG levels, including 
increases in most of the mutants tested, none of these changes were statistically 
significant when compared to wild-type. However, the change in CDP-DAG levels 
within our mutants again could easily be attributed to a back up in the de novo 
synthesis (either a halt of PS production or usage) which causes increases in 
CDP-DAG levels. 
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 In addition to the precursors, we also looked at the levels of the other two 
phospholipids produced from CDP-DAG, PI and PG, as well as CL, which is 
produced from PG (Gibellini, et al., 2010).  Both the cho1Δ/Δ and the psd1Δ/Δ 
psd2Δ/Δ mutants show increases in PI and PG levels.  Where the cho1Δ/Δ PI 
levels increase by around 2.5 fold, the psd1Δ/Δ psd2Δ/Δ increase is more 
modest. For PG we see an increase in both cho1Δ/Δ and psd1Δ/Δpsd2Δ/Δ, at 
approximately 5-fold and 4-fold, respectively.  These findings could be a result of 
more CDP-DAG being available for the production of PI and PG due to a 
blockage of PS synthesis (cho1Δ/Δ) or a build-up in PS (psd1Δ/Δ psd2Δ/Δ). PI 
and PG seem to be tightly controlled, however, because in all other mutant and 
reintegrant strains, the levels return to wild-type. Finally, levels of CL correspond 
well with the changes in PG within our mutant strains. This indicates that some of 
the excess PG produced can be further modified to produce CL. These findings 
correlate well with studies in S. cerevisiae and confirm our previous results with 
TLC (Atkinson, et al. 1980b, Chen, et al. 2010).  Interestingly, as with PS, the 
most abundant species of PI and PG appear to be 34:n, thus it is possible that 
most CDP-DAG destined for PS synthesis is 34:n, but our lipidomics yields of 
CDP-DAG were too low to verify this, and it may be 34:n CDP-DAG is so rapidly 
processed into other lipids that it is hard to detect at steady-state. 
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Phosphatidylserine Synthesis in PS synthase and PS decarboxylase 
mutants  
The psd1Δ/Δ psd2Δ/Δ mutant exhibits a large increase in PS levels (Fig. 1.2), 
which is presumed to be caused by decreased decarboxylation of PS to PE.  
However, it is possible that this is due to increased PS synthase activity instead.  
This seemed doubtful, but to test this, an in vitro PS synthase assay was 
performed on cellular membranes, which were isolated from cell lysates via a 
27,000xg centrifugation step.  Additional low density membranes were isolated 
via a 100,000xg centrifugation step.   However, as highly variable results were 
found in the 100,000xg membrane prep, data was generated from the 27,000xg 
membranes which provided more consistent results.   The assay was used to 
compare the incorporation of [3H]-serine into membranes upon the addition of 
CDP-DAG between wild-type, cho1Δ/Δ, cho1Δ/Δ::CHO1, psd1Δ/Δ, psd1Δ/Δ 
psd2Δ/Δ, and psd1Δ/Δ::PSD1 strains.  Wild-type levels of PS synthase activity 
were seen in the psd1Δ/Δ and psd1Δ/Δ psd2Δ/Δ strains, indicating that these 
strains have similar enzyme activities as the wild-type organism (Fig. 1.3).  Thus, 
the excess PS in the psd1Δ/Δ psd2Δ/Δ mutant is likely a product of the loss of 
PS decarboxylase activity and build-up of substrate. 
 As expected from this assay, the cho1Δ/Δ mutant exhibited no PS 
synthase activity.  However, the cho1Δ/Δ::CHO1 reintegrant strain had only 
about 10% of the activity of the wild-type.  This compares with the decreased PS  
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Figure 1. 3. PS Synthase Activity Across Strains 
Cho1p activity within different mutant strains of C. albicans. 
Cellular membranes containing Cho1p were isolated and 
treated with CDP-DAG and [3H]-serine. Activity is measured 
as counts per minute per milligram of protein. Values are 
shown as an average of three experiments averaged and 
normalized to the wild-type (WT) control. P < 0.0001.  
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levels in the reintegrant as measured by lipidomics (Fig. 1.2).  Haploinsufficiency 
may account for this lower activity.   
 
C. albicans Cho1p enzyme kinetics are similar to those reported for S. 
cerevisiae 
The wild-type and other strains seemed to have similar PS synthase activity 
levels, but it was of interest to know more about the enzyme kinetics of C. 
albicans Cho1p, if it is to be considered for potential use as a drug target.  The 
Km and apparent Vmax of this enzyme was calculated for both serine and CDP-
DAG (Fig. 4). L-serine, where the CDP-DAG was held constant at 0.1 mM, 
yielded a Km of 1.2±0.57 mM and an apparent Vmax of 0.15±0.02 
nmole/minute/mg of protein (Fig. 1.4A).  For CDP-DAG, where the serine was 
held constant at 2.5 mM, a Km of 43.17±19.18 μM and an apparent Vmax of 
0.19±0.023 nmole/minute/mg of protein (Fig. 1.4B) was obtained. Interestingly, 
the intracellular concentration of serine in S. cerevisiae has been estimated to be 
around 2 mM on average (Hans, et al. 2003), which fits well with the Km for 
serine.  These assays were performed on the crude 27,000xg membranes in 
order to determine their kinetics within native membranes. These compare 
relatively closely with what has been reported for S. cerevisiae (Bae-Lee and 
Carman 1984). 
 To control for the possibility that any similar substrate molecules to serine 
might give a similar activity, which could cast doubt on the accuracy of the assay,  
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Figure 1. 4. Enzyme Kinetics for Cho1p 
The PS synthase assay was performed with varying concentrations of substrate 
over time courses to generate enzyme kinetics for both substrates. (A) The 
Michaelis-Menton curve for the l-serine substrate shows a Km of 1.243 ± 0.5715 
mM and an apparent Vmax of 0.1514 ± 0.02059 nmole/min/mg of protein. (B) The 
Michaelis-Menton curve for the CDP-DAG substrate shows a Km of 43.17 ± 19.18 
μM and an apparent Vmax of 0.1919 ± 0.02361 nmole/min/mg of protein. 
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we determined whether increasing concentrations of cold  D-serine or threonine 
(similar amino acid) could compete with [3H]-L-serine for incorporation into [3H]-
PS.  Only at the highest concentration of 200 mM (400x) did the cold D-serine 
show any competition with L-serine (Fig. 1.5).  Threonine showed no statistically 
significant competition with L-serine, even at 200 mM (400x).  As a control, cold 
L-serine eliminated incorporation of [3H]-L-serine at a 10x concentration (5 mM).  
Thus, this assay would not yield a product with these two similar molecules (D-
serine or threonine), thus suggesting that the assay is specifically measuring 
activity against L-serine.  
 
Discussion 
The loss of de novo PE synthesis and/or PS synthesis has striking effects on the 
phospholipidome, which are consistent with what we know from fungal 
phospholipid metabolism.  In particular, the loss of the de novo pathway for PS 
and/or PE synthesis appears to increase the synthesis of other CDP-DAG-
dependent phospholipids like PI and PG (Fig. 1.2).  Surprisingly, PE and PC 
levels appear to be buffered against change, presumably by the activity of the 
Kennedy pathway. The 34:n species are the most prominent forms of PS, and 
34:2 in particular is the most actively used substrate by PS decarboxylase 
enzymes to synthesize PE, and the 34:2 species is also what builds up in PI and 
PG, which may suggest that either Cho1p preferentially uses 34:2 CDP-DAG, or 
34:2 CDP-DAG is what it encounters in its subdomains in the ER. 
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 Figure 1. 5. Cho1p Specificity for L-serine. 
The PS synthase assay was performed with 0.5 mM [3H]-serine and 0.1 mM 
CDP-DAG. An excess of d-serine (A) or L-threonine (B) was added at varying 
concentrations. Only D-serine or L-threonine at concentrations 400-fold that of L-
serine show any inhibition in [3H]-PS production. Values are shown as an 
average of three experiments averaged and normalized to the wild-type control. 
P = 0.0361.   
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 Finally, our analysis of the enzymology of Cho1p from C. albicans reveals 
it is very similar to S. cerevisiae, and that changes in the enzyme activity, for 
example in the CHO1 compared to cho1Δ/Δ::CHO1 strains, seem to correlate 
with one another rather closely. These analyses set the stage for better 
understanding how strategies to inhibit de novo PS or PE synthesis, which are 
required for virulence of C. albicans, may impact overall lipid profiles and ability 
to cause disease. 
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CHAPTER II 
SB-224289 ANTAGONIZES THE ANTIFUNGAL MECHANISM OF 
THE MARINE DEPSIPEPTIDE PAPUAMIDE A  
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Abstract  
  
In order to expand the repertoire of antifungal compounds a novel, high-
throughput phenotypic drug screen targeting fungal phosphatidylserine (PS) 
synthase (Cho1p) was developed based on antagonism of the toxin papuamide 
A (Pap-A). Pap-A is a cyclic depsipeptide that binds to PS in the membrane of 
wild-type C. albicans and permeabilizes its plasma membrane, ultimately causing 
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cell death. Organisms with a homozygous deletion of the CHO1 gene (cho1ΔΔ) 
do not produce PS and are able to survive in the presence of Pap-A. Using this 
phenotype (i.e. resistance to Pap-A) as an indicator of Cho1p inhibition, we 
screened over 5,500 small molecules for Pap-A resistance and identified SB-
224289 as a positive hit.  SB-224289, previously reported as a selective human 
5-HT1B receptor antagonist, also confers resistance to the similar toxin 
theopapuamide (TPap-A), but not to other cytotoxic depsipeptides tested. 
Structurally similar molecules and truncated variants of SB-224289 do not confer 
resistance to Pap-A suggesting that the toxin-blocking ability of SB-224289 is 
very specific.  Further biochemical characterization revealed that SB-224289 
does not inhibit Cho1p, indicating that Pap-A resistance is conferred by another 
undetermined mechanism.  Although the mode of resistance is unclear, 
interaction between SB-224289 and Pap-A or TPap-A suggests this screening 
assay could be adapted for discovering other compounds which could 
antagonize the effects of other environmentally- or medically-relevant 
depsipeptide toxins. 
 
Introduction 
Patients with a compromised immune system are prone to develop nosocomial 
infections which can be fungal, bacterial, parasitic, or viral in nature.  Candida 
spp. are pathogenic fungi responsible for the majority of fungal infections arising 
within hospitals (Mishra, et al. 2007, Morrell, et al. 2005).  Of these, the species 
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found most often is Candida albicans (Papon, et al. 2013). This fungus most 
commonly causes mucosal infections including vaginal infections and oral thrush, 
but it can also cause life-threatening infections.  The most serious of these 
include fungal endocarditis and systemic bloodstream infections which have 
mortality rates around or greater than 30% (Baddley, et al. 2008, Pfaller and 
Diekema 2007). 
 There are currently three primary classes of antifungals used to treat 
invasive Candida infections.  The first line defense includes azoles (e.g. 
fluconazole) and echinocandins (e.g. caspofungin).  However, resistance and 
tolerance to these drugs can lead to treatment failures (Alexander, et al. 2013, 
Dannaoui, et al. 2012, Pfaller 2012, Srinivasan, et al. 2014). The mainstay of 
second line defense is the polyene amphotericin B, a drug that must be carefully 
administered due to its nephrotoxic potential (Ghannoum and Rice 1999, 
Holeman and Einstein 1963).  As a result of drug resistance, poor oral 
availability, and toxic side effects including drug-drug interactions (Mukherjee, et 
al. 2005), there is a clear need for new antifungal drugs to treat Candida 
infections. 
 Previously, the fungal phosphatidylserine (PS) synthase (Cho1p) was 
identified as a promising antifungal drug target for several reasons. First, Cho1p 
has been demonstrated to be required for Candida albicans virulence in a mouse 
model of systemic infection (Chen, et al. 2010).  Mice infected with a strain of C. 
albicans where both alleles of the Cho1p gene are deleted (cho1ΔΔ) were able to 
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survive indefinitely, whereas mice infected with the wild-type strain succumbed to 
infection within two weeks (Chen, et al. 2010).  Second, the Cho1p enzyme is 
conserved among many pathogenic fungi (Braun, et al. 2005, Chen, et al. 2010). 
Last, Cho1p is absent within mammals (Atkinson, et al. 1980b, Braun, et al. 
2005, Chen, et al. 2010, Kuge, et al. 1986).  Based on these observations, we 
hypothesized that high affinity inhibitors of Cho1p should render the organism 
unable to cause infection within a host, be active against a broad range of fungal 
pathogens, and be highly selective with minimal side effects in mammals. 
Based on this hypothesis, we set out to identify inhibitors of this pathway using a 
cell based high-throughput screening approach.  The assay is based on the 
action of a PS-dependent toxin, papuamide A (Pap-A), which is a cyclic 
depsipeptide isolated from marine sponges of the genus Theonella. Pap-A kills 
C. albicans and other yeasts by binding to PS in the membrane and forming 
pores that disrupt the integrity of the membrane (Andjelic, et al. 2008, Parsons, et 
al. 2006).  We wished to exploit the PS-specific nature of Pap-A toxicity and 
identify compounds that block PS synthesis or alternatively interfere with PS 
metabolism, by selecting those small molecules that allow C. albicans survival in 
the presence of Pap-A. Thus, the Pap-A killing assay was adapted into a robust 
384-well plate screening assay and tested against a reference set of bioactive 
compounds including many known drugs. 
 This screen showed a good statistical window and yielded several 
promising hits.  However, we found that Pap-A resistance is not specific enough 
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to conclude that a compound targets Cho1p, as other mechanisms can be 
responsible for this protection phenotype.  In this study we describe the 
characterization of a positive hit, SB-224289, which in turn showed interesting 
and highly specific behavior that blocks Pap-A mediated cellular poisoning. 
 
Materials and Methods 
Strains Used 
The SC5314 (wild-type) strain of C. albicans and mutants used in this study have 
been previously described (Chen, et al. 2010) and are as follows: cho1∆∆ 
(YLC337), and cho1∆∆::CHO1 (YLC344).  The media used to culture strains was 
YPD (1% Bacto yeast extract, 2% Bacto peptone, and 2% dextrose (Thermo 
Fisher Scientific, San Jose, CA)) (Guthrie 2002). 
 
Compounds 
The 5,760 bioactive compound library is a collated compound set of approved 
drugs (675 compounds) and biologically active compounds that have been 
documented to interact with wide range of targets (approximately 5095 
compounds) including Sigma Aldrich’s Library of Pharmacologically Active 
Compounds (LOPAC), Prestwick, and Microsource compound libraries. The 
library compounds were all independently verified for purity and identity by 
UPLC-MS analysis.  Papuamide A was obtained from Flintbox in association with 
David Williams from the University of British Colombia, Canada.  SB-224289 
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(Cat. # 1221), MG-624 (Cat. # 1356), and valinomycin (VA; Cat. # 3373) were 
ordered from Tocris Bioscience.  GMC 2-29 (Cat. # 1080) and SB-216641 (Cat. # 
1085) were ordered from Axon MedChem.  Staurosporine (CGP 41251) was 
ordered from Selleckchem. Kahalalide F (KF) was a kind gift from Dr. Fernando 
Albericio at the Institute for Research in Biomedicine, Barcelona, Spain.  
Theopapuamide (TPap-A) was provided by Dr. Mark Hamann at University of 
Mississippi, University, Mississippi, USA.  Compounds 2945, 2946, 3047, and 
3048 were synthesized as described previously (Gaster, et al. 1998).  Details of 
the synthesis and compound characterization data are provided the manuscript 
(Cassilly et al., 2016). 
 
Papuamide A resistance assay 
Strains were grown overnight in liquid YPD shaking at 30°C to saturation, and 
cultures were diluted to 2 x 104 cells/ml in YPD.  Compounds of interest were 
diluted to twice the working concentration by serial dilution in a 96 well plate or by 
preparing separately and adding to the wells directly, in a volume of 37.5 μl of 
YPD.  Then 37.5 μl of cells at 2 x 104 cells/ml in YPD were added. Plates were 
incubated at 37°C for 6 hours or 3 hours depending on the experiment, and then 
75 μl of YPD containing depsipeptide (Pap-A at 8 μg/ml, VA at 6 μg/ml, KF at 30 
μg/ml, or TPap-A at 12 μg/ml) was added to each well, diluting those 
concentrations by half. This addition was followed by a 37°C overnight 
incubation. 
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 Cell survival was measured the next day by fluorescence intensity or 
optical density.  For fluorescence intensity, Alamar Blue (Invitrogen, Waltham, 
MA) was added to the wells at a 1:10 dilution.  Plates were allowed to incubate 
again at 37°C for 30 minutes to 2 hours until color change was apparent.  
Fluorescence was then read at excitation 550 nm and emission 590 nm.  For 
optical density, plates were removed from overnight incubation and absorbance 
was read in a plate reader at a wavelength of 600 nm.  All measurements were 
performed on a Cytation3 BioTek plate reader using Gen 5 software. 
 
High throughput screen for Pap-A resistance 
The 5,760 compound library was screened in a total of eighteen 384 well plates 
(Nunc) at a final concentration of 50-75 μM. Approximately 0.155 μl of compound 
dissolved in DMSO were inoculated into 10 μl of YPD in each well from ~10 mM 
stock plates using a BioMek robot with pin tools. Wild-type and cho1∆∆ (positive 
control strain) were grown in liquid YPD in a 30°C shaker overnight and cultures 
were diluted to 104 cells/ml in YPD, and 10 μl were added to each well of the 384 
well plate containing the test compound using a Wellmate. Plates were incubated 
for 6 hours at 37°C, and then 10 μl of YPD containing 12 μg/ml Pap-A was added 
to give a final concentration of 4 μg/ml in 30 μl of YPD. Plates were then 
incubated for another 16 hours at 37°C to allow selection for Pap-A resistance.  
The following day, cell survival was measured by adding Alamar Blue (Invitrogen, 
Waltham, MA) at a 1:10 dilution using a Wellmate.  Plates were allowed to 
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incubate again at 37°C for 2 hours.  Fluorescence was then read at excitation 
550 nm and emission 590 nm on an Envision plate reader (Perkin Elmer, 
Waltham, MA).  In each plate, three of the columns of wells were used as 
controls. One column contained no compounds and no cells and served as 
background control. The positive control column contained cho1ΔΔ plus Pap-A, 
as it showed resistance. An additional control was wild-type with no drugs and no 
Pap-A for maximal wild-type growth. The averaged background readings from 
the wild-type cells plus compounds in the presence of Pap-A served as the 
negative control in each plate. 
 
Phosphatidylserine Synthase Assay 
This procedure was done as described in (Bae-Lee and Carman 1984, Matsuo, 
et al. 2007) with minor alterations.  Cultures were grown overnight and then 
diluted to approximately 0.1 OD600/ml in 1 L YPD, and were shaken at 30°C for 6 
to 10 hours.  Cells were harvested by centrifugation at 6,000 x g for 20 minutes.  
Pellets were then transferred to 50 ml conical tubes and washed with water and 
re-pelleted.  Supernatant was removed and the wet weight of the samples was 
taken.  Cell pellets were stored overnight in -80°C.  The following day, a cold 
mixture of 0.1 M Tris-Cl pH 7.5, 5 mM β-mercaptoethanol (BME), 10% glycerol , 
and protease inhibitors 1.7 μg/ml PMSF, 1 μg/ml leupeptin, and 1 μg/ml pepstatin 
(RPI, Corp., Mount Prospect, IL, USA) was added to the frozen pellets (1 ml/g 
[wet weight]) and allowed to thaw on ice.  Cells were lysed using a French press 
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(three passes at approximately 13,000 lb/in2). The homogenate was centrifuged 
at 4°C for 5 minutes at 3,000 rpm to clear unbroken cells and heavy material. 
Supernatant was then spun again at 27,000 x g for 10 minutes at 4°C.  For some 
experiments, the resulting supernatant was then spun at 100,000 xg to collect the 
lower density membranes.  Pellets were resuspended in 500 μl to 1 ml of 0.1 M 
Tris-Cl pH 7.5, 5 mM BME, 10% glycerol, and protease inhibitors.  This mixture 
was aliquoted into microcentrifuge tubes and homogenized to break apart 
clumps, keeping on ice as much as possible. Total crude protein concentration 
was determined using a Bradford Assay.  The optimal assay mixture contained 
50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 0.5 mM MnCl2, 0.1 mM CDP-DAG 
(Avanti Polar Lipids, Alabaster, AL) added as a suspension in 1% - 20% Triton X-
100, and 0.4 - 0.5 mg protein in a total volume of 0.1 ml.  SB-224289 and MG-
624 were added to the reaction mixture at varying concentrations to monitor their 
ability to inhibit [3H]-PS production.  The PS synthase assay was performed by 
monitoring the incorporation of 0.5 mM L-serine spiked with 5% [3H]-L-serine (or 
0.02 μM) (Cat# ART 0246, ARC, Inc., St. Louis, MO, USA) into the chloroform-
soluble product at 37°C for a predetermined amount of time. The reaction was 
terminated by the addition of 1 ml chloroform: methanol (2:1).  Following a low-
speed spin, 800 - 1000 μl of the supernatant was removed to a fresh tube and 
washed with 200 μl 0.9% NaCl.  Following a second low-speed spin, 400 - 500 μl 
of the organic phase was removed to a new tube and washed with 500 μl of 
chloroform: methanol: 0.9% NaCl (3:48:47).  Following a third low-speed spin, 
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200 - 300 μl was transferred into scintillation vials (Thermo Fisher Scientific, San 
Jose, CA).  Tubes were dried under the chemical hood and 2.5 ml Cytoscint-ES 
liquid scintillation cocktail (MP Bio, Santa Ana, CA, USA) was added to each tube 
and counted in a Packard TriCarb 2900TR Liquid Scintillation Analyzer. 
 
Statistical analysis 
Graphs were made using GraphPad Prism version 6.04.  Unpaired t-tests were 
used to determine significance between results.  RISE (Robust Investigation of 
Screening Experiments) software was used to analyze data from the high 
throughput screen and was used to calculate Z-factors, identify 95th and 99th 
quantile data, and identify compounds that yielded hits of greater than 90% of 
positive control (cho1∆∆). 
  
Results 
Screen for compounds that confer Pap-A resistance 
A novel screen was developed with an original goal of identifying compounds that 
inhibit the Cho1p PS synthase enzyme.  This screen utilizes the unique activity of 
Pap-A, a toxin isolated from Theonella spp. of sponges (Ford 1999).  Pap-A has 
been shown to selectively compromise the integrity of membranes containing PS 
(Andjelic, et al. 2008, Parsons, et al. 2006).  As a result, Pap-A is toxic to wild-
type C. albicans.  However, the cho1ΔΔ mutant, which lacks Cho1p, and thus 
has no PS in its membranes, is able to survive in the presence of Pap-A 
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Figure 2. 1. Resistance to Pap-A Correlates 
with Decreases in PS. 
The cho1ΔΔ mutant is resistant to all 
concentrations of papuamide A (Pap-A) indicating 
a total lack of PS. The cho1ΔΔ::CHO1 reintegrant 
strain is more resistant to Pap-A than the wild-type 
(WT), but less resistant than the cho1ΔΔ mutant. 
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(Fig. 2.1) (Chen, et al. 2010).  A reintegrated strain, cho1ΔΔ::CHO1 which has 
one allele of CHO1 and intermediate levels of PS (Chen, et al. 2010) shows 
intermediate resistance (Fig. 2.1).  This feature of Pap-A was employed as a 
selection tool in our screen to identify those compounds that inhibit Cho1p.  We 
hypothesized that some compounds that allow wild-type growth in the presence 
of Pap-A would do so by decreasing levels of PS in membranes. 
 The screen was performed on approximately 5,600 diverse 
pharmacologically active compounds as representative set of chemical space.  
Each plate contained a column for each control: 1) cho1ΔΔ + Pap-A as a positive 
control 2) no cells/no Pap-A as a background control 3) wild-type cells with no 
drugs or Pap-A for a wild-type growth control.  The remainder of the plate was 
reserved for compound testing by pin transfer, and served as a control for 
background of wild-type cells killed by Pap-A. 
 The majority of test wells (black open circles in Fig. 2.2), which contained 
cells that were killed by Pap-A, read near the no drug/no cell background control 
(red circles, Fig. 2.2). Compounds were tested at a final concentration of 50-75 
μM for their ability to provide resistance to wild-type C. albicans against a lethal 
dose of Pap-A (4 μg/ml). After incubation overnight, the viability indicator Alamar 
Blue was added and fluorescence measured at 590 nm as a proxy for survival. 
Of the tested compounds, 21 (filled in blue circles) showed viability greater than 
or equal to 90% of the cho1ΔΔ positive control (green circles) (Fig. 2.2).  These  
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Figure 2. 2. Screen of FDA-approved Bioactive Compounds for Those that 
Confer Pap-A Resistance 
5,760 compounds were screened for their effects on the growth of wild-type C. 
albicans (open black circles) in the presence of 4 μg/ml Pap-A. Cell growth was 
measured by transformation of the dye Alamar Blue over approximately 3 hours 
at 37°C. The cho1ΔΔpositive control cells growth in the presence of Pap-A with 
no compounds from the library are represented by green circles. Compounds 
that allowed wild-type cells to display >90% (above the blue line) of the growth 
of cho1ΔΔ control were designated with filled-in blue circles. Around 95% of the 
tested compounds showed growth levels closer to the negative control, wells 
which contained no cells or drugs (open red circles). The horizontal lines show 
the 99th quantile (purple) where 99% of the compounds exhibited growth and the 
95th quantile (yellow) 95% of the compounds lie. The vertical lines divide the 
compounds by the 384-well plate in which they were screened which correlate to 
plate numbers along the bottom. A full description of the screening method is 
found in Materials and Methods. 
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21 compounds, were considered first round positive hits and were selected and 
tested for reproducibility in providing Pap-A resistance (data not shown).  Of 
these 21 first round hits, two compounds reproducibly conferred Pap-A 
resistance to the wild-type cells: SB-224289, a serotonin receptor antagonist 
(Selkirk, et al. 1998b), and MG-624, a nicotinic acetylcholine receptor antagonist 
(Fig. 2.3A). 
 Dose response curves were performed to determine the lowest 
concentrations of SB-224289 and MG-624 that could confer Pap-A resistance.  
Serial dilutions starting at 200 μM revealed that SB-224289 could confer 
resistance down to 25 μM, while MG-624 was not consistently effective at 
producing Pap-A resistance.  We found that effects of SB-224289 at 
concentrations above 400 μM could not be determined as this was greater than 
its solubility limit in the test media (data not shown).  Efforts were focused on SB-
224289, which showed consistent efficacy at a concentration range from 100 μM 
to 25 μM (Fig. 2.3B).   
 
 Identification of structural features that enable SB-224289 to confer Pap-A 
resistance 
In order to determine if Pap-A resistance is a property common to compounds 
with a similar structure to SB-224289, we searched the other compounds 
screened in our library and found one structural analog, GR127935, which did 
not provide Pap-A resistance (Fig. 2.4A, data not shown). Two other structural  
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Figure 2. 3. Compounds that Conferred Pap-A Resistance to C. 
albicans Wild-type Yeast 
(A) Structures of hits identified from the screen. (B) Comparison of the ability of 
the hits to confer Pap-A resistance to wild type C. albicans; SB-224289, MG-624, 
and DMSO as a control. 
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Figure 2. 4. The Full Structure of SB-224289 is Required to Provide Pap-A 
Resistance 
(A) and (B) show the structures of purchased or synthesized analogs of SB-
224289, respectively. In (C) and (D) 1x104 cells/ml were treated with a serial 
dilution of SB-224289, test compounds or DMSO control, and then allowed to 
incubate for 6 hours at 37°C. Pap-A was added at either 4 μg/ml or 5 μg/ml after 
6 hours the plate was incubated at 37°C overnight. Alamar Blue was added and 
fluorescence signal measured at 590 nm indicating survival of cells. 
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analogs of SB-224289, GMC 2-29 and SB-216641, were tested to assess their 
ability to confer Pap-A resistance to wild-type C. albicans (Fig. 2.4A&C).  We 
found that neither analog rescued cells when compared with the SB-224289 
control. This finding prompted us to hypothesize that the areas of structural 
dissimilarity between SB-224289 and GR127935, GMC 2-29, and SB-216641—
specifically the spirofuro-indole ring structure unique to SB-224289—may be the 
key to conferring Pap-A resistance. We synthesized four SB-224289 ring 
structure homologues, 2945, 2946, 3047, and 3048 (Fig. 2.4B), and tested their 
ability to provide Pap-A resistance to wild-type C. albicans. Although we 
expected protection against Pap-A at similar or even lower concentrations, none 
of the synthesized SB-224289 ring structures provided resistance to Pap-A (Figs 
2.4B & D). These data indicate that the full molecular structure of SB-224289 is 
required for producing Pap-A resistance to wild-type C. albicans. 
 
Exploration of the Mechanism of Action of SB-224289 
We hypothesized that SB-224289 inhibited the PS synthase enzyme, Cho1p, 
thus reducing levels of PS and allowing wild-type cells to survive despite the 
activity of Pap-A.  In order to test this hypothesis, we performed a PS synthase 
assay to assess the activity of Cho1p with the addition of varying concentrations 
of SB-224289.  Upon addition of SB-224289, no changes were seen in the 
activity of the Cho1p enzyme as compared to the wild-type control, indicating that 
SB-224289 does not directly inhibit the PS synthase enzyme in this in vitro assay 
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Figure 2. 5. SB-224289 and MG-624 Do Not Inhibit the Activity of Cho1p. 
PS synthase activity shown as counts per minute per milligram of protein, 
quantifying 3H-L-serine incorporated into PS. Addition of varying concentrations 
of SB-224289 (A) and MG-624 (B) did not have an inhibitory effect on PS 
production. 
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(Fig. 2.5A). Furthermore, a PS synthase assay was performed with MG-624 at 
varying concentrations. Again, no PS synthase inhibition was observed in any 
concentration tested (Fig. 2.5B). 
 To further investigate the mode of action of SB-224289, we assessed the 
compound’s ability to inhibit PS synthesis in vivo.  If the compound must be 
metabolized or modified internally in order to inhibit Cho1p, we should see a 
decrease in PS levels only when treating live cells with SB-224289.  Previous 
studies showed that cho1ΔΔ, which has no PS, shows a distinct phenotype of β 
(1-3)-glucan unmasking (Davis, et al. 2014b).  Based on this, we performed an 
assay to determine if treatment with SB-224289 would cause the β (1-3)-glucan 
in the cell wall to become exposed.  Cells were treated with SB-224289 for 3 
hours and then stained with β (1-3)-glucan antibody.  However, epifluorescence 
microscopy showed no indication that β (1-3)-glucan was exposed in SB-224289-
treated cells (data not shown).  PS is also a precursor for the synthesis of 
phosphatidylethanolamine (PE), in a pathway where PS is decarboxylated to 
form PE.  As a result, the cho1∆∆ mutant, since it lacks PS, requires 
ethanolamine in the medium so it can make PE from imported ethanolamine via 
the Kennedy pathway.  If SB-224289 is a PS synthase inhibitor, then it should 
have caused ethanolamine auxotrophy in wild-type C. albicans, however, this 
was not the case (data not shown). 
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Figure 2. 6. SB-224289 Protects Against Theopapuamide, but Not Other 
Depsipeptides. 
(A) The structure of several depsipeptides are shown. For each of these 
compounds, 1x104 cells/ml were treated with serially diluted concentrations of 
SB-224289 (SB) and were incubated for 3 hours at 37°C. Following this 
incubation, (B) 3 μg/ml valinomycin (VA), (C) 15 μg/ml kahalalide F (KF), or (D) 6 
μg/ml theopapuamide (TA) was added and further allowed to incubate overnight. 
Optical density (OD) was read at 600 nm the next day as a measure of cell 
survival. 
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SB-224289 specifically blocks the activity of Pap-A and not other 
membrane disruptors 
Naturally-produced depsipeptides share similar structures (Fig. 2.6) and can be 
medically relevant like the antibiotic valinomycin (VA) produced from 
Streptomyces spp. (Kroten, et al. 2010, Tempelaars, et al. 2011), the emetic 
toxin cereulide produced by the foodborne pathogen Bacillus cereus (Agata, et 
al. 1995, Andersson, et al. 1998, Kroten, et al. 2010, Zuberovic Muratovic, et al. 
2014), and anti-tumor drug prospect kahalalide F (KF) found in sea slugs 
(Suarez, et al. 2003).  A previous study found that a serotonin receptor 
antagonist, ondansetron hydrochloride, abolished the emetic effect of cereulide in 
Asian house shrews (Agata, et al. 1995).  Theopapuamide A (TPap-A) is a close 
structural relative of Pap-A and was previously shown to have potent antifungal 
activity (Plaza, et al. 2009, Ratnayake, et al. 2006).  Based on these studies, we 
were interested in determining if SB-224289 would block the activities of similar 
depsipeptide toxins. 
 First, we tested if SB-224289 could rescue cells from toxic levels of VA.  
We treated C. albicans with serially diluted concentrations of SB-224289, 
followed by treatment with 6 μg/ml of VA. We found that no concentration of SB-
224289 was sufficient to provide protection to cells (Fig. 2.6A).  We further 
measured the ability of SB-224289 to mitigate the toxicity of KF and TPap-A (Fig. 
2.6B & C).  SB-224289 was unable to protect wild-type cells against KF, but we 
found that SB-224289 was able to provide protection against TPap-A. 
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Discussion 
The screen described in this communication was originally intended to identify 
inhibitors of the fungal PS synthase. However, the identified hit compound, SB-
224289, does not inhibit PS synthesis even though it interferes with the lethal 
effects of Pap-A on C. albicans cells that contain PS. The evidence that SB-
224289 does not block PS synthesis comes from several secondary screens 
based on the cho1ΔΔ mutant’s characteristic phenotype (Chen, et al. 2010).  For 
example, the cho1∆∆ mutant is an ethanolamine auxotroph because C. albicans 
uses PS as a precursor for production of PE, a vital phospholipid, in one of its 
two PE synthesis pathways.   Thus, ethanolamine must be supplemented in the 
medium so that the organism can produce PE through the alternative Kennedy 
Pathway.  We saw no indication that treatment with SB-224289 caused wild-type 
C. albicans to become an ethanolamine auxotroph (data not shown), indicating 
that it does not interfere with PS synthesis.  A second useful phenotype is 
increased exposure of β (1-3)-glucan in the cell wall upon loss of PS.  The cause 
of this exposure in cho1ΔΔ is currently unknown, but it is very specific to the loss 
of PS rather than PE (Davis, et al. 2014b).  As with the previous assay, treatment 
with SB-224289 does not lead to exposure of ß (1-3)-glucan, thus indicating that 
it does not interfere with PS synthesis (data not shown).  Finally, SB-224289 did 
not interfere with PS synthesis in an in vitro assay (Fig. 2.5A).   
 The most interesting aspect of the blockade of the lethal effects of Pap-A 
on C. albicans by SB-224289 is its specificity.  Seven different analogs 
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representing fragments of SB-224289 or the entire molecule fail to rescue C. 
albicans from Pap-A-induced cytotoxicity. These results indicate that the activity 
of SB-224289 is specific and relies on the entire structure of the molecule (Fig. 
2.4), possibly, due to a specific three-dimensional conformation which could only 
be adopted by the full SB-224289.   In addition, SB-224289 could only inhibit the 
toxicity of depsipeptides that were structurally highly similar.  For example, we 
saw no indication that SB-224289 provided protection to wild-type C. albicans 
treated with VA or KF (Fig. 6).  However, as expected, SB-224289 was able to 
abrogate the cytotoxicity of TPap-A, a close structural relative of Pap-A (Fig. 6) 
likely to bind PS as well. Altogether, these data suggest that there might be a 
physical interaction between the two compounds that inhibits the toxic effects of 
Pap-A.  More specifically, structural differences in the tail regions of these related 
depsipeptides may confer their selectivity.   It is also possible that SB-224289 
impacts cellular physiology in a way that creates a protective response, but it is 
unclear what such a mechanism might entail. 
 Further studies are needed to understand the nature of the interaction 
between SB-224289 and Pap-A and the mechanism that leads to protection of C. 
albicans cells against Pap-A toxicity. Although SB-224289 is clearly not acting by 
inhibiting Cho1p, the selective inactivation of the Pap-A toxin by SB-224289 
indicates a path to the discovery of other compounds that can inactivate similar 
membrane active toxins.  In fact, the assay described herein could be easily 
adapted from use with Pap-A to any number of membrane potent toxins to find 
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antagonists.  The compounds discovered by this approach would be useful for 
treatments against environmental toxins that occur during algal blooms that affect 
drinking water, food contamination, etc.  It could also be useful as a method for 
identifying potential drug interactions that would counter-indicate compounds or 
combination therapies being considered as potential anti-cancer or anti-microbial 
drugs. 
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CHAPTER III 
SB-224289 DISRUPTS THE PROPER LOCALIZATION OF 
PHOSPHATIDYLSERINE, PHOSPHATIDYLINOSITOL (4,5)-
BISPHOSPHATE, AND THE PLASMA MEMBRANE ATPASE 1 IN 
SACCHAROMYCES CEREVISIAE 
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Abstract 
 
In previous work, a series of drug screens were performed in order to identify 
chemical inhibitors of the fungal phosphatidylserine (PS) synthase, as it 
represents an excellent drug target in pathogenic fungi. Preliminary studies on a 
promising hit, SB-224289, showed that this compound did not inhibit the PS 
synthase as was hypothesized, but acted by an unknown mechanism to provide 
resistance to the PS-specific toxin papuamide A. Further studies were conducted 
in order to understand the mechanism of action of SB-224289 using fluorescent 
microscopy of plasma-membrane-localized probes. Our studies suggest that SB-
224289 causes a physiological response in the model yeast Saccharomyces 
cerevisiae which we hypothesize is a disruption of cellular trafficking (i.e. 
112 
 
endocytosis). Further, preliminary screening of a lethal concentration of SB-
224289 against a mutant library of S. cerevisiae identified Rho5 as a possible 
target of SB-224289. Although this is speculation and remains to be 
experimentally tested, it is possible that SB-224289 interferes with this protein in 
some way. A compound that modulates endocytosis, like SB-224289 may, could 
prove useful in research on membrane trafficking. 
 
Introduction 
Our lab previously performed a drug screen to identify small molecule inhibitors 
of the fungal phosphatidylserine (PS) synthase. This enzyme represents an 
excellent drug target as it is absent in mammals, and has been shown to be 
important for virulence (Cassilly, et al. 2016, Chen, et al. 2010). This drug screen 
worked by identifying compounds that allowed Candida albicans to survive in the 
presence of the PS-specific toxin papuamide A. Pap-A works by binding PS and 
causing lysis and eventual death of cells (Andjelic, et al. 2008, Chen, et al. 2010). 
We hypothesized that compounds that allowed survival of C. albicans in the 
presence of Pap-A could be PS synthesis or trafficking inhibitors. 
 From this screen, we identified SB-224289 as possible inhibitor of PS 
synthesis in Candida albicans.  We found that certain concentrations of SB-
224289 resulted in cell survival in the presence of this toxin. Initial hypotheses 
were formed that SB-224289 inhibited PS synthesis, but these were rejected 
because cells treated with the drug did not share the same phenotypic 
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characteristics as the cho1ΔΔ mutant control. In addition, no direct evidence was 
observed that SB-224289 inhibited the function of the C. albicans PS synthase in 
an in vitro enzyme assay. Based on these findings, it was concluded that SB-
224289 likely interacted with Pap-A to produce resistance to the toxin, but no 
data could confirm this suspicion (Cassilly, et al. 2016). 
 Continued studies of the SB-224289 mechanism of action indicated that 
the compound may have a physiological effect on the fungus that was hidden 
from our previous methods of experimentation. We made various strains of 
Saccharomyces cerevisiae expressing fluorescent probes specific for PS, 
phosphatidylinositol 4,5-bisphosphate (PI4,5P2), and plasma membrane ATPase 
1 (Pma1), and determined the effect of SB-224289 on these probes. Our findings 
show that SB-224289 causes a disruption in the normal plasma membrane 
localization of all three fluorescent markers. These results indicate that SB-
224289 may disrupt normal plasma membrane trafficking in yeast. 
  In order to test these hypotheses, we performed a screen on the Boone 
Mutant Library of S. cerevisiae looking for mutants that were resistant to a lethal 
concentration of SB-224289 (Owen Ryan Ph.D. Thesis). From this screen, we 
were able to identify possible targets of SB-224289. 
 Based on our findings, it appears that SB-224289 does not interfere solely 
with phospholipid trafficking and localization, as was previous suspected. Rather, 
the results indicate that SB-224289 may disrupt the trafficking of some cellular 
components within cells. This conclusion is supported by the punctate 
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localization of GFP-Pma1p inside the cells treated with SB-224289. These 
punctate spots are likely vaculolar, where the protein is transported for 
degradation; however, further studies will need to be performed to confirm and 
support this hypothesis. Although SB-224289 does not act as an inhibitor of PS 
synthesis or trafficking, a compound that disrupts cellular trafficking could still be 
useful as a tool in general biological research. 
 
Materials and Methods 
Strain Production 
Wild-type Σ S. cerevisiae (TRY181) and a cho1Δ deletion mutant (BMY2), which 
is unable to produce PS, were used. Using a standard lithium acetate 
transformation method we created the strains used in this study (Gietz and 
Woods 2002). Transformation of GFP-Lact-C2 into WT and cho1Δ S. cerevisiae: 
GFP-Lact-C2 (pGFP-Lact-C2) was transformed into wild-type and cho1Δ using 
the URA3 marker to produce ura3Δ his3Δ pGFP-Lact-C2 and ura3Δ his3Δ cho1Δ 
pGFP-Lact-C2, respectively. Transformation of mCherry-Lact-C2 into WT and 
cho1Δ S. cerevisiae: mCherry-Lact-C2 (pGPD416-mCherry-Lact-C2) was 
transformed into wild-type and cho1Δ using the URA3 marker to produce ura3Δ 
his3Δ pGPD416-mCherry-Lact-C2 and ura3Δ his3Δ cho1Δ pGPD416-mCherry-
Lact-C2, respectively. Transformation of GFP-2x Ph(PLCδ) into ura3Δ his3Δ 
pGPD416-mCherry-Lact-C2 and ura3Δ his3Δ cho1Δ pGPD416-mCherry-Lact-C2 
S. cerevisiae: The GFP-2x Ph(PLCδ) was cut from pRS426GFP-2×PH(PLCδ) 
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using BamHI and SalI and ligated into pRS423 to produce pRF1. pRS423GFP-
2×PH(PLCδ) (pRF1) was transformed into ura3Δ his3Δ pGPD416-mCherry-Lact-
C2 and ura3Δ his3Δ cho1Δ pGPD416-mCherry-Lact-C2 using the HIS3 marker 
to produce ura3Δ his3Δ pGPD416-mCherry-Lact-C2 pRS426GFP-2×PH(PLCδ) 
and ura3Δ his3Δ cho1Δ pGPD416-mCherry-Lact-C2 pRS426GFP-
2×PH(PLCδ),respectively. Transformation of the CEN plasmid PMA1-GFP into 
WT and cho1Δ S. cerevisiae: pCEN PMA1-GFP wild-type and cho1Δ using the 
URA3 marker to produce ura3Δ his3Δ pCEN PMA1-GFP and ura3Δ his3Δ cho1Δ 
pCEN PMA1-GFP, respectively. 
All strains and plasmids used in this study can be found in Tables 3.1 and 3.2, 
respectively. 
 
Fluorescent Microscopy 
To confirm the presence and assess the localization of all fluorescent probes 
used, overnight cultures were diluted back to 0.1 or 0.2 OD600/ml and allowed to 
grow for 2-4 hours shaking at 30° C before fluorescent microscopy was 
performed on a Leica DMRXA microscope. All images were analyzed using Leica 
Application Suite 3.4. 
 
SB-224289 Treatment 
Overnight cultures of selected strains were diluted to 0.2 OD600 and allowed to 
grow for 3-4 hours. Cultures were then diluted to 0.1 OD600/ml and 100 - 200 μL  
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Table 3. 1. Strains Produced in this Study 
Strain  Organism  Genotype  Source  
Σ (TRY 181)  S. cerevisiae  ura3Δ his3Δ  Lab Strain  
BMY2  S. cerevisiae  ura3Δ his3Δ cho1 Δ  Lab Strain  
RF01  S. cerevisiae  
ura3Δ his3Δ pGFP-
Lact-C2  This study  
RF04  S. cerevisiae  
ura3Δ his3Δ cho1Δ 
pGFP-Lact-C2  This study  
RF09  S. cerevisiae  
ura3Δ his3Δ 
pGPD416-mCherry-
Lact-C2 This study  
RF10  S. cerevisiae  
ura3Δ his3Δ cho1Δ 
pGPD416-mCherry-
Lact-C2 This study  
RF21  S. cerevisiae  
ura3Δ his3Δ 
pGPD416-mCherry-
Lact-C2 pRS426GFP-
2×PH(PLCδ) This study  
RF18  S. cerevisiae  
ura3Δ his3Δ cho1Δ 
pGPD416-mCherry-
Lact-C2 pRS426GFP-
2×PH(PLCδ) This study  
CDCS41  S. cerevisiae  
ura3Δ his3Δ pCEN 
PMA1-GFP  This study  
CDCS42  S. cerevisiae  
ura3Δ his3Δ cho1Δ 
pCEN PMA1-GFP  This study  
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  Table 3. 2. Plasmids Used in this Study 
Plasmid Inserts Source 
p200 
(pGFP-Lact-
C2) 
GFP-Lact-C2, URA3, 
Cen/Ars, AmpR 
Yeung et al., 
2008 
pGPD416-
mCherry-
Lact-C2 
mCherry-Lact-C2, 
URA3, AmpR 
Fairn et al., 
2011 
pRS423 HIS3, AmpR Lab Strain 
pRS426GFP-
2×PH(PLCδ) 
GFP-2x Ph(PLCδ), 
URA3, AmpR 
Addgene 
plasmid # 
36092 
pRF1 
GFP-2x Ph(PLCδ), 
HIS3, AmpR This study 
pCENPMA1-
GFP 
PMA1-GFP, URA3, 
Cen, AmpR 
Balguerie et 
al., 2002 
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of the cells were either treated with 100 μM SB-224289 or an equivalent volume 
of DMSO as a negative control. This concentration of SB-224289 was shown to 
be non-fungicidal to the tested cell concentration in viable plate counts. All 
samples were then incubated at 30˚C shaking for 1 hour followed by fluorescent 
microscopy.  
SB-224289 Mutant Library Screen 
For every Saccharomyces cerevisiae mutant library 96-well plate being tested, 
10 ml of YPD was made containing either 50 μM SB-224289 or an equal volume 
of DMSO as a negative control. For every library 96-well plate being tested, 100 
μl of the corresponding media was added to each well, having one set of plates 
for SB-224289 and another set for DMSO. The 96-pin tool inoculator was placed 
in 100% ethanol and flamed to sterilize. The pins were then dipped into the stock 
S. cerevisiae mutant library plate after cooling. The pins were then dipped into 
the test plates to inoculate each well. Inoculated plates were placed in a 
stationary 30ºC incubator for 48 hours. 
 To measure the optical density, each well’s contents were resuspended by 
pipeting several times up and down to mix, then measuring the OD600 in a Biotek 
Cytation 5 Imaging Reader plate reader. Plates were incubated again at room 
temperature and checked again for growth after 72 or 96 hours. If growth was 
observed, OD600 was measured again. To ensure that no bacterial contamination 
had occurred during the experimental proceedings, all “positive hit mutant 
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strains” found in the SB-224289 plates were viewed under a Leica DMRXA 
microscope.  
 Once positive hits were found, the strains were streaked onto YPD and 
incubated at 30ºC for 1-2 days. After strains were grown up on YPD plates, liquid 
cultures of 5ml YPD with were inoculated and incubated in a shaking incubator at 
30ºC overnight. These cultures were diluted back to a 0.01 OD600/ml in 1ml YPD. 
A serial dilution of SB-224289 was then performed in a 96-well plate, with the 
highest final concentration of SB-224289 being 100 μM. Wild-type (TRY181) S. 
cerevisiae was used as a negative control. Plates were incubated at 30ºC for 1-2 
days and then optical density was measured, after mixing the wells, at 24, 48, 
and 72 hours. All strains that exhibited greater growth than TRY 181 at 50-100 
μM SB-224289 concentrations were considered hits and streaked again on YPD 
plates. 
 
Results 
After previous research with SB-224289 (Selkirk, et al. 1998b), we concluded 
that the compound did not inhibit PS synthesis within Candida albicans, as was 
hypothesized, but likely had a compound-compound interaction with Papuamide-
A (Cassilly, et al. 2016). The hypothesis of a compound-compound interaction, 
though explanatory for the Pap-A resistance provided by SB-224289, was never 
confirmed via experimentation (HPLC runs performed with both compounds were 
inconclusive (data not shown)). PS localization can be analyzed in the model 
yeast, Saccharomyces cerevisiae using a GFP labeled version of the C2 domain 
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of the bovine protein Lactadherin (Lact-C2) that specifically binds PS (Andersen, 
et al. 2000, Shi, et al. 2004).  We acquired a version of GFP-tagged Lact-C2 
(pGFP-Lact-C2) (Yeung, et al. 2008) which we transformed into our TRY181 and 
cho1Δ lab strains of Saccharomyces cerevisiae. The strains produced were: 
wildtype carrying pGFP-Lact-C2 and cho1Δ carrying pGFP-Lact-C2. Attempts 
were made to transform a codon-optimized GFP-Lact-C2 into C. albicans; 
however, the probe seemed to be expressed too highly in the chosen strains and 
did not show proper or expected localization (data not shown). Because of this 
problem, and the fact that many fluorescent probes can be easily used in S. 
cerevisiae, all studies done using GFP-Lact-C2 were performed in S. cerevisiae. 
 GFP-Lact-C2 localizes to the membrane in the wild-type where PS is 
enriched. In cho1Δ which is devoid of PS, GFP-Lact-C2 is diffuse throughout the 
cell. In an effort to understand the effect of various compounds on PS-
localization, we performed a series of compound treatments followed by 
fluorescent microscopy to determine where GFP-Lact-C2 localized as an 
indication of what might be happening to PS localization. In these experiments, 
we expected that SB-224289 would have no effect on GFP-Lact-C2 localization if 
the compound truly acted via an indirect method to inhibit Pap-A toxicity. 
However, our findings showed that treatment with 100 μM SB-224289 (shown to 
be non-lethal at the cell concentration in this plate assay as assessed by viable 
plate counts) caused a dramatic alteration in localization of the GFP-Lact-C2 in 
the cell (Fig. 3.1). These results indicated that SB-224289 could have a major 
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effect on PS trafficking or turn-over within the cell. In addition, the specificity of 
this physiological response is demonstrated by the fact that two structural 
analogs of SB-224289—GMC 2-29 and SB-21664—did not produce any 
disruption in GFP-Lact-C2 localization (Fig 3.1C). These data were replicated in 
wildtype and cho1Δ strains of S. cerevisiae carrying the red-fluorescently-marked 
Lact-C2 plasmid (pGPD416-mCherry-Lact-C2) (data not shown). 
 In order to further understand the extent of SB-224289 activity, we wished 
to determine if the compound had an effect on other phospholipid localization. 
The Plekstrin homology domain (PH domain) is a domain of approximately 120 
amino acids that has been shown to bind PI(4,5)P2 in the membrane of S. 
cerevisiae (Lemmon 2007). We hypothesized that localization of the PH domain 
fused with GFP (GFP-2x Ph(PLCδ)) would be unaffected by SB-224289 if the 
activity of the compound is specific to PS trafficking. 
 The plasmid pRS426GFP-2×PH(PLCδ) was transformed into wild-type and 
cho1Δ strains carrying pGPD416-mCherry-Lact-C2 to produce strains with a red 
fluorescent signal showing PS localization and green fluorescent signal showing 
PI4,5P2 localization. As expected, in the wild-type we saw localization of the 
GFP-2x Ph(PLCδ) at the membrane. Surprisingly, in cho1Δ we saw variable 
localization at the membrane, with part of the GFP-2x Ph(PLCδ) present as 
diffuse signal in the cytoplasm (Fig. 3.2). This is likely due to problems with 
phospholipid trafficking that are produced by the loss of PS. A recent paper  
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Figure 3. 1. SB-224289 Disrupts GFP-Lact-C2 Localization to PS 
(A) Fluorescent micrographs of GFP-Lact-C2 localization in cho1Δ, wild-type, 
or wild-type treated with SB-224289. (B) Quantification of GFP-Lact-C2 
localization to the plasma membrane in cho1Δ, wild-type, or wild-type treated 
with SB-224289. (C) Structural analogs of SB-224289, GMC 2-29 and SB-
216641 do not cause a disruption in GFP-Lact-C2 localization. 
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described a model where PS is delivered to the plasma membrane in a protein-
mediated exchange with PI4P (Moser von Filseck, et al. 2015). It is possible that 
the loss of PS causes a disruption in proper localization of PI species, and thus 
an alteration in the localization of the GFP-2x Ph(PLCδ), although this has yet to 
be confirmed. 
 We performed treatment of wildtype S. cerevisiae carrying pRS426GFP-
2×PH(PLCδ) and pGPD416-mCherry-Lact-C2 with 100 μM concentration of SB-
224289. Our expectation was that if SB-224289 activity was specifically altering 
PS localization or trafficking, that we may see no difference or change in GFP-2x 
Ph(PLCδ) localization, indicating no change in PI4,5P2 localization or trafficking. 
However, we saw diffusion of the GFP-2x Ph(PLCδ) away from the plasma 
membrane in cells treated with SB-224289 (Fig. 3.2). These results are similar to 
the GFP-Lact-C2 localization studies which may indicate that SB-224289 inhibits 
trafficking or turnover of PS at the plasma membrane, and further, has an impact 
on some PI species’ localization as well. 
 In order to determine if SB-224289 activity was specific to phospholipid 
trafficking, we wished to determine the effect of SB-224289 on membrane protein 
localization. To do this, we selected the highly abundant, membrane-bound 
ATPase, Pma1 (Schmitt, et al. 2006). We acquired the plasmid CEN PMA1-GFP 
from Dr. Amy Chang and Dr. Annick Breton (Balguerie, et al. 2002, Huang and 
Chang 2011) and transformed it into our TRY181 and cho1Δ lab strains. In both 
strains, Pma1-GFP is localized to the plasma membrane (Fig. 3.3). Our  
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Figure 3. 2. SB-224289 Disrupts GFP-2x Ph(PLCδ) 
Localization to PI(4,5)P2 
(A) Fluorescent micrographs of GFP-2x Ph(PLCδ) localization 
in cho1Δ, wild-type, or wild-type treated with SB-224289. (B) 
Quantification of GFP-2x Ph(PLCδ) localization to the plasma 
membrane in cho1Δ, wild-type, or wild-type treated with SB-
224289.  
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Figure 3. 3. SB-224289 Disrupts CEN PMA1-GFP 
Localization 
Fluorescent micrographs of CEN PMA1-GFP localization 
in cho1Δ, wild-type, or wild-type treated with SB-224289.  
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hypothesis was that if the SB-224289 activity is specific to phospholipid 
trafficking, it would not affect the localization of Pma1-GFP. Interestingly, when 
the wildtype and cho1Δ were treated with 100 μM concentration of SB-224289, 
we saw a mislocalization of Pma1-GFP into intracellular punctate spots (Fig. 3.3). 
These findings led us to hypothesize that SB-224289 causes a disruption in 
normal trafficking of cellular material (i.e. endocytosis), instead of having a 
specific effect on phospholipid trafficking alone. 
 In order to test this hypothesis, we attempted to treat Pma1-GFP cells with 
100 μM concentration of SB-224289 and then perform a western blot to compare 
expression of Pma1 protein to an untreated control. Our expectation was that if 
SB-224289 was causing an internalization of Pma1 that it would be degraded in 
the vacuole, causing a decrease in signal on the western blot. However, because 
of non-specificity of several GFP antibodies tested and the concentration of SB-
224289 required for treatment, we were unable to detect differences in Pma1-
GFP expression via western blot (data not shown). 
 Thus, we took a new approach to identify the pathway(s) targeted by SB-
224289 activity. To do this, we screened a Whole Genome Mutant Library of S. 
cerevisiae against a lethal concentration of SB-224289 (50 μM at this cell 
concentration) in a 96 well plate format (Ryan, et al. 2012). Cells that survived 
the high dosage of SB-224289 were considered hits and re-screened against a 
serial dilution of SB-224289. 
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 Of 3648 total strains tested, we found 96 resistant strains in the initial 
screen, resulting in a positive hit rate of 2.63% (Fig. 3.4). Of these initial hits, 27 
mutant strains came out as true positive hits from the serial dilutions, resulting in 
a positive hit rate of 28.12% from the initial screen hits, or 0.74% from the total 
library. Although this project has not been fully completed and our results are 
speculation at this point, one possible target in particular (Rho5p) seemed to be 
connected to many of the other possible targets identified (Fig. 3.5) indicating 
that it may be inhibited or affected in some way by SB-224289. 
 
Discussion 
In this project, we utilized fluorescent markers to examine the effects of SB-
224289 on localization of PS; PI4, 5P2; and Pma1p. In all cases, SB-224289 
caused a re-distribution of the fluorescent probes away from the membrane into 
cytosolic or punctate spots (Figs 3.1 – 3.3).  These findings demonstrate that SB-
224289 has a physiological effect on yeast cells as opposed to prior conclusions 
that SB-224289 simply produced Pap-A resistance via physical compound-
compound interactions. Based on the membrane probe disruption observed in 
our experiments, we hypothesized that SB-224289 might disrupt trafficking, (i.e. 
endocytosis) of cellular material. 
 In order to test this, we performed a large scale S. cerevisiae mutant 
library screen against a lethal concentration of SB-224289. We were able to 
identify a few possible targets of SB-224289. One target in particular seemed to 
have a connection to several of the other identified targets: a GTP-binding  
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Figure 3. 4. Screen of Mutant S. cerevisiae Library 
Of 3648 total strains tested, 96 were resistant to 50 μM SB-224289, resulting in a 
positive hit rate of 2.63%. All mutants treated with SB-224289 are shown in navy 
and hits are shown above the arbitrary hit line of 0.5 OD600. Negative control 
strains, treated only with DMSO, are shown in purple. 
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Figure 3. 5. Gene Maps Connecting True Hits from the Mutant Screen 
(A) All hits from the screen (shown in Table 3.3) are shown mapped with 
connections to one another. (B) RHO5 demonstrates a great number of 
connections with several other identified targets, supporting the case that this 
could be a main target of SB-224289. 
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protein, Rho5p. Rho5p regulates a MAP kinase branch of the PKC1-mediated 
signal transduction pathway, which is globally important for yeast physiology 
(Schmitz, et al. 2002). Thus, it is possible that by targeting Rho5p, SB-224289 
could interfere with this pathway and thus cause a disruption in normal celluar 
processes. However, because this is unconfirmed, these are only hypotheses 
that remain to be tested. 
 Currently we are in the process of transforming the true positive hit mutant 
strains of S. cerevisiae with the GFP-PMA1 and GFP-Lact-C2 probes to 
investigate how their localization differs with or without SB-224289 treatment. We 
are interested in both of these probes to assess whether SB-224289 continues to 
disrupt the localization of all components of the cell membrane by affecting 
certain proteins hypothesized as targets of SB-224289 function. 
 Further, we would like to analyze how SB-224289 might be impacting the 
localization of other proteins at the plasma membrane, like Ste2p. A GFP-tagged 
version of this lab has been produced in S. cerevisiae (Becker Lab) and we plan 
to treat this strain with SB-224289 to determine its effect on Ste2p. 
 Last, this project would also benefit by futher treating our fluorescent-
probe-expressing strains of S. cerevisiae with compounds known to block 
endocytosis, like Latrunculin, to determine which facet of cellular trafficking 
specifically is affected by SB-224289 treatment. 
 Although this project does not have a firm conclusion, it furthers research 
into the mechanism of action of SB-224289. We also were able to optimize 
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conditions for the mutant library screen, to which SB-224289 appeared to be very 
sensitive. This screening approach could easily be translated for use against 
other compounds with unknown mechanisms of action. 
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CHAPTER IV 
MAPPING THE SUBSTRATE BINDING SITES IN THE 
PHOSPHATIDYLSERINE SYNTHASE IN CANDIDA ALBICANS 
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Abstract 
 
The fungal phosphatidylserine (PS) synthase is required for virulence, conserved 
in fungi, but does not have a homolog in mammals, and thus represents a 
potential drug target in pathogenic fungi, such as Candida albicans. The 
substrate-binding sites of Cho1 have not been previously characterized, 
therefore we have performed biochemical characterization of this enzyme. Cho1 
has two substrates: cytidyldiphosphate-diacylglycerol (CDP-DAG) and serine. 
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Previous studies in phospholipid biosynthetic enzymes from a variety of 
microorganisms have identified a conserved CDP-alcohol binding motif, known 
as the CAPT motif, which is also present within the sequence of C. albicans 
Cho1. Sequence alignments between PS synthase and phosphatidylinositol (PI) 
synthases from several microbes were used to identify a putative serine binding 
site as well. Alanine site directed mutagenesis of both motifs has defined the 
crucial residues within both motifs that are required for PS synthesis, but are not 
required for protein expression or stability. The results of this project will lead to 
more direct and rational approaches for finding Cho1 inhibitors, helping ultimately 
to identify more effective antifungals. In addition, these findings provide a greater 
understanding of enzymes involved in fungal phospholipid biosynthesis. 
 
Introduction 
The phosphatidylserine (PS) synthase enzyme in Candida albicans represents 
an excellent drug target for three reasons: 1) It is required for virulence (Chen, et 
al. 2010), indicating that inhibitors of this enzyme would render the organism 
incapable of causing infection; 2) it is absent in mammals (Braun, et al. 2005), so 
inhibitors potentially would have no toxic side effects for the host; and 3) it is 
conserved among many fungi, so a drug could potentially be effective against 
multiple fungal pathogens. 
An important goal then is to discover an inhibitor of Cho1 that can be used 
as a lead compound for drug development.  In order to better facilitate this, the 
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binding sites for the two substrates of Cho1, cytidyldiphosphate-diacylglycerol 
(CDP-DAG) and serine need to be described. Small molecule screening is very 
effective approach to identify inhibitors of enzymes (Cassilly, et al. 2016), but we 
are also interested in taking a more rational approach for identifying inhibitors. 
This included biochemically identifying substrate binding motifs.  Identification of 
these sites in the protein can allow a more directed approach for identifying and 
modifying inhibitors via small molecule screening, which could ultimately increase 
chances of finding PS synthase inhibitors. 
 The PS synthase enzyme (originally denoted as: cytidine 5'-diphospho-
1,2-diacyl-sn-glycerol: L-serine O-phosphatidyltransferase) was first identified in 
Saccharomyces cerevisiae in 1980 (Atkinson, et al. 1980a, Atkinson, et al. 
1980c, Kovac, et al. 1980). Initial characterization of the yeast PS synthase 
included protein purification (Bae-Lee and Carman 1984, Letts, et al. 1983), 
determination of Michaelis-Menton kinetics (Bae-Lee and Carman 1984, Carman 
and Matas 1981, Carson, et al. 1982, Kovac, et al. 1980), understanding the 
regulation of Cho1 (Bae-Lee and Carman 1990, Bailis, et al. 1987, Carson, et al. 
1982, Hromy and Carman 1986, Kelley, et al. 1988, Kinney and Carman 1988, 
Letts and Henry 1985, Poole, et al. 1986), and identifying the localization of the 
enzyme (Kohlwein, et al. 1988, Kuchler, et al. 1986b). Beyond the fungal PS 
synthase, characterization of bacterial PS synthases was also performed 
(DeChavigny, et al. 1991, Dowhan 2013, Dutt and Dowhan 1977, Dutt and 
Dowhan 1981, Dutt and Dowhan 1985, Ge and Taylor 1997, Kanfer and 
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Kennedy 1964, Okada, et al. 1994, Raetz and Kennedy 1972, Rilfors, et al. 
1999). Within these studies, a distinction between the two subclasses of PS 
synthases was formed. Subclass I is present primarily in some Gram negative 
bacteria and subclass II is primarily found in Gram positive bacteria and yeast 
(Koonin 1996, Matsumoto 1997, Sohlenkamp, et al. 2004, Sung, et al. 1997). 
Last, characterization of mammalian PS synthases have also been performed, 
although these enzymes share little similarity to any microbial PS synthases, and 
indeed function by a completely different mechanism (Kuge and Nishijima 1997, 
Ohsawa, et al. 2004, Sturbois-Balcerzak, et al. 2001, Vance and Steenbergen 
2005b).  
 A highly conserved motif, D-(X)2-D-G-(X)2-A-R-(X)2-N-(X)5-G-(X)2-L-D-
(X)3-D, was identified in yeast phosphatidylinositiol synthase (PIS1), 
phosphatidylserine synthase (CHO1), and the E. coli 
phosphatidylglycerophosphate synthase (PGPS) (Gopalakrishnan, et al. 1986, 
Nikawa, et al. 1987a, Nikawa, et al. 1987b). This motif was further identified in 
yeast cholinephosphotransferase (CPT1) and ethanolaminephosphotransferase 
(EPT1) (Hjelmstad and Bell 1990, Hjelmstad and Bell 1991, McMaster and Bell 
1994). All of these enzymes bind alcohols and CDP-alcohols, and catalyze the 
formation of a phosphodiester bond between the CDP-alcohols and the 
secondary alcohol (Hjelmstad and Bell 1990, Hjelmstad and Bell 1991). 
Subsequently, threonine and serine residues located within this motif in E. coli 
phosphatidylglycerolphosphate synthase (PGPS) and Bacillus subtilis 
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phosphatidylserine synthase (PSS), respectively, were mutated to proline to 
determine the importance of this motif. While not a part of the conserved motif 
itself, this amino acid change in both circumstances was non-conservative and 
decreased enzyme activity, supporting the hypothesis that this motif is crucial for 
enzyme function (Saha, et al. 1996, Usui, et al. 1994), although with the caveat 
that proline could be disrupting the secondary structure of the protein. Since 
these initial studies, this CDP-alcohol phosphatidyltransferase (CAPT) motif, was 
narrowed to D-G-(X)2-A-R-(X)8-G-(X)3-D-(X)3-D, and was identified to be almost 
invariably conserved in numerous other lipid biosynthetic enzymes, including 
those of Gram positive and Gram negative bacteria, archea, fungi, plants, and 
mammals (Dewey, et al. 1994, Dryden and Dowhan 1996, Matsumoto 1997, 
Matsuo, et al. 2007, Sohlenkamp, et al. 2004, Tanaka, et al. 1996).  In 1998, 
Williams et al., characterized the CAPT motif in yeast CPT1 by alanine scanning 
mutagenesis which provided detailed importance of each residue within the 
conserved motif (Williams and McMaster 1998). 
 More recently, two enzymes from the CDP-alcohol 
phosphatidyltransferase family from Archaeoglobus fulgidus were shown to 
contain this motif on helices TM2 and TM3 of the solved crystal structures. In 
these studies, the CAPT motif was also widened to include an N-terminal 
aspartic acid, making the current, more general motif: D-(X)2-D-G-(X)2-A-R-(X)7-
12- G-(X)3-D-(X)3-D (Nogly, et al. 2014, Sciara, et al. 2014). This was further 
confirmed in the phosphatidylinositol-phosphate synthase from Renibacterium 
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salmoninarum where the CAPT motif was again found within TM2 and TM3 of 
the solved crystal structure (Clarke, et al. 2015). To our knowledge, these are the 
only three CDP-alchohol phosphatidyltransferase enzymes with solved crystal 
structures. 
 Based on the above studies there is sequence homology to guide a 
search for the CAPT motif in Cho1, but the motif specific for the other substrate, 
serine, is unknown.  In fact, for many of the CDP-DAG binding enzymes such as 
PI synthase and PGP synthase, the binding sites for the non-CDP substrate are 
unclear.  Thus, identification of the serine binding site—or some residues 
involved in serine binding, even if it is not the full motif—in Cho1 will facilitate a 
better understanding of this class of enzymes which are crucial for phospholipid 
biosynthesis in all kingdoms of life. 
 Previously we described the apparent Km and Vmax for PS synthase, as 
well as its role in the phospholipidome of C. albicans. Further, we probed the 
specificity of the active site of this protein for L-serine by competition assays with 
the closely related amino acids L-threonine and D-serine to an in vitro assay. We 
found that only very high concentrations of these substrates could compete with 
serine, indicating that the enzyme seems to be fairly specific for L-serine, which 
agrees with previous studies in S. cerevisiae and even E. coli (Bae-Lee and 
Carman 1984, Cassilly, et al. 2017, Kanfer and Kennedy 1964, Mitoma, et al. 
1998). Although these studies provided important preliminary information, they 
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did not reveal insights into the active sites themselves. In the present 
communication, we map the substrate binding sites for Cho1p. 
 
Materials and Methods 
Strains and Media 
In this study we used the cho1∆∆ (YLC337) and cho1∆∆::CHO1 (YLC344) 
mutants created within the SC5314 (wild-type) strain of C. albicans, which have 
been described previously (Chen, et al. 2010). The media used to culture strains 
was YPD (1% Bacto yeast extract, 2% Bacto peptone, and 2% dextrose (Thermo 
Fisher Scientific)) or minimal medium (0.67% yeast nitrogen base, 2% dextrose) 
supplemented with 1 mM ethanolamine where indicated (Guthrie 2002). 
 
Genetic Cloning and Site-Directed Mutagenesis 
The plasmid pYLC314 containing the MET3 promoter (PMET3) was generated by 
digesting pBluescript SK+ with EcoRI and ligating this to a PCR product carrying 
the SAT1 marker and PMET3 generated from pYLC229 that is flanked by EcoRI 
sites that were created by primers JCO165 and JCO166 (Chen, et al. 2008).  We 
also derived a vector from this one that lacks PMET3, but retains the SAT1 marker 
by digesting the plasmid with PstI, which cut on either side PMET3, to remove it, 
and then religated the vector to itself to create pBluescript-SAT1.  The CHO1 
gene was amplified from SC5314 genomic DNA using primer CCO54, which sits 
1000 bp upstream of CHO1 start site and includes a 5’ XhoI cut site, and CCO55 
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which sits at the 5’ end of CHO1 and includes a 3’ 2x HA tag followed by an AatII 
cut site. The downstream region of CHO1 was amplified using CCO56, which sits 
immediately downstream of the CHO1 stop codon and contains a 5’ AatII cut site 
followed by a 1x HA tag before the downstream sequence, and CCO57, which 
sits 500 bp downstream of the CHO1 stop site and includes a 3’ HindIII cut site. 
Once amplified, both fragments were double digested with their respective 
enzyme combinations. The plasmid pBluescript-SAT1 was digested with XhoI 
and HindIII and all three fragments were ligated together to create pCDC4. 
 Site-directed mutagenesis was performed using a primer based method. 
Forward and reverse primers approximately 35-40 bp in length were made for 
each mutation where the codon of interest was modified as conservatively as 
possible to produce alanine (Table 4.1). The plasmids were linearized with MluI 
prior to transformation into cho1∆∆ by electroporation.  PCR products generated 
from isolated genomic DNA from all SDM CHO1 transformant strains using 
primers CCO136 and CCO137 were sequenced using CCO105 or CCO20 to 
ensure that the genes were reintegrated correctly and that no spurious mutations 
had arisen. 
 To generate PMET3-PIS1, a 3X FLAG tagged version of PIS1 gene was 
amplified from pCDC21 using primers TRO1039 and TRO1043 which introduced 
BamHI and NotI sites, which were used to clone it into pYLC314 in front of the 
PMET3 promoter to produce pCDC27. For insertion of the putative PS synthase 
serine-binding motif into the PIS1 sequence, primers CCO141 and CCO142 were  
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Table 4. 1. Primers Used in this Study. 
Oligonucleotide  Sequence Mutation 
CCO20 GGAATCAAAAGATACTGTG   
CCO54 aaaactcgagCTGTAGAGCAGTTGGTTG    
CCO55 
aaaaGACGTCATAGGGATAGCCGGCATAGTCAGGAACAT
CGTATGGGTAAACGGCCGCTGGTTTAGGAATTTTTAAA
GAT    
CCO56 
aaaaGACGTCCCGGACTATGCAGGATCCTATCCATATGA
CGTTCCAGATTACGCTCCGGCCGCCTAGAGATGATTCT
AAAATAGAAT     
CCO57 aaaaaagcttCAGAACCAGAATTATTGTTTC   
CCO58 GGGGTTATTTTTCGATTTTTTTGctGGTAGAGTTGCAAG D128A 
CCO59 CTTGCAACTCTACCagCAAAAAAATCGAAAAATAACCCC D128A 
CCO60 ATTTTTCGATTTTTTTGATGctAGAGTTGCAAGATTAAG G129A 
CCO61 CTTAATCTTGCAACTCTagCATCAAAAAAATCGAAAAAT G129A 
CCO62 TTTTTGATGGTAGAGTTGCAgctTTAAGAAATAAATCATC R133A 
CCO63 GATGATTTATTTCTTAAagcTGCAACTCTACCATCAAAAA R133A 
CCO64 ATAAATCATCATTAATGGctCAAGAGTTAGATTCATTAG G142A 
CCO65 CTAATGAATCTAACTCTTGagCCATTAATGATGATTTAT G142A 
CCO66 TAATGGGACAAGAGTTAGctTCATTAGCTGATTTGGTATC D146A 
CCO67 GATACCAAATCAGCTAATGAagCTAACTCTTGTCCCATTA D146A 
CCO68 GTTAGATTCATTAGCTGctTTGGTATCATTTGGGGTATC D150A 
CCO69 GATACCCCAAATGATACCAAagCAGCTAATGAATCTAAC D150A 
CCO82 GTTGGGGTTATTTTTCGcTTTTTTTGATGGTAGAGTTG D125A 
CCO83 CAACTCTACCATCAAAAAAAgCGAAAAATAACCCCAAC D125A 
CCO88 GGTTTTATGTGGATTAACAgctTTGGCTAGATTTAATATC R186A 
CCO89 GATATTAAATCTAGCCAAagcTGTTAATCCACATAAAACC R186A 
CCO90 GATTAACAAGATTGGCTgctTTTAATATCTCCGTC R189A 
CCO91 GACGGAGATATTAAAagcAGCCAATCTTGTTAATC R189A 
CCO94 GGTTTTATGTGGATTAACAAGAgctGCTAGATTTAATATC L187A 
CCO95 GATATTAAATCTAGCagcTCTTGTTAATCCACATAAAACC L187A 
CCO96 CAAGATTGGCTAGAgcTAATATCTCCGTCAATAAC F190A 
CCO97 GTTATTGACGGAGATATTAgcTCTAGCCAATCTTG F190A 
CCO105 CTCTCAGTATTGTTCAAAC   
CCO141 
CTGATAACATAGCATACATATGCATATAAAATCTAGCCAA
TCTTGTTAATCCACATAAAACCCAATGAGATGATAAATCT
AAACTGACTAGT   
CCO142 
ACTAGTCAGTTTAGATTTATCATCTCATTGGGTTTTATGT
GGATTAACAAGATTGGCTAGATTTTATATGCATATGTATG
CTATGTTATCAG   
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used for site-directed mutagenesis to produce pCDC28. These plasmids were 
linearized with XbaI prior to transformation into C. albicans cho1∆∆ by 
electroporation (Chen, et al. 2010). All plasmids and strains can be found in 
Tables 4.2 and 4.3, respectively. 
 
Western Blots 
Protein isolation and western blotting were performed with some modifications to 
previously published methods (Piispanen, et al. 2013) and according to the 
manufacturers’ protocols (LI-COR). Cultures were grown overnight in 5 ml YPD, 
diluted to 0.1 OD600/ml in 25 ml of YPD and allowed to grow until reaching early 
log phase (0.7 – 1 OD600/ml). In the case of PIS1, the strains were grown 
overnight in minimal medium containing 1 mM ethanolamine until cultures 
reached log phase. Cultures were pelleted, washed with water and frozen 
overnight at -80°C. Pellets were then thawed on ice, resuspended in 1X PBS 
containing a protease inhibitor cocktail (Roche 4693124001) along with additional  
protease inhibitors (phenylmethylsuphonylfluoride (PMSF), leupeptin, and 
pepstatin (RPI P20270-5.0, L22035-0.005, P30100-0.005) and broken with 200 
μl volume of glass beads (Sigma G1145-500G) in a bead-beater at 4°C for one 
minute six times, with one minute pauses in between. Samples were spun at 
5,000 rpm for 1 minute to clear debris and transferred to a new tube on ice. 
Again, samples were cleared by spinning at 5,000 rpm for 8 minutes. This twice- 
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Table 4. 2. Plasmids Used in this Study 
Plasmid  Inserts  Source  
pYLC314-TBR NATR, AmpR  Lab Strain  
pCDC4  NATR, AmpR , CHO1 Shaner et al., 2004  
pCDC15  NATR, AmpR , CHO1D125A Fairn et al., 2011  
pCDC8  NATR, AmpR , CHO1D128A Lab Strain  
pCDC14  NATR, AmpR , CHO1G129A Addgene plasmid # 36092  
pCDC10  NATR, AmpR , CHO1R133A This study  
pCDC12  NATR, AmpR , CHO1G142A Lab Strain  
pCDC11  NATR, AmpR , CHO1D146A Lab Strain  
pCDC9  NATR, AmpR , CHO1D150A This study  
pCDC23  NATR, AmpR , CHO1R186A This study  
pCDC24  NATR, AmpR , CHO1L187A This study  
pCDC22  NATR, AmpR , CHO1R189A This study  
pCDC25  NATR, AmpR , CHO1F190A This study  
pYLC314 pMET3, NATR, AmpR  Joseph Chen, Reynolds Lab 
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Table 4. 3. Strains Produced in this Study. 
Organism  Marker  Plasmid  Gene/Mutation  Name  
C. albicans Nourseothricin  pCDC4  CHO1-HAx3 CDCS59 
C. albicans Nourseothricin  pCDC15  CHO1-HAx3D125A  CDCS60 
C. albicans Nourseothricin  pCDC8  CHO1-HAx3D128A  CDCS61 
C. albicans Nourseothricin  pCDC14  CHO1-HAx3G129A  CDCS62 
C. albicans Nourseothricin  pCDC10  CHO1-HAx3R133A  CDCS63 
C. albicans Nourseothricin  pCDC12  CHO1-HAx3G142A  CDCS64 
C. albicans Nourseothricin  pCDC11  CHO1-HAx3D146A  CDCS65 
C.albicans Nourseothricin  pCDC9  CHO1-HAx3D150A  CDCS66 
C. albicans Nourseothricin  pCDC23  CHO1-HAx3R186A  CDCS67 
C. albicans Nourseothricin  pCDC24  CHO1-HAx3L187A  CDCS68 
C. albicans Nourseothricin  pCDC22  CHO1-HAx3R189A  CDCS69 
C.albicans  Nourseothricin  pCDC25  CHO1-HAx3F190A  CDCS70 
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cleared supernatant was moved to fresh tubes on ice and a Bradford assay was 
performed to determine protein concentration. 
 Proteins were separated by SDS-PAGE. 40 μg of protein per sample were 
loaded into the wells of a 6% stacking/10% separating gel and run at 35 mAmps, 
followed by transfer to PVDF membranes (926-31099 LI-COR) using a blot 
module (GE Healthcare Life Sciences 80-6418-96) for one hour at 400 mAmps. 
Membranes were dried for one hour at room temperature, blocked using 
TBS:Odyssey Blocking Buffer (1:1) (927-50100 LI-COR), and incubated 
overnight at 4˚C in TBST:Odyssey Blocking Buffer (1:1) with primary antibodies 
according to the tag (HA.11; Covance (Reynolds, et al. 2008) or FLAG 637301; 
BioLegend 637301). The following day, after 4 washes in TBST at room 
temperature, membranes were incubated with IRDye® 680RD Goat-anti-Rat 
(926-68076) or IRDye® 800CW Goat-anti-Mouse (926-32210) secondary 
antibodies (LI-COR) at room temperature for at least one hour. Membranes were 
then washed 4x with TBST and then imaged using a LI-COR Odyssey scanner. 
 
In vitro PS Synthase Assay 
The PS Synthase assay was performed as described previously in (Cassilly, et 
al. 2017) with the exception that the 37°C incubation times were increased to 45 
minutes. 
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Protein Pull Down 
Protein was isolated as partially described in (Graham, et al. 1994) by growing 
200 ml YPD cultures to approximately 1.5 to 2.5 OD600/mL. Samples were 
centrifuged at 3,300 rpm for 5 minutes, then resuspended in 20 ml YPD 
(approximately 18 - 20 OD600/mL). Protease inhibitors (phenylmethylsuphonyl 
fluoride, leupeptin and pepstatin), 50 mM HEPES buffer, and 40 mM β-
mercaptoethanol (BME) was added. Zymolyase (~100 ug/ml) (120493-1 AmsBio) 
was added and cultures were shaken at 37°C for 1 hour. Resulting spheroplast 
cultures were centrifuged at 3,300 rpm for 5 min. Pellets were washed with 
spheroplasting buffer (1 M sorbitol, 20 mM Tris-HCl pH 7.5), then resuspended in 
approximately 5 ml resuspension buffer (1 M sorbitol, 10 mM triethanolamine pH 
7.5, 1 mM EDTA) and stored at –80°C. 
 The next day, cells were lysed using osmotic lysis (Graham, et al. 1994). 
Pellets were thawed on ice and then 20 ml of lysis buffer (0.1 M sorbitol, 10 mM 
triethanolamine pH 7.5, 1 mM EDTA) was added, sitting for 5 min. Dounce 
homogenization (>30 strokes) was then used on ice to break cells further. 
Homogenate was centrifuged at 4°C for 6 min at 1000 xg to clear unbroken cells. 
Supernatant was spun at 27,000× g for 10 min at 4°C and pellets were 
resuspended in residual liquid after eluting the supernatant. The thick mixture 
was mini-homogenized to break clumps. Last a Bradford assay was performed to 
quantify protein. 
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 The protein pull-down was described in part as in (Hauser, et al. 2007). 
2.5 mg of cho1ΔΔ::CHO1-HAx3 and cho1ΔΔ::CHO1 protein was incubated at 
37°C with 0.1 mM L-serine and 25 mM cysteine analog for 30 minutes. There 
was also an untreated control for both cho1ΔΔ::CHO1-HAx3 and cho1ΔΔ::CHO1.  
Following this incubation, the protein was solubilized in RIPA buffer (1X TBS, 
0.1% SDS, 1% Triton X-100) overnight, rotating at 4°C. The next day, according 
to the manufacturer’s protocol, Anti-HA magnetic beads (Pierce PI88836) were 
washed 2x in TBS-T (500 mM Tris Base, 1.5 M NaCl, pH 7.5, 0.05% Tween-20) 
using a magnetic stand. The beads were then added to the protein samples and 
again incubated overnight, rotating at 4°C. The following day, the samples were 
washed with RIPA buffer 4-5x. The samples were then washed 4x with TBS to 
remove all detergent. Samples were stored at 4°C or given directly for MS/MS 
analysis. 
 
Homology Modeling 
The homology model was produced using Molecular Operating Environment 
(MOE) software. A Protein Data Bank (PDB) search was performed using the 
Cho1 protein sequence, and was found to have at least 25% sequence similarity 
to the three published crystal structures in (Clarke, et al. 2015, Nogly, et al. 2014, 
Sciara, et al. 2014). Several homology models were produced using each of the 
three crystal structures as templates. The final homology model of Cho1p 
presented in this manuscript was produced by threading the sequence of Cho1p 
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onto AF2299, a CDP-alcohol phosphotransferase, which had approximately 
32.4% sequence similarity and 18.7% sequence identity with Cho1p (using the 
EMBOSS Stretcher alignment tool). 
 
Statistical Analysis 
All statistical analysis was performed on GraphPad Prism 7 using a student’s t-
test. 
 
Results 
The CDP-alcohol phosphatidyltransferase (CAPT) binding motif (D-G-(X)2-A-R-
(X)8-G-(X)3-D-(X)3-D) is almost invariably conserved in enzymes binding CDP-
alcohols even across kingdoms (Table 4.4), indicating the importance of this 
motif in the function of these types of enzymes (Okada, et al. 1994). One 
exception lies in some Gram negative bacteria, such as E. coli, where this motif 
is not present within certain enzymes (e.g. Pss) binding CDP-DAG, indicating 
divergence (Matsumoto 1997). 
 Previously Williams et al., performed detailed site directed mutagenesis on 
the CAPT motif in CPT1 cholinephosphotransferase in S. cerevisiae (Table 4.4). 
They found that mutation of Gly114, Gly127, Asp131, and Asp135 caused loss of 
activity while mutants of Ala117 and Arg118 showed a decrease in activity, and 
Asp113 showed wild-type activity (Williams and McMaster 1998). Using S. 
cerevisiae Cpt1 as a guide, we tested whether amino acids conserved in the  
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Table 4. 4. CAPT Motif Largely Conserved in Enzymes Binding CDP-
Alcohols Across Kingdoms 
Organism  Enzyme  CDP-Binding Motif  Reference  
C. albicans  PS Synthase  DFFDGRVARLRNKSSLMGQELDSLAD  
This 
research 
C. albicans  PI Synthase  DAFDGYAARKFNQGTRFGAVLDMVTD  
This 
research 
C. parapsilosis PS Synthase DFFDGRVARLRNKSSLMGQELDSLAD 
This 
research 
C. glabrata PS Synthase DFFDGRVARLRNRSSLMGQELDSLAD 
This 
research 
S. cerevisiae  PS Synthase  DFLDGRVARLRNRSSLMGQELDSLAD  
Takeda et 
al., 2014; 
Matsuo et 
al., 2007  
S. cerevisiae  CPT  DMHDGMHARRTGQQGPLGELFDHCID  
Williams et 
al., 1998  
S. pombe  PS Synthase  DFLDGKVARWRGKSSLMGQELDSLAD  
Matsuo et 
al., 2007  
B. subtilis  PS Synthase  DFFDGMAARKLNAVSDMGRELDSFAD  
Okada et al., 
1994  
R. 
salmoninarum  PIP synthase DIIDGLMARLLFREGPWGAFLDSYLD  
Clarke et al., 
2015 
S. meliloti  PS Synthase  DGIDGRIARLLKATSSFGVQMDSLAD  
Sohlenkamp 
et al., 2003; 
KEGG 
Sinorhizobiu
m meliloti 
1021  
A. fulgidus  
CDP-alcohol 
phosphotransferase 
AF2299 DGCDGEIARLKFMESKYGAWLDGVLD  
Sciara et al., 
2014 
A. fulgidus  IPCT-DIPPS AYYDGWIAREINRKVSLRISRL—LAD  
Nogly et al., 
2014 
* gray highlighted residues represent the conserved amino acids 
  
152 
 
CAPT motif of multiple enzymes shown in Table 4.4 were important for catalysis 
in the Candida albicans PS synthase using alanine site directed mutagenesis. 
 We generated an HAx3-tagged version of the CaCHO1 on a SAT1 
marked plasmid and integrated it into the cho1∆∆ mutant genome.  
Transformants were screened for expression of Cho1-HAx3 by Western blot (Fig 
4.1A) and the ability of a representative transformant expressing Cho1-HAx3 
expression to complement cho1∆∆ for PS synthase enzyme activity was tested.   
Cho1-HAx3 restored PS synthase activity to the cho1∆∆ strain (Fig. 4.1B).  In 
addition, the CHO1-HAx3 gene was able to at least partially restore growth to 
cho1∆∆ on minimal medium lacking ethanolamine (data not shown). 
It should be noted that several bands were observed that bound to an anti-
HA antibody, but none of these were present in the cho1∆∆ control (Fig. 4.1B). 
We suspect that the band at 34 KDa is the full-length protein, which correlates 
with the predicted molecular weight of 34.8 KDa. Proteolytic maturation of 
enzymes is a well-documented phenomenon (Hartmann, et al. 2014) and 
previous studies found similar findings with the PS synthase in S. cerevisiae 
(Choi, et al. 2010, Dey, et al. 2017, Kinney and Carman 1988), showing a 30 
KDa band and a 23 KDa band in western blot analysis. Although our band sizes 
differ (36, 34, and 29 KDa), we do see a difference of 7 KDa between our largest 
band and our smallest, which matches with what has been seen in S. cerevisiae. 
These previous studies found that the 30 KDa band was likely proteolytically 
degraded to produce the 23 KDa band, but that both forms of the protein were  
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Figure 4. 1. Enzyme Activity and Expression of Cho1p-HAx3 
(A) Western blot showing expression of Cho1p-HAx3 (HA1) as compared to a 
negative control. Several bands are present, possibly indicating degradation (29 
KDa) or phosphorylation of Cho1p (36 KDa). (B) Protein was collected from 
cho1ΔΔ, cho1ΔΔ::CHO1-HA, cho1ΔΔ::CHO1-HAx3 and used in an in vitro PS 
synthase assay. A small, but statistically significant decrease is seen in the HAx3 
tagged version of Cho1p. * p = 0.0013 
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active (Kinney and Carman 1988, Kohlwein, et al. 1988). 
 
Confirmation of the CAPT-Motif’s Importance in Enzyme Activity 
We performed site-directed mutagenesis of the non-alanine residues in the 
CAPT motif. Each residue was mutated to alanine within the CHO1-HAx3 in the 
pCDC4 plasmid as described in materials and methods. The mutant plasmids 
were transformed into cho1ΔΔ, checked for correct reintegration by PCR and 
then colonies representing each mutation were screened for those that showed 
expression of Cho1-HAx3 similar to wild-type by western blot (Fig. 4.2, Table 
4.5). Membranes were isolated from each of the amino acid substitution mutants, 
along with cho1∆∆::CHO1-HAx3 and cho1∆∆ controls, to assess activity of each 
mutant protein by the in vitro PS synthase assay. In contrast to the findings in the 
CAPT domain from S. cerevisiae Cpt1p (Williams and McMaster 1998), the 
D125A, D128A, G142A, and D146A from the Cho1 PS synthase CAPT motif 
showed 0% of Cho1p-HAx3 activity. G129A and D150A showed 4% and 67.5% 
of the Cho1p-HAx3 activity, respectively (Fig. 4.3). The R133A mutant originally 
showed decreased activity, however this reintegrated plasmid also showed lower 
expression levels by western blot, so, we performed another enzyme assay on a 
highly expressed R133A mutant and found that activity correlated with 
expression, leading us to believe that R133A does not significantly impact the 
activity of Cho1p-HAx3 (Fig. 4.3, data not shown). 
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Figure 4. 2. Expression of Cho1p-HAx3 CAPT Motif Mutants 
Protein was collected from cho1ΔΔ, cho1ΔΔ::CHO1-HAx3 (HA1) and each CAPT 
motif point mutant used in a western blot to assess expression. Expression from 
two western blots per mutant were quantified against tubulin standards using 
Image J and the average was taken to determine approximate expression values 
(shown in Table 4.5).  
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Table 4. 5. Average (AVG) expression via 
western blotting (WB) CAPT motif (top) and 
predicted serine binding motif (bottom) 
mutants 
Strain WB#1 WB#2 AVG % WT  
cho1ΔΔ  1.724 0.887 1.3055 4.3 
HA1  31.685 28.325 30.005 100 
D125A  36.884 18.863 27.874 93 
D128A  67.666 27.896 47.781 159 
G129A  131.73 53.005 92.368 308 
R133A  16.29 20.702 18.496 62 
G142A  20.758 13.762 17.26 58 
D146A  14.069 35.931 25 83 
D150A  26.714 24.955 25.835 86 
          
cho1ΔΔ  0.061 0.1421 0.1015 0.9 
HA1  3.1951 20.359 11.777 100 
R186A  3.4295 14.435 8.9324 81 
L187A  2.1733 12.09 7.1315 65 
R189A  1.7103 19.024 10.367 95 
F190A4  1.3978 17.989 9.6934 88 
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Figure 4. 3. Enzyme Activity of Cho1p-HAx3 CAPT-Motif Mutants  
Protein was collected from cho1ΔΔ, cho1ΔΔ::CHO1-HA, cho1ΔΔ::CHO1-HAx3 
and each of the CAPT motif point mutants and used in an in vitro PS synthase 
assay. All mutants show statistically significant decrease or abolishment of 
activity. * p = 0.0046, ** p = 0.0016, all other = p < 0.0003  
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Assessment of Predicted Serine Binding Motif’s Role in Enzyme Activity 
In addition to CDP-DAG, Cho1 also binds serine as a substrate, and we were 
interested in determining the serine binding site of Cho1. The serine binding site 
is of particular interest in this study as CDP-DAG binding is common to several 
enzymes that bind CDP-alcohols, whereas the serine binding site is more 
specific to this enzyme. 
 However, unlike the CAPT motif, there is little known, to our knowledge, 
about where serine binds in Cho1. Previous work on the mammalian PS 
synthase, PSS1, identified an asparagine (Asn-209) residue as likely playing a 
role in serine binding or recognition (Ohsawa, et al. 2004). However, as the Cho1 
protein from C. albicans shares little amino acid similarity with mammalian PSS1, 
and in sequence alignment, a corresponding Asn-209 residue is entirely absent 
within CHO1, this informed our search relatively little. 
 We took a two-pronged approach to identify where serine might bind in 
Cho1.  PI synthase and PS synthase from yeast are similar enzymes in that both 
bind CDP-DAG and a small molecule as substrates to generate their respective 
phospholipids. Candida albicans Pis1 shares 28.5% amino acid similarity with 
Cho1 and only differs enzymatically in binding inositol instead of serine. We 
hypothesized that alignment and comparison of sequences between the two 
genes might reveal a conserved serine binding site in Cho1. We aligned the Pis1 
amino acid sequences from C. albicans, Saccharomyces cerevisiae, and 
Schizosaccharomyces pombe with the Cho1 amino acid sequence from the 
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same organisms (Fig. 4.4). From this alignment, we found a highly conserved 
sequence in all of the PS synthase linear sequences that was entirely absent 
from the Pis1 linear sequences (X-V-L-C-G-L-X-R-L-A-R-F).  We predicted that 
this might be part of the serine binding motif. Site directed mutagenesis of the 
latter portion of the motif was performed as described previously for the CAPT 
motif. We screened for colonies with roughly equal average expression of mutant 
forms of CHO1-HAx3 compared to the cho1ΔΔ::CHO1-HAx3 background strain 
(Fig. 4.5A, Table 4). We isolated membranes from each mutant and the control 
(wild-type and cho1∆∆) strains and performed an in vitro PS synthase assay to 
compare them. Each mutated residue in the latter portion of this motif 
demonstrated a complete abolishment of activity as assayed in our in vitro 
enzyme experiment with the exception of F190A which showed 59% of the 
background activity (Fig. 4.5B).  
 
Homology Model Predicting Cho1p Structure 
Cho1 is a membrane protein that has not yet been crystalized. However, there 
are several CDP-alcohol binding phospholipid biosynthetic proteins that have 
been crystalized recently. Using Molecular Operating Environment software, we 
threaded the sequence of CHO1 onto the solved crystal structures of these 
proteins: two archeal and one bacterial membrane-bound proteins with CAPT 
motifs (Clarke, et al. 2015, Nogly, et al. 2014, Sciara, et al. 2014). This 
experiment produced a homology model that demonstrates the close proximity of  
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Figure 4. 4. Sequence Alignment Reveals Possible Serine Binding Motif 
Alignment of a portion of the PS synthases and PI synthases from C. albicans, S. 
cerevisiae, and S. pombe. Highly conserved sequence, hypothesized to be 
serine binding site in PS synthases, is highlighted in yellow.  
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Figure 4. 5. Expression and Enzyme Activity of Cho1p-HAx3 Predicted 
Serine Binding Motif Mutants 
(A) Protein was collected from cho1ΔΔ, cho1ΔΔ::CHO1-HAx3 (HA1) and each 
predicted serine binding motif point mutant used in a western blot to assess 
expression. Expression from two western blots per mutant were quantified 
against tubulin standards using Image J and the average was taken to determine 
approximate expression values (shown in Table 4.5). (B) Protein was collected 
from cho1ΔΔ, cho1ΔΔ::CHO1-HA, cho1ΔΔ::CHO1-HAx3 and each of the 
predicted serine motif point mutants and used in an in vitro PS synthase assay. 
All mutants show statistically significant decrease or abolishment of activity. * p = 
0.0032, all other = p < 0.0001  
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the serine binding site (yellow) with the CAPT motif (cyan) (Fig 4.6). These data 
further support the findings in our experimental work. 
 
Discussion 
 In this study we found that most of the amino acids in the predicted CAPT 
motif in C. albicans Cho1-HAx3 are necessary for PS synthesis. However, there 
were some differences from what has been observed in the CAPT motifs from 
some other enzymes.  For example, as opposed to the findings in S. cerevisiae 
Cpt1 (Williams and McMaster 1998), only mutations of Asp125, Asp128, Gly142, 
and Asp146 caused loss of activity, while mutations of Gly129 and Asp150 
showed a severe to modest decrease in activity, and Arg133 showed nearly wild-
type level activity (Fig. 4.3). In the Cpt1 enzyme from S. cerevisiae, Williams et 
al., published that replacing Gly114, Gly127, Asp131, and Asp135 with alanine 
abolished enzyme activity, while Ala117 and Arg118 mutants displayed 
decreased activity and mutation of Asp113 had no detectable effect on enzyme 
function (Williams and McMaster 1998). Williams and McMaster noted that, 
because the amino acid glycine does not have a functional group, it is possible 
that the importance of the glycine residues could be steric and control binding or 
positioning of the substrates. Further, the alanine and arginine residues within 
the Cpt1 CAPT motif were predicted to be important in binding and positioning of 
the CDP-alcohol substrate (Williams and McMaster 1998). 
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Figure 4. 6. Predicted Structure of Cho1p Based on Homology Modeling  
(A) Cho1p amino acid sequence was threaded onto the crystal structure of the 
AF2299 CDP-alcohol phosphotransferase (PDB accession number 4O6N via 
Clarke et al., 2014) using Molecular Operating Environment 2015.1 software. The 
CAPT motif is shown in cyan and the predicted serine binding motif is shown in 
yellow. (B) Shows a closer view of the proximity of the CAPT motif to four amino 
acids of the predicted serine binding site. 
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Figure 4.6 continued  
A 
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Figure 4.6 continued  
 
 
B 
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 Last, the final two aspartic acid residues within the yeast Cpt1 were 
identified as probable catalytic residues (Williams and McMaster 1998). Within C. 
albicans Cho1p-HAx3, we did not see a severe loss of activity for the D150A 
mutation, which was the case for the second aspartic acid in the motif in yeast 
CPT1. As a result, we suspect the catalytic residue in C. albicans Cho1p is one 
of the three remaining aspartic acids: D125, D128, or D146. Despite the slight 
differences between our findings and those of the yeast CPT1, which is not 
totally unexpected given the difference in substrate and organism, our data 
supports and confirms the importance of the CAPT motif in proper enzyme 
function of Cho1p in C. albicans (Williams and McMaster 1998). 
 In addition to confirming the importance of the predicted CAPT motif in 
Cho1, we predicted a possible serine-binding motif based on sequence 
alignment from three different yeasts. This motif, X-V-L-C-G-L-X-R-L-A-R-F, is 
highly conserved across PS synthase orthologs in these organisms, while it is 
entirely absent from the Pis1p enzymes of the same three organisms (Fig. 4.4). 
Site directed mutagenesis of the latter four residues in the motif produced an 
almost complete abolition of activity. The only exception was the F190A mutation 
which statistically significantly decreased activity, but only to 59% that of the 
background strain (Fig. 4.5B). Although from these results we cannot say for 
certain whether our mutations are affecting substrate binding, catalysis, or 
protein stability/folding, it is clear that this sequence is critical for enzyme 
function. 
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 In order to gain some insight into how these motifs might be arranged 
relative to one another, we produced a homology model of Cho1. This homology 
model, created by threading Cho1 sequence on the solved structures of other 
membrane-bound CAPT-motif-containing proteins (Clarke, et al. 2015, Nogly, et 
al. 2014, Sciara, et al. 2014), has provided at least a preliminary view of what 
Cho1 might look like. The model predicts a six-transmembrane domain protein 
structure with relatively close proximity of the predicted substrate binding sites. 
Many of the residues within the CAPT motif are charged and have been found to 
be part of a hydrophilic face of the 2nd and 3rd transmembrane domains of this 
protein (Saha, et al. 1996). This correlates well with the homology model which 
shows the CAPT motif spanning TM (2/3). The predicted serine-binding motif 
(yellow) is located deep within the hypothesized membrane-bound portion, but it 
is possible that there is a hydrophilic core that might allow substrate entry into 
this site. This correlates well with the hypothesis that C. albicans Cho1 has a 
cytosolic-facing hydrophilic core where substrates bind, which has been 
demonstrated in PIS1 in yeast (Bochud and Conzelmann 2015). There is a long, 
unstructured N-terminus that is predicted to be soluble and is likely important for 
proper membrane insertion, although this has yet to be confirmed in C. albicans 
(Sperka-Gottlieb, et al. 1990). 
 We have demonstrated here, for the first time, the importance of the CAPT 
motif within the PS synthase from a medically-relevant, pathogenic fungus. 
Further, we have begun efforts to identify binding location of the second 
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substrate in this reaction, an area that is still relatively unstudied. We have 
produced a homology model of Cho1p that places both of the substrate binding 
sites in close proximity. These findings contribute not only to the general 
understanding of phospholipid synthesizing enzymes, but also provide crucial 
information on candidate locations of this protein where binding of small 
molecules may inhibit activity. Because Cho1p represents such a promising drug 
target, this data may lead to a more refined approach for discovering inhibitors.  
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CONCLUSION 
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The findings from the projects in this dissertation have not always returned 
expected results; however, they have provided some interesting and beneficial 
data nonetheless. The primary goal of this work began as a search for small 
molecules that inhibit the phosphatidylserine (PS) synthase enzyme in Candida 
albicans. The secondary goal, which became equally as important as the 
primary, was the characterization of the PS synthase protein itself. 
 One of the first projects undertaken in this work was to describe the PS 
synthase’s contribution in the phospholipidome of C. albicans. Previous studies 
described the phospholipid content of C. albicans, or showed PL mutant’s 
phospholipid profile via TLC, but the work described in chapter two is the first 
time mass spectrometry was used to define the lipid profiles of certain PL 
mutants. In this study, we were able to identify that specific species of PS were 
preferentially used to produce PE. In addition, we found that, in the event that 
ethanolamine and choline are readily available within the medium, the Kennedy 
pathway is able to compensate for the de novo loss of PE and PC production. 
We were also able to describe the enzyme kinetics for the PS synthase, the 
values of which correspond well with previously published data for 
Saccharomyces cerevisiae. These data helped to inform our screening 
approaches described next. 
 In chapter three, the use of cho1ΔΔ mutant phenotypic traits as indicators 
that compounds inhibit the PS synthase is discussed. This project looked for 
compounds that could counteract Papuamide A, which is toxic to cells containing 
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PS in their membranes. Thus, by counteracting Pap-A toxicity, hit compounds 
were hypothesized to inhibit PS production by inhibiting PS synthase activity. 
 We identified a compound, SB-224289, which showed reproducible Pap-A 
resistance. After further characterization, we concluded that SB-224289 did not 
behave as we hypothesized, indicating that this trait of providing Pap-A 
resistance was not specific enough for use in large scale screens. Indeed, at the 
end of this chapter, we concluded that SB-224289 likely physically interacted with 
Pap-A to abrogate the negative effects of the toxin. 
 Interestingly, as described in chapter four we found that when we 
continued experimentation on SB-224289 in S. cerevisiae, it seemed to disrupt 
proper localization of PS and another phospholipid PI54P. Thus, SB-224289 did 
not behave by inhibiting the PS synthase enzyme, but instead controlled some 
facet of phospholipid trafficking. Further investigation showed that SB-224289 
treatment also caused a disruption in proper localization of Pma1p, a membrane 
bound ATPase. Based on this, it seemed that SB-224289 activity acted more 
generally by disrupting some component of cellular trafficking, possibly 
endocytosis. We performed a screen on yeast homozygous mutants to determine 
the intracellular target of SB-224289. In this assay, although it is as yet 
incomplete, we identified Rho5p as a possible target for SB-224289. The direct 
mechanism is unclear at the current time, but as Rho5p is active in many 
pathways, it is conceivable that SB-224289 could interfere with one branch 
pathway that controls endocytosis within yeast. However, this is speculation at 
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the current time and further research will be conducted to either confirm or refute 
these hypotheses. While unexpected given our initial goals of the Pap-A toxicity 
screen, it still produced interesting results as a compound that induces large-
scale endocytosis could be useful in laboratory work. 
 In addition, as described in appendix three we performed a second Pap-A 
toxicity screen, this time on plant extract fractions. It is well known that many 
plants have innate defenses against fungal pathogens. Thus, we hypothesized 
that there might be PS synthase inhibitors in the secondary metabolite milieu 
produced by plants. We performed another screen and identified a fraction from 
the leaf extract of the rain tree that allowed C. albicans to survive in the presence 
of Pap-A. As described for SB-224289, we found that the rain tree extract did not 
inhibit PS synthase as we hypothesized. We continued characterization of this 
plant extract in an attempt to identify the bioactive component, but found that the 
complexity of molecules within the plant extract precluded our ability to isolate 
the single molecule producing our phenotypic trait. 
 Because of the difficulties encountered with our Pap-A toxicity screening, 
we tried to take a more direct approach to identify compounds that inhibit the 
fungal PS synthase. To do this, we used a phenotypic trait of cho1ΔΔ as an 
indicator that the PS synthase had been inhibited. As described in appendix one, 
this phenotypic trait was ethanolamine auxotrophy. Ethanolamine auxotrophy 
describes cells that must have ethanolamine provided in the medium to survive. 
This is a trait of cho1ΔΔ because PS is a precursor to the de novo production of 
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PE, which is an essential phospholipid. Without PE, the cells cannot grow. 
However, there is a secondary, scavenging pathway called the Kennedy pathway 
that produces PE without the requirement for PS first. We hypothesized that PS 
synthase inhibitors would cause the cells to become ethanolamine auxotrophs, 
and thus unable to grow in minimal medium deplete of ethanolamine. We 
performed a screen on small molecules, looking to identify ones that might cause 
ethanolamine auxotrophy in minimal medium. Any positive hits that were 
identified in this initial screen were then further confirmed by adding 
ethanolamine back to the medium and looking for a recovery of growth (via the 
Kennedy pathway of producing PE from exogenous ethanolamine). 
 Although we found positive hits in our initial screen, we never identified a 
compound that showed a reproducible return of growth when ethanolamine was 
returned to the medium. However, although we did not find compounds that 
induced ethanolamine auxotrophy, and thus inhibit the PS synthase, we did 
identify a compound that showed effective inhibition of growth of C. albicans. 
This compound, called Lee-3664, showed effective killing of C. albicans at low 
concentrations, while also showing relatively low cytotoxicity against mammalian 
cells. Based on this, further characterization of this compound, as well as 
chemical modification of its structure, is underway with collaborators at St. Jude. 
 Because of the difficulties we faced with the high-throughput screening 
approaches with small molecules, we became interested in taking a different 
approach for identifying PS synthase inhibitors. We hypothesized that, by 
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identifying the important functional locations on PS synthase, we might be better 
able to target those in a rational manner. Thus, in order to do this, we performed 
various site-directed mutagenesis experiments to identify substrate binding sites 
on the protein. 
 As described in chapter five, the fungal PS synthase is known to bind to 
CDP-DAG and serine. Previously published data has shown a well-conserved 
motif for many enzymes that bind CDP- molecules. We performed site-directed 
mutagenesis on this sequence within the PS synthase and found that indeed 
there was a significant decrease in enzymatic activity upon loss of many of these 
amino acids. In addition to the CDP-DAG binding site, we were interested, 
perhaps more so, in determining where serine binds the protein. Unlike CDP-
DAG, there is little in the literature known about where serine binds in any 
protein. Thus, we performed sequence alignments of fungal PS synthase and PI 
synthases to guide our hypothesis of where serine binds. We identified an amino 
acid sequence that was well conserved across several fungal PS synthases but 
absent in PI synthases.  When the amino acids in this sequence were mutated 
individually to alanines, the enzyme showed a complete abolishment of activity. 
Although at this point we cannot say for certain whether this is the true binding 
site of serine or these amino acids are important in another way for the enzyme 
function, this characterization has revealed another location on the protein where 
inhibition may be beneficial in stopping the function of the enzyme. 
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 Last, there is little known about PS trafficking and dynamics within any 
organism. Because of this, we were interested in determining how long PS 
remains at the plasma membrane of S. cerevisiae. As described in appendix two, 
we produced several yeast strains carrying fluorescent molecules to demonstrate 
localization of PS. We also wished to put the PS synthase under a repressible 
promoter whereby we could control the production of PS and follow its 
movement, appearance, or disappearance within the cell. Unfortunately, all 
attempts at producing repressible PS synthase in this yeast were not entirely 
successful at producing a clean shut off of PS expression. As a result, we used 
lyso-PS treatment in a cho1Δ to measure PS duration at the membrane. This 
lyso-PS was added exogenously into the medium of cho1Δ cells which took up 
the lyso-PS, modified it in the ER, and then returned it to the plasma membrane. 
We observed an appearance of PS at the membrane within fifteen to thirty 
minutes that remained up to 300 minutes after removal of exogenous lyso-PS, 
although diffusion began to occur at later time points. These findings, although 
not exactly as occurs naturally, demonstrate the potential for PS to remain in the 
membrane for extended periods of time. 
 The last project we worked on was crystallization of Cho1p as described in 
appendix four. Although this project was begun too late for a structure to be 
solved, we did take the first important steps for protein crystallization. Strains of 
S. cerevisiae were produced where both the S. cerevisiae and C. albicans PS 
synthase were highly expressed and tagged with Hisx6. These strains will allow 
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isolation and purification of the protein in future experiments using affinity 
chromatography. Although it may be a daunting task, once a crystal structure is 
solved, it will greatly advance our understanding of the protein in general, and as 
a drug target. In fact, modern technology allows for computational screening with 
solved protein structures whereby small molecules can be docked within the 
proposed active site of the protein. These identified molecules that “fit” well into 
the active site would then further be tested in in vitro and in vivo assays to 
determine efficacy. As described in chapter five, a homology model was 
produced that predicted the structure of the PS synthase, but it is well 
documented that homology models are not always accurate. We attempted to 
use the homology model of Cho1p in the computational screen, but the 
parameters determining “hit” compounds were too loose, allowing too many hits 
to be identified. Thus, it is our intention to perform another computational screen 
with increased confidence once a crystal structure is solved. 
 In addition to the future computational screen, another screening 
approach is underway. This approach utilizes three different expression profiles 
of the drug target in genetically altered C. albicans. First is an overexpressed 
version of the protein, second is a wild-type version, and third is an under- or 
non-expressed protein. Each of these strains also expresses a unique 
fluorescent marker that differentiates it from the other strains. These strains are 
pooled in 96-well plates and treated with the compound of interest. After 
incubation, fluorescence is monitored to determine if there has been an effect on 
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the strains. If the target itself is being specifically inhibited, there should be a 
dose-response of efficacy. For instance, the overexpressed strain should be 
completely inhibited as there is more target for the compound to inhibit. The wild-
type should also be susceptible, but perhaps to a lesser degree. And last, the 
deletion or under-expressed protein strain should grow relatively well since the 
drug target is present in decreased levels. Thus, this method allows 
differentiation of compounds that are outright toxic (i.e. kill all of the strains) and 
those that are selectively toxic based on the drug target. 
 This approach is in the beginning stages with Glen Palmer and 
collaborators from the UT Health Science Center. Strains have been constructed 
and large scale screens are slated to go forward. This methodology seems 
promising and will hopefully reduce much of the nonspecific activity of drugs that 
we have seen in our previous screening approaches. 
 In conclusion, the work in this dissertation has described an entirely new 
physiological behavior for the compound SB-224289. Although a clear answer for 
its exact mechanism is not known, a molecule that disrupts proper trafficking of 
cellular material (i.e. endocytosis) could be useful in labs that study of these 
processes in yeast. 
 Further, the findings of this dissertation have provided a greater general 
understanding of Cho1p and its importance and activity within the pathogenic C. 
albicans. Research is still underway to more-confidently describe the substrate-
binding sites of Cho1p, but our findings demonstrate two motifs that may play 
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important roles in enzyme function. Because of the highly conserved nature of 
the CAPT motif residues, it seems likely that decreases in activity in the CAPT-
motif mutant versions of Cho1p are likely a result of disruption of CDP-DAG 
binding or catalytic activity of the enzyme. To further confirm this, Km and Vmax 
analysis would need to be performed on some of the still-functional mutant 
versions of Cho1p to determine where the true disruption lies. 
 Second, although there is little evidence to confidently demonstrate that 
our predicted serine-binding motif is truly important in serine binding, three of the 
four residues within this motif were shown to abolish activity of the protein, 
indicating at least that they are important in some way to enzyme function. 
Because of the questions that still remain regarding this motif, and the possibility 
that it is not involved in serine-binding as hypothesized, it will be even more 
important that future experiments include active site labeling which can more 
definitively identify residues important in serine binding. 
 Last, this research has made possible many Cho1p inhibitor screening 
approaches that were not possible before its completion. Although there are 
clearly difficulties in screening for inhibitors of Cho1p, this research has provided 
an excellent path forward in further screening approaches to identifyi inhibitors. 
Plus, it has lended credence to the hypothesis that Cho1p represents an 
excellent drug target. Because Cho1p is crucial to the de novo production of 
several major phospholipids (PS, PE, and PC), its disruption renders this 
organism unable to grow and cause infection in the host. In addition, although it 
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is not required that a drug target be absent within the host organism for 
specificity, the fact that Cho1p is absent within mammals may remove the added 
possibility of toxicity to the host, as it is an issue in some antifungal drugs on the 
market today.These reasons alone support the usefulness of pursuing Cho1p as 
a drug target; however, there are also many tools that allow for the study of 
Cho1p as well as PS levels, localization, and biosynthesis. These tools include 
the in vitro PS synthase assay, microscopy of GFP-Lact-C2-expressing strains of 
S. cerevisiae, lipidomics, and more. Further, there are excellent phenotypic traits 
that can be used in secondary screens to confirm the activity of possible Cho1p 
inhibitors (i.e. Papuamide-A assay, ethanolamine auxotrophy, β-glucan 
unmasking in the cell wall). These tools and secondary screening traits have 
been developed, utilized, or optimized within this dissertation work. This array of 
tools and secondary screens available for use in studying Cho1p support its 
excellent potential as a drug target.  
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Abstract 
The pathogenic fungus Candida albicans is the leading cause of hospital-
acquired fungal infections in immunocompromised individuals. Invasive 
bloodstream infections have a 30% mortality rate. Three antifungal classes are 
used to treat invasive fungal infections including azoles, echinocandins, and 
polyenes.  Rising drug resistance and drug toxicity have made these compounds 
less effective and new drugs are needed. The fungal phosphatidylserine (PS) 
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synthase (Cho1p) has been suggested as a drug target because it is: 1) required 
for C. albicans virulence, 2) conserved among fungi, and 3) absent from 
mammals.  Thus, Cho1p inhibitors could be broad-range antifungals with few 
detrimental side effects.  To identify Cho1p inhibitors, we have taken a novel 
compound screening approach. Cells lacking Cho1p cannot survive without 
supplemented ethanolamine because de novo biosynthesis of 
phosphatidylethanolamine (PE), a vital phospholipid, is downstream of PS 
production.  Thus, these cells only survive by making PE from imported 
ethanolamine by an alternative pathway. We screened compounds for their 
ability to inhibit growth of wildtype C. albicans in media lacking ethanolamine, but 
not in media containing ethanolamine, thus indicating ethanolamine auxotrophy.  
A set of three large-scale, high-throughput screens were performed. Although we 
did not succeed in identifying PS synthase inhibitors from these screens, we 
were able to identify a compound of interest, named Lee-3664, that seems highly 
toxic to fungi. Further compound modifications and testing are underway on this 
compound. 
 
Introduction 
In addition to the drug screen performed with Papuamide A (Cassilly, et al. 
2016), we also screened compounds for their ability to phenocopy the cho1∆∆ 
mutant. One particularly useful phenotypic trait is ethanolamine auxotrophy (i.e. 
the inability to survive without ethanolamine supplemented in the medium). In the 
194 
 
de novo pathway, PS is a precursor for synthesis of PE, so PE synthesis is also 
blocked when PS synthesis is disrupted, as in the case of the cho1∆∆ mutant 
(Chen, et al. 2010). PE is an essential phospholipid, and without it C. albicans is 
unable to survive. The cho1∆∆ can circumvent this blockage of the de novo 
pathway by using the alternative Kennedy Pathway to import exogenous 
ethanolamine for the production of PE (Cassilly, et al. 2017). However, this only 
works in culture media as there is insufficient ethanolamine in the mouse host to 
support PE synthesis during an infection, which likely contributes to avirulence in 
the cho1∆∆ mutant (Davis et al., in preparation). We hypothesized that 
compounds that cause wild-type C. albicans to become an ethanolamine 
auxotroph could be inhibiting an enzyme within the PS synthesis pathway. 
 In order to test this hypothesis, we developed a screen where we grew the 
wild-type organism in ethanolamine deplete synthetic medium. The organism 
was then treated with compounds from a selected library and allowed to incubate 
overnight. Wells that contained actively growing cells, like the wild-type DMSO 
negative control, were considered negative hits (because they are not 
ethanolamine auxotrophs) while wells that contained no growth were considered 
initial hits. 
 To eliminate false positives, specifically compounds that are inherently 
toxic to the cells, we developed a secondary screen that supplemented 1 mM 
ethanolamine to the medium. This exogenous ethanolamine would be substrate 
for the Kennedy Pathway to circumvent the need for PS, and thus allow growth of 
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the cho1∆∆ mutant. As a result, in this secondary screen, compounds that 
inhibited growth in the ethanolamine negative screen, but not in the presence of 
ethanolamine, were considered true hits. True hits were then further screened 
more stringently to determine the lowest concentration at which the compounds 
were effective. 
 We performed three different small-scale but high-throughput screens for 
compounds that caused a loss of growth in minimal medium. These compounds 
were then tested in a minimum inhibitory concentration (MIC) curve in duplicate 
with media +/- ethanolamine to find the minimum concentration that caused 
ethanolamine auxotrophy. Unfortunately, we were unable to identify any hits that 
induced ethanolamine auxotrophy in the wild-type organism reproducibly. 
However, one beneficial aspect of our screening approach was the alternative 
ability to identify compounds that are fungicidal (i.e. compounds that inhibited 
growth in both +/-ethanolamine conditions, indicating that they might be toxic to 
fungi instead of simply inhibitory to a particular pathway). Although we were 
unable to identify PS synthase inhibitors through this screen, we did identify one 
compound in particular with promise as a fungicidal drug. 
 
Materials and Materials 
Strains and culture methods 
The strains used in this study were wild-type (SC5314), cho1Δ, cho1ΔΔ 
(YLC337), and psd1Δ/Δpsd2Δ/Δ::PMet3-PSD1 (YLC331). Strains were previously 
published and described (Chen, et al. 2010) and can be found in Table A1.1. 
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Minimal medium (0.67% yeast nitrogen base without amino acids (Difco), 2% 
dextrose (ThermoFisher Scientific)) and YPD rich medium (1% yeast extract, 2% 
peptone, 2% dextrose) were used where indicated (Guthrie 2002). 
 
Genetics and Cloning 
The plasmid pYLC314 which contains an ACT1 promoter and nourseothricin 
resistance gene (SAT1) followed by PMET3 was isolated from E. coli. To insert this 
sequence in front of the CHO1 gene in cho1Δ, we designed one primer 
containing the sequence upstream of CHO1 followed by the ACT1 promoter 
beginning (CCO14) and a second, reverse primer containing the 3’ portion of 
PMET3 followed by sequence just before the start codon of CHO1 (CCO15) (Table 
A1.1) This portion was amplified using PCR, then purified and transformed into 
cho1Δ. Selection was performed on YPD-nourseothricin plates. This produced 
cho1Δ PMET3-CHO1. 
 
Secondary Screens for Ethanolamine Auxotrophy 
Further screening of transformants was performed using serial dilution on 
minimal medium agar plates supplemented with: 1) nothing, 2) 2.5 mM cysteine/ 
2.5 mM methionine, 3) 1 mM ethanolamine, or 2.5 mM cysteine/ 2.5 mM 
methionine 1 mM ethanolamine. A starting culture of 0.1 OD600/ml was diluted 
1:10 five times and then spotted on each plate. Positive and negative growth  
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Table A1. 1. Strains, Plasmids, and Primers Used or Produced in this Study 
Name Organism  Genotype  Source  
SC5314 
(Ca157) C. albicans   
Lab 
Strain  
Ca159 
(YLC337)  C. albicans cho1ΔΔ 
Chen et 
al., 2010 
YLC331 C. albicans psd1Δ/Δpsd2Δ/Δ::pMet3-PSD1  
Joseph 
Chen 
CDCS11 S. cerevisiae cho1Δ PMET3-CHO1 
Becker 
Lab 
pYLC314 E. coli PMET3, AmpR, SAT1 
Joseph 
Chen 
CCO14   
TTCAAACAAGCATTTTGTTATATATAA
CGGTTTTCTTTTTTTCATCTCGTTTTA
TTTATTTACACATTTTTTCGTCAAAAC
TAGAGAATAATAAAG 
This 
Study 
CCO15   
TTCTGAATCTGATACAATTGCTGATTC
TTGGTGCTTGGAGAACCCGGTAGCT
GATGAGTCTGTCATGAATAGGTTTTC
TGGGGAGGGTATTT 
This 
Study 
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controls included the wild-type and cho1ΔΔ. Plates were allowed to dry and 
incubated at 30°C overnight before pictures were taken. 
 Additionally, a form of the above assay was performed in 96-well plates 
with liquid medium instead. Appropriate cell cultures were grown overnight in 5 
ml to stationary phase in 5 ml YPD shaking at 30°C. Cultures were pelleted and 
washed with sterile water 2x. Cells were resuspended in minimal medium and 
diluted to an OD600/ml of 0.1. Cells were then counted on a hemocytometer twice 
and diluted to 2.5 x 103 cells/ml. 50 μl of the dilutions were pipetted into a 96-well 
plate, then additional medium was added containing either 1) nothing, 2) 5 mM 
cysteine/ 5 mM methionine, 3) 2 mM ethanolamine, or 5 mM cysteine/ 5 mM 
methionine 2 mM ethanolamine.  Plates were incubated at 30°C overnight. The 
following day, Alamar Blue was added according to the manufacturer’s protocol 
and  (Cassilly, et al. 2016), then fluorescence was read in a plate reader as a 
proxy of growth. 
 
Ethanolamine auxotrophy screening 
 Wild-type and cho1ΔΔ were grown overnight in 5 ml of YPD shaking at 30°C. 
The following day cultures were transferred to 15 ml conical tubes and 
centrifuged at 3,000 rpm for 3 minutes. Supernatant was decanted and cells 
were washed 2x with sterile water. On the last wash, cells were resuspended in 
minimal medium and the OD600/ml was taken using a spectrophotometer. 
Cultures were diluted to an OD600/ml of 0.1 in 5 ml of minimal medium. Using a 
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hemocytometer, cells were counted for each strain twice then diluted to 1.6 x 106 
cells/ml. These dilutions were pipetted into either a 96- (100 μl/well) or 384- (40 
μl/well) well plate and incubated at 30°C overnight. Compounds from each library 
used were added to a concentration of ~10 μM using a automated pintool as 
described in (Cassilly, et al. 2016). 
 The following day, CellTiter Glo was added according to the 
manufacturer’s protocol and luminescence was measured to assess growth of 
the organism. To define positive hits, all data was copied from BMG Pherastar 
software into an Excel spreadsheet. Before proceeding raw Relative 
Luminescence Units (RLU) were normalized to each other (0<n<1, 0 = positive 
control, 1 = negative control). Data analysis proceeded using normalized RLU 
(nRLU). DMSO negative control wells were averaged and Fluconazole positive 
control wells were averaged. These averages provided our experimental maxima 
and minima of nRLU for each plate. A fungicidal index (FI) was developed by 
dividing the nRLU in the experimental well by the average of the plate’s DMSO 
negative control wells’ nRLU in EA- plates (0<FI<1, lower the FI, the more 
fungicidal the compound). To investigate recovery between EA+ and EA- wells, a 
Recovery Index (RI) was developed by dividing the nRLU of corresponding wells 
from the EA+ plate by the nRLU from the EA- plate. Therefore, a larger value 
indicated greater recovery in the EA enriched media. To determine a hit in our 
screen, the RI was divided by the FI (RI/FI). Therefore, the larger number, the 
more recovery from adding EA in the presence of a compound active against C. 
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ablicans. Data was then graphed, with each compound along the x-axis and 
nRLU along y-axis. We followed up on the top 20 hits (top 20 highest numbers 
from RI/FI). Hits were follow upon by MIC determination in 96 well format in EA-
/EA+ conditions. MIC was determined using Alamar Blue. 
 
Mammalian Cytotoxicity 
Vero (Kidney epithelial cells; ATCC CCL-81) and HEPG2 ( Liver Hepatocellular 
Carcinoma cells; ATCC HB-8065) monolayers were trypsinized (ATCC 30-2101) 
and quantified using disposable SD100 cell counting chambers and Cellometer 
Auto T4 (Nexcelom Bioscience, MA). Cells were seeded at 5000 cells/well (10-15 
% confluency) into white, flat bottom 96-well plates (Nunc 136101, 
ThermoFisher) using enriched Dulbecco’s Modified Eagle’s Medium (Hyclone: 
DMEM/ High Glucose) for Vero cells and Eagle’s Minimum Essential Medium ( 
EMEM; ATCC 30-2003) for HEPG2 cells, each containing 10 % Fetal Bovine 
Serum (ATCC-30-2020). Plates were incubated overnight at 37°C in the 
presence of 5% CO2. All compounds were solubilized in DMSO and serially 
diluted in respective media for each cell line. A serial dilution of DMSO only was 
made to monitor for diluent toxicity against HEPG2 and Vero. Equal volume of 
media containing compound dilutions was transferred to plates containing 
seeded cells using Biomek FXP liquid handling robot (Beckman Coulter,CA). The 
plates were briefly spun and incubated for 72 hours.  After 72 hours of 
incubation, viability was indirectly measured using the CellTiter-Glo® 
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Luminescent Cell Viability (G7572 Promega) assay. Assay plates were read at 
peak emission wavelength of 590 nm on a PHERAstar FS Multilabel reader 
(BMG, Cary,NC). The raw data was normalized to no drug (DMSO only) wells as 
100% viability standard. The concentration of test compounds that inhibited 
growth by 50% (IC50 value) was computed using nonlinear regression based 
fitting of inhibition curves using log [inhibitor] vs. Response-variable slope (four 
parameters) - symmetrical equation, in GraphPad Prism version 7 (GraphPad 
Software, La Jolla California USA, www.graphpad.com). 
 
Results 
Initially we wanted to set strong positive and negative controls for our screen. In 
previous work, we found that the cho1∆∆ mutant showed relatively poor growth 
return in the presence of ethanolamine (Chen, et al. 2010). Because of this, 
detection of recovered growth of the cho1ΔΔ mutant in our screen presented a 
possible challenge in using cho1ΔΔ mutant as the positive control for identifying 
hits. 
 We were interested in producing a strain of C. albicans with CHO1 under 
the repressible promoter PMET3. In this case, PMET3-CHO1 should produce Cho1p 
when grown in conditions where methionine and cysteine are absent, but not 
produce the protein when grown in the presence of methionine and cysteine 
(Care, et al. 1999). This would give us a way of controlling Cho1p expression via 
the action of compounds (i.e. cysteine and methionine) which is a close analog of 
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what we were screening for (i.e. small molecules that inhibit Cho1p). We used 
PCR to amplify PMET3 from pYLC314 (Joseph Chen) with overhangs matching to 
the upstream region of CHO1. We made many attempts to integrate the 
construct into the genome of a heterozygous cho1Δ mutant. We isolated one 
positive colony where PMET3-CHO1 appeared to have integrated (CDCS11). As 
shown in Figure A1.A, cho1ΔΔ cannot grow on minimal medium due to 
ethanolamine auxotrophy while cho1Δ::PMET3-CHO1 grows because it is 
expressing Cho1p under these conditions. In Figure A1.1B, cho1ΔΔ grows in 1 
mM ethanolamine supplemented medium because it can produce PE via the 
Kennedy Pathway. The cho1Δ:: PMET3-CHO1 strain grows equally as well in 
minimal medium containing ethanolamine as in medium unsupplemented with 
ethanolamine. In Figure A1.1C, cho1ΔΔ cannot grow on minimal media with 2.5 
mM cysteine and 2.5 mM methionine because it has to have ethanolamine to 
grow. In addition, cho1Δ:: PMET3-CHO1 strain does not grow when 2.5 mM 
cysteine and 2.5 mM methionine are supplemented because the presence of 
these components shut off the PMET3 which is controls expression of Cho1p and 
thus, the organism becomes an ethanolamine auxotroph under these conditions. 
Last, in Figure A1.1D, the cho1 ΔΔ mutant has a modest return of growth on 
minimal medium supplemented with 2.5 mM cysteine and 2.5 mM methionine 
and 1 mM ethanolamine because it is able to produce PE via the Kennedy 
Pathway. The cho1Δ::PMET3-CHO1 strain also has a modest return of growth 
when ethanolamine is added due to the same reason. Although these results  
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Figure A1. 1. Growth Phenotype of the cho1Δ::PMET3-CHO1 Strain 
The cho1ΔΔ and cho1Δ::PMET3-CHO1 strains were compared for growth 
phenotype on minimal medium supplemented with (A) nothing, (B) 1 mM 
ethanolamine, (C) 2.5 mM cysteine and 2.5 mM methionine, (D) 1 mM 
ethanolamine and 2.5 mM cysteine and 2.5 mM methionine. 
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were precisely as expected, this phenotype unfortunately seemed to disappear 
over time and we could never replicate this data in new transformations. Thus, 
the project to produce cho1Δ::PMET3-CHO1 was abandoned. 
 Despite this problem we continued efforts to produce an adequate positive 
control for our screen. Previously in the Reynolds Lab, a strain had been 
produced where the PSD1 gene was under PMET3 control: 
psd1Δ/Δpsd2Δ/Δ::PMET3-PSD1 (Joseph Chen). This strain is also an 
ethanolamine auxotroph under certain circumstances because, even though it 
can produce PS, it can only convert that PS to PE in medium lacking cysteine or 
methionine (i.e. when the Psd1p enzyme is produced). To confirm that this strain 
behaved as expected, we tested the ability of psd1Δ/Δpsd2Δ/Δ::PMET3-PSD1 to 
respond to methionine, cytsteine, and ethanolamine. We found that this strain 
showed no growth in the presence of cysteine and methionine alone, but that 
upon the addition of 1 mM ethanolamine, was recovered for growth (Fig. A1.2). 
This was an excellent proxy of what we expected to see with small molecule 
inhibitors in our screening approach. However, while psd1Δ/Δpsd2Δ/Δ::PMET3-
PSD1 showed excellent ethanolamine auxotrophy recovery at UTK, 
reproducibility of this phenotype was never secured at St. Jude, and thus the 
cho1ΔΔ mutant was included as a positive control in our high-throughput screens 
instead of psd1Δ/Δpsd2Δ/Δ::PMET3-PSD1. 
 At UTK we performed several assays to determine the appropriate 
conditions for use of cho1ΔΔ mutant as a positive control (Table A1.2, Fig.  
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Figure A1. 2. Use of PMET3-PSD1 as a positive control 
When grown without 1 mM ethanolamine (A) the cho1ΔΔ strain 
cannot grow under any circumstance and the psd1ΔΔpsd2ΔΔ::PMET3-
PSD1 can grow only without the presence of met/cys. However, when 
1 mM ethanolamine is added to the medium (B) there is a return of 
growth to both cho1ΔΔ and psd1ΔΔpsd2ΔΔ::PMET3-PSD1 nearly to 
wild-type levels in the presence of met/cys*. Medium also contained 
50 mM Hepes to allow for measurement with Alamar Blue.*Too high 
concentrations of met/cys appear toxic (>/= 0.63 mM). Abbreviations: 
met/cys = methionine and cysteine. 
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A1.3). While the cho1ΔΔ mutant was sufficient as a positive control at UTK, 
detectable growth of this control was never observed at St. Jude for any of the 
screens performed. 
 In a pilot study at St. Jude Children’s Research Hospital (St. Jude), we 
assessed 1,831 bioactive, FDA-approved compounds 
(http://www.selleckchem.com/screening/chemical-library.html) to identify those 
which produce ethanolamine auxotrophy in wild-type C. albicans growing in 
medium lacking ethanolamine (i.e. phenocopy the cho1ΔΔ mutant). This initial 
screen revealed 13 initial hits (0.7% hit rate).  The Z-scores for most of the plates 
were above 0.5, indicating a reliable screen by standard HTS statistical appraisal 
(Zhang, et al. 1999).  Each of the 13 hits was rescreened in triplicate under a 
dose-response curve in media +/-ethanolamine using controls of compounds that 
had no effect or were toxic. Unfortunately, this revealed that none of the 
bioactives induced ethanolamine auxotrophy, although several were directly 
inhibitory to growth. 
 We performed a second screen with a 510-compound library subset from 
the Medicines for Malaria Venture (https://www.mmv.org/).  Due to the 
effectiveness against the eukaryotic organism Plasmodium, we were interested 
to see if these compounds were also effective against C. albicans. From this 
screen, we obtained no compounds that induced reproducible ethanolamine 
auxotrophy in wild-type C. albicans. 
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Table A1. 2. UTK-Determined Parameters for Ethanolamine Auxotrophy 
Screening 
Plate Medium 
Cell 
Concentration 
(cells/ml) 
Incubation 
Temperature 
(°C) 
Viability 
Indicator 
Primary 
Screen  
384-
well  
0.67% yeast 
nitrogen base, 
2% dextrose  1 x 104  30  
CellTiter 
Glo  
Counter 
Screen  
96-
well  
0.67% yeast 
nitrogen base, 
2% dextrose, 
50 mM 
HEPES, 1 mM 
Ethanolamine  1 x 104  30  
Alamar 
Blue  
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Figure A1. 3. Use of cho1ΔΔ as a positive control 
(A) When grown without 1 mM ethanolamine the cho1ΔΔ and psd1ΔΔpsd2ΔΔ 
strains cannot grow due to ethanolamine auxotrophy. The psd1ΔΔ strain shows a 
severe growth defect at the highest cell concentration and is undetectable at the 
lower cell concentrations. The only cell growth is seen in wild-type and 
cho1ΔΔ::CHO1 which can synthesize PE de novo. (B) When the medium is 
supplemented with 1 mM ethanolamine, cho1ΔΔ, psd1ΔΔ, and psd1ΔΔpsd2ΔΔ 
show a return of growth nearly equal to the wild-type and cho1ΔΔ::CHO1 strains 
at the highest cell concentration.  
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 The last library screened was the Maybridge Collection of 1,342 fragments 
(http://www.maybridge.com/portal/alias__Rainbow/lang__en/tabID__230/Deskto
pDefault.aspx). These fragments are increasingly useful due to their diversity in 
structure as well as their high potential to be combined or modified to improve 
efficacy. On average, these compounds were within the size range of 200 to 300 
Da and soluble in water. From this screen we identified 20 true hits that produced 
ethanolamine auxotrophy; however, upon performing dose response 
experiments, none reproducibly retained this phenotype. 
 Although we saw no compounds from any screen that produced 
ethanolamine auxotrophy, we did find 18 total initial hits that appeared to be 
fungicidal. These hits thus became of primary interest and were screened further 
for minimum inhibitory concentration (MIC) against fungi and tested for 
mammalian cytotoxicity. After cytotoxicity testing against HepG and VERO cells, 
we identified two promising compounds. One had a fungal MIC of less than 0.57 
μM and a cytotoxicity index of 27.5 μM. The second had a fungal MIC of 4.6 μM 
and a cytotoxicity index of greater than 109 μM. Because of the excellent 
cytotoxicity index of the second compound, we began to focus on this compound, 
now named Lee-3664. 
 Unfortunately, while this compound showed great promise at St. Jude, the 
fungal MIC experiments could not be reproduced at UTK. This seems to indicate 
that conditions must be completely uniform to produce desired phenotypes. 
However, despite the issues in reproducibility, work is currently underway at St. 
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Jude to further characterize Lee-3664 mechanism of action by screening a 
heterozygote deletion collection of C. albicans. Further, chemists at St. Jude are 
modifying the structure of Lee-3664 to produce analogs with the expectation that 
some of them may be more effective antifungals with lower MICs. 
 
Discussion 
It was our expectation to perform the three described small-scale, high-
throughput screens and then ramp up the approach to include the 520,000 on-
site compound library (Chen 2008) at St. Jude, but because of the challenges 
associated with this work, this goal was abandoned. Indeed, we began this 
screening approach in order to avoid the complexity associated with the 
Papuamide A screen. As these results show, using ethanolamine auxotrophy as 
a screening trait has its own unique set of challenges. However, although this 
work has been met with problems, from finding adequate controls to issues with 
reproducibility across work sites, there is still the potential that interesting 
information may come of this screen in future studies at St. Jude. 
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APPENDIX II 
TRAFFICKING AND STABILITY OF PHOSPHATIDYLSERINE IN 
THE PLASMA MEMBRANE OF YEAST 
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Abstract 
 
Phosphatidylserine (PS) is a phospholipid that is commonly enriched in the inner 
leaflet of the plasma membrane of yeast and other eukaryotes. PS is produced in 
the endoplasmic reticulum and is trafficked to the mitochondria where it can be 
used to produce other phospholipids or to the plasma membrane. Although there 
have been some advances in understanding PS trafficking, little is known about 
the duration of PS at the plasma membrane. Previous studies involving 
extracellular addition of lyso-PS (i.e. PS where one fatty acid tail has been 
removed) suggested a rapid conversion of Lyso-PS into PS, followed by 
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incorporation into the plasma membrane. To further study this, we engineered a 
strain of Saccharomyces cerevisiae where the PS synthase gene (CHO1) is 
controlled by the repressible galactose promoter (PGAL1). In the presence of 
galactose, Cho1p enzyme is expressed, and thus PS is synthesized. However, 
when glucose is present in the medium instead of galactose, PGAL1 represses 
CHO1 and therefore PS production. In addition, we introduced a fluorescent, PS-
specific probe to S. cerevisiae in order to visualize PS via fluorescent 
microscopy. We found that glucose repression of CHO1 via PGAL1 caused a 
diffusion of the fluorescent probe away from the plasma membrane, indicating a 
decrease in PS levels. However, PGAL1 did not completely shut off Cho1p 
production, and thus the results were variable. In addition, we tested the effects 
of membrane-perturbing agents on PS localization and found that some 
compounds cause redistribution of PS within yeast. 
 
Introduction 
Phosphatidylserine (PS) is a glycerophospholipid and is considered a major 
phospholipid in eukaryotic organisms. Within most eukaryotes, PS is enriched in 
the inner leaflet of the plasma membrane and can have significant roles in 
membrane structure and cell signaling (Carman and Han 2011, Lagace and 
Ridgway 2013, Levin 2005, Mioka, et al. 2014). PS is produced in the 
endoplasmic reticulum (ER) by the PS synthase enzyme Cho1p (Carman and 
Han 2011, Cassilly, et al. 2017, Chen, et al. 2010, Osman, et al. 2011). After 
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production, PS can either be trafficked to the plasma membrane or used to make 
phosphatidylethanolamine (PE) in the mitochondria or endosome (Yeung, et al. 
2008). Several studies have been conducted to study trafficking of PS to the 
mitochondria and plasma membrane. These studies describe the mitochondrial 
associated membrane (MAM) and the plasma membrane associated membrane 
(PAM) which are portions of the ER that are closely associated with the 
mitochondria or the plasma membrane, respectively. The MAM and the PAM are 
where the majority of phosphatidylserine synthesis and trafficking are predicted 
to occur (Achleitner, et al. 1999, Kuchler, et al. 1986a, Maeda, et al. 2013, Moser 
von Filseck, et al. 2015, Natarajan, et al. 2004, Osman, et al. 2011, Pichler, et al. 
2001, Pomorski, et al. 2003, Sleight and Pagano 1983, Tamura, et al. 2012, 
Voelker 2003). Despite these studies, little is known about the dynamics of PS 
once it reaches the plasma membrane. 
 Previous work by (Maeda, et al. 2013, Moser von Filseck, et al. 2015) 
described a rapid (within 10 minutes) incorporation of Lyso-PS into PS in the ER, 
and subsequent relocation to the plasma membrane. Although this describes the 
movement of newly formed PS to the membrane, it is through an unnatural 
mechanism whereby Lyso-PS is the starting material that is converted into PS, 
then trafficked back to the plasma membrane (Maeda, et al. 2013). While this is 
informative, it does not describe the natural process of PS trafficking whereby PS 
is produced from CDP-DAG and serine. Understanding this natural trafficking 
and dynamics of PS was the goal of the present study. 
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 In order to observe the movement of PS, we constructed a version of the 
ScCHO1 gene which is under the control of a repressible promoter. The 
galactose promoter (PGAL1) allows expression of a particular gene in the 
presence of galactose and represses the expression of the gene in the presence 
of glucose. By inserting PGAL1 in place of the native CHO1 promoter (PGAL1-
CHO1), we are able to control the expression of Cho1p, and thus the production 
of PS in the cell. Thus, when grown in medium containing galactose, CHO1 
transcribed and translated into protein, allowing the production of PS. 
Alternatively, when in the presence of glucose, CHO1 is shut off, halting the 
production of PS. 
In order to visualize changes in PS localization as a result of the above 
experimentation, we utilized two fluorescent, PS-specific probes GFP-Lact-C2 
and mCherry-Lact-C2. Fluorescent molecules GFP and mCherry were fused to 
the C2 domain of Lactadherin, a bovine protein that binds specifically to PS, to 
create useful PS-specific probes (Fairn, et al. 2011a, Fairn, et al. 2011b). 
Together with the repressible production of Cho1p (PGAL1-CHO1), these tools in 
theory should allow not only control of PS production, but also visualization of PS 
overtime. However, we found that the PGAL1-CHO1 strain was leaky, and even 
when grown in the presence of glucose, produced a small amount of PS. This 
concentration, though low, was still enough to support growth and show 
localization of PS, which precluded our ability to obtain total CHO1 shut off. 
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As a result, we began efforts to utilize a new method using a plant system 
of controlled protein degradation. This system is a naturally occurring process in 
plants where the plant hormone auxin induces the degradation of anything 
bearing a particular sequence. Recently, this auxin-based degradation has been 
developed into a tool to control the proteolysis of specified proteins in other 
systems like yeast (Nishimura, et al. 2009). We wished to utilize this system to 
control degradation of Cho1p in yeast. Although final results were never obtained 
showing auxin-repressible degradation of Cho1p, strains were developed within 
this study, allowing this system to be usable in the future. 
Last, because PS has been shown to be important for virulence of some 
fungi (Chen, et al. 2010, Vale-Silva, et al. 2016), we wished to utilize these tools 
in C. albicans and C. glabrata, but as a result of cloning and expression issues, 
were unable to adapt these techniques for the pathogenic fungi. Findings from 
our experiments, although incomplete, are excellent beginning steps in 
developing a greater understanding of PS dynamics. 
 
Materials and Methods 
Strains Used 
Wild-type Σ S. cerevisiae (TRY181) and the cho1Δ deletion mutant (BMY2), 
which is unable to produce PS, were used. These strains contain auxotrophies 
for uracil and histidine (Table A2.1). All other strains were produced as described 
below. Details on particular strains can be found in Table A2.1. 
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Table A2. 1. Strains Produced or Used in this Study 
Strain  Organism  Genotype  Source  
Σ (TRY 
181)  S. cerevisiae  ura3Δ his3Δ  Lab Strain  
BMY2  S. cerevisiae  ura3Δ his3Δ cho1 Δ  Lab Strain  
RF01  S. cerevisiae  ura3Δ his3Δ pGFP-Lact-C2 This study  
RF04  S. cerevisiae  ura3Δ his3Δ cho1Δ pGFP-Lact-C2 This study  
RF09  S. cerevisiae  
ura3Δ his3Δ pGPD416-mCherry-
Lact-C2 This study  
RF10  S. cerevisiae  
ura3Δ his3Δ cho1 Δ pGPD416-
mCherry-Lact-C2 This study  
RF21  S. cerevisiae  
ura3Δ his3Δ pGPD416-mCherry-
Lact-C2 pRS426GFP-2×PH(PLCδ) This study  
RF18  S. cerevisiae  
ura3Δ his3Δ cho1Δ pGPD416-
mCherry-Lact-C2 pRS426GFP-
2×PH(PLCδ) This study  
RF25  S. cerevisiae  
ura3Δ his3Δ cho1Δ::PGAL1-CHO1 
G418R  This study  
RF26  S. cerevisiae  
ura3Δ his3Δ cho1Δ::PGAL1-CHO1 
G418R pGFP-Lact-C2 This study  
BY25594   S. cerevisiae  
MATaura3-1::ADH1-AtTIR1-
9Myc(URA3) ade2-1 his3-11, 15 
leu2-3, 112 trp1-1 can1-100  
From 
Minetaka 
Sugiyama 
CDCS67 S. cerevisiae 
MATaura3-1::ADH1-AtTIR1-
9Myc(URA3) ade2-1 his3-11, 15 
leu2-3, 112 trp1-1 can1-100 
cho1::CHO1-Deg-KanR  This study  
MG1655  E. coli    
Gift from 
Fozo Lab  
CDCS12 E. coli LactC2-GFP-AmpR This study  
CDCS16 E. coli AmpR This study  
Cg 27  C. glabrata  ura3Δ his3Δ leu2Δ tryp1Δ  Lab Strain  
RF29  C. glabrata  
ura3Δ his3Δ leu2Δ tryp1Δ pGFP-
Lact-C2 This study  
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Table A2. 2. Continued. 
Strain  Organism  Genotype  Source  
SC5314  
(Ca157) C. albicans   Lab Strain  
Ca159 C. albicans cho1ΔΔ 
Chen et 
al., 2010 
CDCS18 C. albicans PENO1::PENO1-GFP-Lact-C2-SAT1 This study  
CDCS24 C. albicans 
cho1ΔΔ PENO1::PENO1-GFP-Lact-
C2-SAT1 This study  
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Strain Production 
We used a standard lithium acetate transformation method to construct the S. 
cerevisiae strains in this study (Gietz and Woods 2002). All strain and plasmid 
information can be found in Tables A2.1 and A2.2, respectively. Transformation 
of GFP-Lact-C2 into WT and cho1Δ S. cerevisiae: GFP-Lact-C2 (pGFP-Lact-C2) 
was transformed into wild-type and cho1Δ using the URA3 marker to produce 
ura3Δ his3Δ pGFP-Lact-C2 and ura3Δ his3Δ cho1Δ pGFP-Lact-C2, respectively. 
Transformation of mCherry-Lact-C2 into WT and cho1Δ S. cerevisiae: mCherry-
Lact-C2 (pGPD416-mCherry-Lact-C2) was transformed into wild-type and cho1Δ 
using the URA3 marker to produce ura3Δ his3Δ pGPD416-mCherry-Lact-C2 and 
ura3Δ his3Δ cho1Δ pGPD416-mCherry-Lact-C2, respectively. Transformation of 
GFP-2x Ph(PLCδ) into ura3Δ his3Δ pGPD416-mCherry-Lact-C2and ura3Δ his3Δ 
cho1Δ pGPD416-mCherry-Lact-C2S. cerevisiae: The GFP-2xPh(PLCδ) was cut 
from pRS426GFP-2×PH(PLCδ) and ligated into pRS423 to produce pRF1 (Table 
A2.2). pRS426GFP-2×PH(PLCδ) (pRF1) was transformed into ura3Δ his3Δ 
pGPD416-mCherry-Lact-C2 and ura3Δ his3Δ cho1Δ pGPD416-mCherry-Lact-
C2using the HIS3 marker to produce ura3Δ his3Δ pGPD416-mCherry-Lact-C2 
pRS426GFP-2×PH(PLCδ) and ura3Δ his3Δ cho1Δ pGPD416-mCherry-Lact-C2 
pRS426GFP-2×PH(PLCδ), respectively. Transformation of PGAL1 into WT and 
cho1Δ S. cerevisiae: PGAL1 was amplified from p73 with primers adapted from 
(Longtine, et al. 1998) (CCO49 and CCO50) containing overhangs of the native 
CHO1 promoter. The PCR product was transformed into wild-type and cho1Δ  
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Table A2. 3. Plasmids Used in this Study 
Plasmid  Inserts  Source  
p200 (pGFP-
Lact-C2) GFP-Lact-C2, URA3, Cen/Ars, AmpR  
Yeung et al., 
2008  
pBS34  mCherry, URA3, AmpR  
Shaner et al., 
2004  
pGPD416-
mCherry-
Lact-C2  mCherry-Lact-C2, URA3, AmpR  
Fairn et al., 
2011  
pRS423  HIS3, AmpR  Lab Strain  
pRS426GFP-
2×PH(PLCδ)  GFP-2x Ph(PLCδ), URA3, AmpR  
Addgene 
plasmid # 
36092  
pRF1  GFP-2x Ph(PLCδ), HIS3, AmpR  This study  
p73  PGAL1, G418R, AmpR  Lab Strain  
EBp42  NATR, AmpR  Lab Strain  
BYP 6740 
(Pmk43)    AmpR, KAN  
Nishimura et 
al., 2009  
BYP 6742 
(Pmk76)   URA3, AmpR  
Nishimura et 
al., 2009  
pCDC2 eGFP-Lact-C2, NATR, AmpR  This study  
pRI1  ApR  
Fozo Lab, 
Opdyke et al., 
2006 
pCDC5 GFP-Lact-C2, AmpR  This study  
pRS423 HIS3, AmpR  Lab Strain  
pUC57   Lab Strain  
pCDC4 GFP-Lact-C2, NATR, AmpR This study  
pCDC2 eGFP-Lact-C2, NATR, AmpR This study  
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using the G418/Kanamycin resistance marker to produce ura3Δ his3Δ 
cho1Δ::PGAL1-CHO1 G418/KanR. Primer sequences can be found in Table A2.3. 
Transformation of GFP-Lact-C2 into ura3Δ his3Δ cho1Δ::PGAL1-CHO1 
G418/KanR S. cerevisiae: GFP-Lact-C2 (pGFP-Lact-C2) was transformed into 
ura3Δ his3Δ cho1Δ::PGAL1-CHO1 G418/KanR using the URA3 marker to produce 
ura3Δ his3Δ cho1Δ::PGAL1-CHO1 G418/KanR GFP-Lact-C2. Cloning of Auxin-
Repressible Degron System: For inserting the “degron sequence” at the C-
terminus of ScCHO1, we adapted the primers from (Nishimura, et al. 2009). First 
we made CCO120 and CCO121 based on pYM3/6_F and pYM3/6_R with 
overhangs matching the ScCHO1 gene just before the stop codon and just after 
the stop codon, respectively. However, because we had no success with these 
oligonucleotides, we ordered a second reverse primer to replace CCO121, called 
CCO143. This primer in combination with CCO120 resulted in a band ~2.4 Kb in 
length when used in PCR of BYP 6740 (Pmk43) (plasmid from Minetaka 
Sugiyama). This PCR product was then transformed into BY25594 (from 
Minetaka Sugiyama). Correct orientation of the insertion was confirmed using 
CCO108  in combination with either CCO144 (3.3 Kb band) or CCO145 (2.1 Kb 
band). Sequencing to confirm the correct sequence insertion was performed 
using CCO140. 
 The strain already contained the E3 ligase with a uracil marker (BYP 6742 
(Pmk76)), but to include the GFP-Lact-C2 probe, we had to move GFP-Lact-C2 
into a plasmid with an alternative marker (pGFP-Lact-C2 contains a uracil marker  
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Table A2. 4. Primers Used in this Study 
Primer  Sequence  Source  
CCO49  
AAGAGAGATACACCTATTTTTTTCA
TTTTGTGGGTGATTGTCATTTTTAG
GAATTCGAGCTCGTTTAAAC  
Adapted from 
Longtine et al., 
1998  
CCO50  
 TCCGTGTGTGGGAATTCTTGAGGT
GCGAAATCTTCATCTGATTCAACC
ATTTTCATTTTGAGATCCGGGTTTT  
Adapted from 
Longtine et al., 
1998  
CCO120  
TTATCCATGGGTGTGGAATGATTTC
GAAGAGCTTGAAAATTCCAAAGCCA
AGCTTCGTACGCTGCAGGTCG  
Adapted from 
Nishimura et al., 
2009  
CCO121  
AAAAGTTATATGTACAAATTTTTTTT
GACGCCAGGCATGAACAAAAACTA
GGTAAGATCTCTTGAATGATCGTTC
CACTTTTTAGC 
Adapted from 
Nishimura et al., 
2009  
CCO143  
AAAAGTTATATGTACAAATTTTTTTT
GACGCCAGGCATGAACAAAAACTA
CGAGTCAGTGAGCGAGGAAGC  This study  
CCO108  ATGGTTGAATCAGATGAA  This study  
CCO144  GAATGTCGTGTGAAGCTG  This study  
CCO145  GTGAGAACTGTATCCTAGC This study 
CCO140 CAGCTGGCAAGAATTGAG This study  
CCO147  
AAAAgcggccgcCCTAACAGCCCAGC
AGC  This study 
CCO148  AAAAgagctcATGGTGAGCAAGGGCG  This study  
CCO32 
GGAATATTACAACCATGGCTGATCC
ATGTCTAAAGGTG  This study  
CCO33 
TACAATCATGACTGATCCATGTCTA
AAGGTG  This study  
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(parent plasmid is pRS416)). Thus, we selected pRS423 which contains a HIS3 
marker. pRS423 was digested with NotI-HF and SacI, then purified. GFP-Lact-C2 
was amplified from pGFP-Lact-C2 using CCO147 which contained a NotI cut site 
3’ of the GFP sequence and CCO148 which contained a SacI cut site 5’ of the 
Lact-C2 sequence. 
 
Candida glabrata 
C. glabrata was transformed with pGFP-Lact-C2 using the same lithium acetate 
transformation method as S. cerevisiae. The produced strain, RF29 can be found 
in Table A2.1 and the plasmid in Table A2.2. 
 
Candida albicans 
Because of the special CTG codon usage in C. albicans, we could not utilize the 
same plasmids for S. cerevisiae or C. glabrata. After several attempts to perform 
multiple tandem site-directed mutagenesis procedures we used Genescript to 
synthesize the plasmid pCDC6 which contains a codon-optimized GFP-Lact-C2 
in pUC57. Unfortunately, no fluorescence was seen upon transformation into C. 
albicans, and thus a new GFP gene (eGFP) was used. The present GFP gene 
was removed from pCDC4 using NcoI and SspI. eGFP was amplified using 
CCO32 which contained a 3’ SspI cut site and CCO33 which contained a BspHI 
cut site (matched up with NcoI cut site), producing pCDC2. This plasmid was 
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digested in the promoter and transformed into both wild-type (CDCS18) and 
cho1ΔΔ (CDCS24). 
 
Escherichia coli 
E. coli strain MG1655 was used for this study. GFP-Lact-C2 was amplified from 
pGFP-Lact-C2 using primers TRO 938 and TRO939 which contain EcoRI and 
HinDIII cut sites respectively. pRI plasmid was then digested using EcoRI and 
HinDIII and gel purified. The digested GFP-Lact-C2 fragment was ligated into 
plasmid pRI to produce pCDC5. This plasmid and the empty vector were 
transformed simultaneously into chemically competent MG1655 to produce 
CDCS12 and CDCS16, respectively. 
 For the transformation, MG1655 was streaked on an LB plate and 
inoculated in 3 ml of LB overnight at 37°C, shaking. The following morning the 
cells were diluted 1:500 in LB and shaken at 37°C until the OD600 reached 
approximately 0.4 to 0.6 (~3 hours). The cells were pelleted at 3600 rpm at 4°C 
for 10 minutes. Pellets were resuspended in water and spun again. The pellet 
was then resuspended in 800 μl of ice cold water then spun down at 13,000 rpm 
at 4°C for 3 minutes. The supernatant was aspirated and then the pellet was 
resuspended in 100 μl of ice cold water. Gene Pulse cuvettes were placed on 
ice, then 40-50 μl of the cells were mixed with 1.5 μl of the ligation or with 0.5 – 1 
μl of pRI empty vector. The cuvettes were electroporated at 25 μF with a 
resistance of 200 Ω and a voltage of 2.5 V. The cuvettes were then immediately 
226 
 
placed on ice and 500 μl of SOC medium was added to rescue for 1 hour at 37°C 
shaking. After the rescue, cells were plated on LB-Ampicillin plates and 
incubated at 37°C overnight. 
 
Fluorescent Microscopy 
To confirm the successful transformation of fluorescent probes into our yeast 
strains, overnight cultures were diluted back to 0.1 or 0.2 OD600 and allowed to 
grow for 2-4 hours shaking at 30°C or until early log phase was reached. Cells 
were then imaged via fluorescent microscopy (Leica). For quantification of 
localized, partially localized, and diffuse GFP-Lact-C2, 80 total frames were 
assessed. The percentages of each category in each frame was calculated and 
then averaged with the rest of the frames for both galactose- and glucose-grown 
strains. All images were analyzed using Leica Application Suite 4.4. 
 
Serial Dilution Plating 
To test the effectiveness of our repressible promoter, ura3Δ his3Δ cho1Δ::PGAL1-
CHO1 G418/KanR were grown overnight, then diluted to 0.1, 0.2, 4 x 10-3, 8 x 10-
4, and 1.6 x 10-6 OD600. 10 μl aliquots were spotted onto minimal medium agar 
plates supplemented with galactose or glucose, +/- 1 mM ethanolamine. Plates 
were incubated at 30°C then viewed the following day for growth. 
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Lipid Extraction and Thin Layer Chromatography 
The ura3Δ his3Δ cho1Δ::PGAL1-CHO1 G418/KanR strain was grown in 5 ml 
minimal medium supplemented with either glucose or galactose overnight, 
shaking at 30°C. Lipids were extracted using a standard hot ethanol extraction 
(Hanson and Lester 1980). Isolated lipids and lipid standards (Avanti) were 
spotted on thin layer chromatography plates (Millipore) and separated with 
chloroform:ethanol:water:trimethylamine (35:30:7:35) solvent system (Chen, et 
al. 2010). Lipids were imaged using primulin dye and UV-light exposure. 
 
Lyso PS Uptake Experiment 
The Lyso-PS protocols from (Maeda, et al. 2013, Moser von Filseck, et al. 2015) 
were adapted for this experiment. Overnight cultures of cho1Δ pGFP-Lact-C2 
were either used directly (stationary phase study) or diluted to 0.1 and allowed to 
grow for 2 hours (log phase study). Cells were washed with cold water, followed 
by lyso-PS (Avanti) addition and a 10 minute incubation on ice. Tubes were then 
incubated at 30˚C and at select time points a 10 μL sample of cells was removed 
and mounted onto slides. For some experiments where time was constraining, 
Prolong Gold (Life Technologies) was used to preserve samples until microscopy 
could be performed. Stationary phase time points: 0, 15, 30, and 60 minutes. Log 
phase time points: 0, 1, 2, and 3 hours.  
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Compound Treatment 
The ura3Δ his3Δ pGFP-Lact-C2 and ura3Δ his3Δ cho1Δ pGFP-Lact-C2 strains 
were used to test the effects of Papuamide-A (Pap-A) (Flintbox), SB-224289 
(Tocris), and Staurosporine (CGP 41251) (SelleckChem) on PS localization. 
Overnight cultures were diluted to 0.2 OD600 and allowed to grow for 3-4 hours. 
Cultures were then diluted to 0.1 OD600 and 200 μL of the ura3Δ his3Δ pGFP-
Lact-C2 were either treated with 50 μg/mL Pap-A, 4.5μg/mL staurosporine, 250 
μM SB-224289, or the solvent (water:methanol (2:1)) for Pap-A and DMSO for 
SB-224289 and staurosporine) as negative controls. ura3Δ his3Δ cho1Δ pGFP-
Lact-C2 was used as a positive control for PS mislocalization. All samples were 
then incubated at 30˚C for 1 hour and 20 minutes followed by fluorescent 
microscopy. A second trial was performed with a decreased concentration of SB-
224289 (100 μM) and cell plating for viability. 
 
Results 
Phosphatidylserine is produced in the endoplasmic reticulum in yeast and can 
either be trafficked to the plasma membrane or the mitochondria where it is used 
to produce phosphatidylethanolamine (PE). Some studies have provided a 
greater understanding of PS trafficking to these areas; however, the duration of 
PS at the plasma membrane is currently unknown. In this work, we undertook 
experimentation to determine the length of time that PS remains at the 
membrane in the model yeast Saccharomyces cerevisiae. 
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 In order to perform these studies, we began by creating strains harboring 
GFP-Lact-C2 (Yeung, et al. 2008). GFP-Lact-C2 binds to PS in the cell and emits 
a green fluorescence, allowing us to visualize PS localization within cells. 
 
GFP-Lact-C2 (pGFP-Lact-C2) in wild-type and cho1Δ S. cerevisiae 
Figure A2.1A shows micrographs of wildtype and cho1Δ S. cerevisiae lab strains 
carrying pGFP-Lact-C2. GFP-Lact-C2 localizes to the membrane in wild-tyep 
where PS is enriched. In cho1Δ, which has no PS, GFP-Lact-C2 is diffuse 
throughout the cell. 
 
mCherry-Lact-C2 (pGPD416-mCherry-Lact-C2) in wild-type and cho1Δ S. 
cerevisiae 
We further wanted to determine if the probe bound to the fluorophore mCherry 
might offer even clearer signal. Figure A2.1B shows micrographs of of wildtype 
and cho1Δ S. cerevisiae lab strains carrying pGPD416-mCherry-Lact-C2 grown 
to log phase. As was shown with GFP-Lact-C2, we see localization of mCherry-
Lact-C2 at the membrane in wild-type whereas diffuse signal in cho1Δ. However, 
although overall we saw diffusion in cho1Δ, we did see some cells with slight 
localization at the membrane, which was not ideal and prompted us to focus on 
GFP-Lact-C2 as our fluorescent probe for PS-localization. 
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Figure A2. 1. Localization of PS in Wildtype and cho1Δ Yeast 
Fluorescent microscopy of (A) wild-type and cho1Δ carrying pGFP-Lact-C2 and 
(B) pGPD416-mCherry-Lact-C2. Images were taken during log phase of growth.  
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GFP-2x Ph(PLCδ) (pRS426GFP-2×PH(PLCδ)) in wild-type and cho1Δ S. 
cerevisiae 
In order to better create a distinction between membrane-bound and diffuse 
GFP-Lact-C2 probe (i.e. PS localization), we wished to incorporate a second, 
plasma membrane positive marker. The Plekstrin homology domain (PH domain) 
is a domain of approximately 120 amino acids that binds to PI4,5P2 in the 
membrane of S. cerevisiae (Lemmon 2007). We hypothesized that localization of 
the PH domain fused with GFP (GFP-2x Ph(PLCδ)) to PI4,5P2 could be used as 
a positive marker for the plasma membrane. This, combined with mCherry-Lact-
C2 would allow us to monitor the precise location of PS in the cell. 
 Under this model, mCherry-Lact-C2 and GFP-2x Ph(PLCδ) would overlap 
(forming a yellow signal) in the wild-type organism. In the cho1Δ, the membrane 
would be green (GFP-2x Ph(PLCδ)) and the cytoplasm would appear red (diffuse 
mCherry-Lact-C2 signal) as a result of absence of PS. We further hypothesized 
that, should this tool be useful, we could add a third component to control PS 
production (place CHO1 under a repressible promoter). Thus, PS should start out 
located at the membrane, but upon the shut off of PS production via our 
repressible promoter, it should visibly diffuse into the cytoplasm. Resulting 
overlay images of the red and green fluorescence under normal conditions 
should show a yellow color around the membrane. When the expression of 
CHO1 is turned off, there should be a separation of colors as the red begins to 
diffuse into the cytoplasm, while the green stays at the membrane.  
232 
 
  pRS426GFP-2×PH(PLCδ) was transformed into wildtype and cho1Δ S. 
cerevisiae already carrying pGPD416-mCherry-Lact-C2. As expected, in wildtype 
there is localization of the fluorescence under both green and red fluorescence 
(Fig A2.2). In addition cho1Δ displayed green fluorescence (GFP-2x Ph(PLCδ)) 
localized at the plasma membrane. When under the red fluorescence, the 
mCherry-Lact-C2 signal is diffuse throughout the cell. However, the results were 
inconsistent throughout experiments with some showing localization of mCherry-
Lact-C2 in cho1Δ, and still others showing low mCherry-Lact-C2 signal all 
together (Fig A2.2). As a result, we began to focus efforts on the use of GFP-
Lact-C2 alone. 
 
Transformation of PGAL1, G418R, AmpR (p73) into WT S. cerevisiae 
Next, in order to study the length of time that PS remains at the membrane, we 
wished to create a strain where the PS synthase gene (CHO1) was under a 
repressible promoter. We engineered the strain cho1Δ::PGAL1-CHO1 which allows 
PS production when the strain is grown in galactose medium, and inhibits PS 
production when the strain is grown in glucose (Eckert and Muhlschlegel 2009, 
Longtine, et al. 1998). 
 We performed two experiments to validate cho1Δ::PGAL1-CHO1. First, the 
strain was grown on minimal medium with: 1) histidine and uracil to account for 
the auxotrophies of the parent strain, 2) galactose or glucose to either repress or  
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Figure A2. 2. Localization of PS and PI4,5P2 in Wild-type 
and cho1Δ Yeast 
Fluorescent microscopy of  (A) and (B) cho1Δ and (C) wild-type 
S. cerevisiae with the PH domain GFP and Lact-C2 mCherry 
under red and green fluorescence in stationary phase.  
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allow PS production, and 3) +/- 1 mM ethanolamine to account for any 
auxotrophy produced by PS decreases (Chen, et al. 2010). 
 As shown in Figure A2.3, in the presence of galactose, PGAL1 is turned on, 
allowing expression of CHO1 and hence the production of PS (Fig. A2.3A). In the 
presence of glucose PGAL1 is shut off, turning off expression of CHO1 and 
preventing PS from being made (Fig. A2.3B). Addition of ethanolamine allows for 
production of PE in the absence of PS via the alternative Kennedy Pathway 
(Cassilly, et al. 2017, Chen, et al. 2010), and allows growth (Fig. A2.3D). 
However, in the presence of glucose without ethanolamine, the organism should 
be unable to grow. Unfortunately, though there is a decrease in growth, the fact 
that the organism is still able to grow (Fig. A2.3C) is an indication that there is an 
incomplete shut off of PGAL1. In this case, we hypothesize that some PS is still 
being produced via leaky repression of CHO1 to the extent that PE can be made 
in the absence of PS. 
In order to confirm our suspicions of an incomplete shut-off of CHO1, we 
isolated lipids from strains grown in all conditions mentioned above. We then 
performed thin layer chromatography to qualitatively measure PS levels within 
each condition. As shown in Figure A2.4, PS is present in cho1Δ::PGAL1-CHO1 
grown in galactose and wild-type negative control, because the CHO1 gene is 
being expressed. Inversely, there is no PS in cho1Δ positive control. However, as 
suggested by the growth of glucose-grown cho1Δ::PGAL1-CHO1 in Figure A2.4,  
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Figure A2. 3. Phenotype of the cho1Δ::PGAL1-
CHO1 on Solid Medium  
Serial dilutions of the cho1Δ::PGAL1-CHO1 strain 
in medium supplemented with (A) galactose 
(Gal) and (B) 1 mM ethanolamine (Etn) or (C) 
glucose (Glu) and (D) 1 mM ethanolamine. 
Results show decreased growth on medium + 
Glu without Etn where both de novo and 
Kennedy PE synthesis are inhibited.  
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Figure A2. 4. cho1Δ::PGAL1-CHO1 TLC 
cho1Δ::PGAL1-CHO1 shows decreased, 
but not complete loss of, PS in presence 
of glucose as compared to strain grown 
in galactose, wild-type, and the cho1Δ 
negative control. These results indicate 
an incomplete shut off of the CHO1 
gene.                                                                      
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there is some PS in the strain grown in glucose, further displaying the incomplete 
shut off of PGAL1. 
Despite these data, we were interested in performing microscopy in an 
effort to identify any GFP-Lact-C2 localization differences in this strain. We 
inserted GFP-Lact-C2 within cho1Δ::PGAL1-CHO1. We then performed 
microscopy to determine the influence of growth in glucose or galactose on PS 
localization. Figure A2.5A shows cho1Δ::PGAL1-CHO1 carrying pGFP-Lact-C2 
grown in galactose. As expected, GFP-Lact-C2 localized around the cell 
membrane. Figure A2.5B, cho1Δ::PGAL1-CHO1 carrying pGFP-Lact-C2 is grown 
in glucose, shutting off PGAL1, and hence repressing the expression of the CHO1 
gene. PS is not being produced, so the GFP-Lact-C2 is diffuse in the cytoplasm. 
Unfortunately, these results were not consistent and we met with high 
variability when viewing the cells under the fluorescent microscope. As shown in 
Figure A2.5C, three localization signatures were seen: 1) distinct localization with 
the PS localized mainly at the membrane, 2) diffuse with no signs of fluorescence 
at the membrane, and 3) partial localization with some fluorescence diffuse and 
localized at the membrane. This further indicated that PGAL1 produced an 
incomplete shutoff of CHO1 and that PS was still being produced to some extent 
in some cells. 
To quantify these findings, we counted the cells falling into the three 
signature fluorescence types. Figure A2.5D shows the quantification of 80 frames 
of fluorescing cells (n=1669 fluorescing cells). Localized, partially localized, and 
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Figure A2. 5. Localization of PS in cho1Δ::PGAL1-CHO1::GFP-Lact-C2 S. 
cerevisiae  
(A) Shows the cho1Δ::PGAL1-CHO1::GFP-Lact-C2 S. cerevisiae  grown in 
galactose medium, with localized PS at the membrane. (B) shows the strain 
grown in glucose and the diffusion of Lact-C2-GFP into the cytoplasm. (C) 
Examples of cells localized, partially localized, and diffuse. (D) Quantification of 
GFP-Lact-C2 localization reveals that shut off of Cho1p (i.e. cells grown in 
glucose) causes quantitative decreases in plasma membrane localization of the 
probe, but that the result is not consistent. Galactose grown cells showed less 
growth and weaker fluorescence due to the nature of the galactose carbon 
source compared to glucose. Localized, partially localized, and diffuse 
fluorescing cells are calculated as a percent of total cells counted. n = 1669 
fluorescing cells.  
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diffuse fluorescing cells were calculated as percentages of each frame, then 
averaged to produce an overall percentage. Although there is a significant 
increase in the mislocalization when the strain is grown in glucose, the frames 
are not completely uniform, and the variability was judged as too high to continue 
these experiments. Additionally, since galactose is not as preferable of a carbon 
source as glucose, the cells showed less growth, and also a weaker fluorescence 
signal.  
 
Exogenous Addition of Lyso PS 
Previous studies found that addition of lyso-PS (PS with one fatty acid chain) to 
cho1Δ strain which produces no PS caused the cells to uptake the lyso-PS and 
recycle it in the cell as PS. The lyso PS is converted to PS and transferred to the 
membrane from the ER (Maeda, et al. 2013, Moser von Filseck, et al. 2015). We 
wished to reproduce this result by adding lyso-PS to cho1Δ carrying pGFP-Lact-
C2. Then we monitored the movement of PS through the cell over a time course 
via fluorescent microscopy. We added lyso PS to cultures for 10 minutes at room 
temperature to allow for uptake. Tubes were then placed in the 30˚C water bath 
to allow for trafficking within the cells. 
Under the green fluorescence, the cells showed diffuse GFP-Lact-C2 
signal for the 0 and 15 minute time points (Fig A2.6). We hypothesize that lyso-
PS is taken up here, and in the process of being repackaged in the ER. The cells 
began to show localization around the 30 minute time point where they have  
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Figure A2. 6. Time Course of PS Localization in cho1Δ Upon Addition of 
Lyso PS  
cho1Δ S. cerevisiae carrying pGFP-Lact-C2 shows a plasma membrane 
localization of PS within 30 minutes of incubation at 37°C.  
241 
 
likely sent re-modeled PS to the plasma membrane. At 60 minutes, the PS is 
more localized at the membrane. It remains localized at 120 and 180 minute time 
points, though some of the signal begins to diffuse back in to the cytoplasm. 
 
Compound Experiment 
After having engineered the wildtype and cho1Δ carrying pGFP-Lact-C2 strains, 
we were interested in using this tool (GFP-Lact-C2) to determine effects of 
membrane-perturbing agents on PS localization. Papuamide-A, SB-224289, and  
staurosporine were chosen because previous experiments have been performed 
that indicate that these compounds either disrupt PS trafficking or plasma 
membrane structure in Candida albicans (Andjelic, et al. 2008, Cassilly, et al. 
2016, Cho, et al. 2013b, Cho, et al. 2012, Selkirk, et al. 1998a). Papuamide-A is 
a compound that binds to PS in the plasma membrane and causes cell lysis and 
death (Andjelic, et al. 2008, Cassilly, et al. 2016, Chen, et al. 2010). 
Staurosporine blocks endosomal sorting and recycling of PS, and hence inhibits 
the trafficking of PS to the membrane (Cho, et al. 2013b, Cho, et al. 2012). SB-
224289 is 5-HT1B receptor antagonist that has been shown to cause trafficking 
problems in S. cerevisiae, and likely promotes massive endocytosis (Chapter 2 
and 3) (Cassilly, et al. 2016, Selkirk, et al. 1998a). 
To test the effects of these compounds on PS localization, we treated log 
phase wild-type carrying pGFP-Lact-C2 with varying concentrations of each 
compound and examined the GFP-Lact-C2 probe signal via fluorescent 
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microscopy. All data was compared to an untreated control and cho1Δ (Fig 
A2.7A). As shown in Figure A2.7C, when wild-type was treated with Pap-A, 
accumulation of fluorescence inside the cells was observed, as well as a 
decrease in cell size, indicating the process of cell death (compare to Fig A2.7B). 
This was further demonstrated by plating the treated cell sample on solid 
medium. Samples treated with Pap-A were not viable, whereas untreated cells 
grew. When treated with staurosporine, which is supposed inhibit the trafficking 
of PS to the membrane, PS was seen trapped in punctuate spots within the 
cytoplasm (Fig A2.7E, compare with Fig A2.7D). Last, cells treated with SB-
224289 showed accumulation of GFP-Lact-C2 in the cytoplasm, and a decrease 
in signal at the membrane (Fig A2.7G, H, compare with Fig A2.7F). Viability 
plating of staurosporine and SB-224289-treated cells indicated no signs of cell 
toxicity via a fungicidal mechanism. 
 
Efforts to Adapt PS Trafficking Tools in Other Microbes 
Because of the usefulness of these tools developed in S. cerevisiae, we wished 
to move them into other systems, including pathogenic fungi (C. albicans and C. 
glabrata) and bacteria (E. coli). 
 In C. albicans, we inserted the GFP-Lact-C2 gene into an ENO1 locus of 
wild-type and cho1ΔΔ as described in materials and methods. Although 
fluorescent signal was observed in both strains (Fig A2.8C and D), there seemed 
to be a great deal of unexpected localization of GFP-Lact-C2 at the membrane in  
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Figure A2. 7. Effect of Membrane-Perturbing Agents on Cells 
(A) cho1Δ carrying pGFP-Lact-C2 control while (B) wild-type carrying pGFP-Lact-
C2 untreated with a methanol:water solution, and (C) treated with 50 μg/mL Pap-
A. (D) wild-type carrying pGFP-Lact-C2 treated with DMSO, while (E) shows the 
strain treated with 4.5 μg/mL Staurosporine. (F) wild-type untreated with DMSO, 
while (G) the strain treated with SB-224289 at 250 μM or (H) 100 μM.  
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Figure A2. 8. Localization of PS E. coli and C.  
albicans  
Fluorescent microscopy of (A) empty vector (B) 
GFP-Lact-C2 in E. coli. Fluorescence exposure = 
3.5 sec and (C) cho1ΔΔ and (D) wild-type C. 
albicans expressing GFP-Lact-C2.  
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cho1ΔΔ. Because this strain produces no PS, this result was attributed to a high 
concentration of GFP-Lact-C2 within the cells that may show localization or 
accumulation as an artifact. 
 For C. glabrata, a strain bearing GFP-Lact-C2 was produced, however, 
efforts to produce a cho1ΔΔ strain were not successful and thus abandoned. 
 Last, for E. coli, we also expressed GFP-Lact-C2 in a common lab strain. 
However, because of the high concentration of the probe within the cells, high 
auto-fluorescence in our empty vector control, as well as poor resolution on 
microscopes available to us, no distinction or localization could be determined 
and this project was discontinued (Fig A2.8A and B). 
 
Discussion 
In this project, we have introduced PS specific probes, GFP-Lact-C2 and 
mCherry-Lact-C2 into wild-type and cho1Δ strains of S. cerevisiae. In both 
instances, we observed probe localization to the membrane in wild-type cells 
where PS is enriched. Alternatively, in cho1Δ strains, we saw diffuse signal as 
PS is not present in these strains. 
After introducing the mCherry-Lact-C2 probe into S. cerevisiae, we 
decided utilize a second probe for another phospholipid, PI4,5P2, as a 
membrane specific probe. We hypothesized that this would allow us to monitor 
the movement of PS through the cell based on a separation of colors in 
overlapped pictures of the two probes under either red or green fluorescence. 
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The localization at the membrane under the green fluorescence demonstrated 
the localization of GFP-PH-Domain bound to the membrane, while the low signal 
under the red fluorescence demonstrates the diffusion of the mCherry-Lact-C2 
probe into the cytoplasm. Upon the introduction of GFP-PH-domain, we found 
inconsistencies in the cells when viewed under red fluorescence. Most of the 
cells that showed clear localization around the membrane under the green 
fluorescence showed low or undetectable signal under the red fluorescence. The 
mCherry-Lact-C2 probe was diffuse in the cho1Δ, because PS is not being 
produced. Although the cells might have shown diffuse red fluorescence as 
predicted, the signal was bleached soon after the fluorescence was switched to 
the red color. This would have presented a challenge in performing time-lapse 
experiments with the two colors, because if the pictures are overlapped and the 
mCherry-Lact-C2 does not fluoresce as brightly as the PH domain-GFP, we 
would not be able to sufficiently observe a separation of colors. As a result, 
although elegant in theory, this project proved insufficient for our purposes. 
 We next focused efforts on controlling PS synthesis in vivo. We utilized 
the PGAL1 promoter which represses PGAL1 in the presence of glucose, 
suppressing the PGAL1-CHO1 gene in our construct. We expected no growth on 
minimal medium as a result of ethanolamine auxotrophy, but found that the strain 
grown in glucose (i.e. PGAL1-CHO1 repressed) was able to grow, though at a 
lesser degree than the strain grown in galactose (i.e. PGAL1-CHO1 expressed). 
This finding was further supported by thin layer chromatography where PS was 
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still present in the repressed strain, though at a lower degree. These findings 
indicated that PGAL1-CHO1 was not fully repressed in our experiments, despite 
what has been previously reported about PGAL1  providing a very tight shut off in 
S. cerevisiae (Longtine, et al. 1998), thus confounding our efforts to control PS 
production.  
 Despite this issue, we still wanted to determine if repressing PGAL1-CHO1 
—albeit incompletely—might have an effect on PS localization intracellularly. We 
transformed the GFP-Lact-C2 probe into the PGAL1 strain, then viewed it under a 
fluorescent microscope. We saw an increase in mislocalization when the strain 
was grown in glucose (i.e. PGAL1-CHO1 repressed), showing more diffuse signal 
than when grown in galactose (i.e. PGAL1-CHO1 expressed). However, some 
frames showed cells with localized GFP-Lact-C2 signal in cho1Δ, while some 
showed more diffuse signal. In addition, there were many cells that showed 
partial localization, indicating that some PS was still being made within the 
population of cells. This inconsistency precluded our ability to fully take 
advantage of these tools for controlling PS production. Thus, due to the 
incomplete shutoff, the cho1Δ::PGAL1-CHO1 strain was deemed insufficient for 
the time-lapse experiments in monitoring the trafficking of PS and its duration at 
the plasma membrane. 
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Lyso PS Experiment 
Because of the issues with cho1Δ::PGAL1-CHO1, we decided to utilize the strains 
produced in this study to determine the effects of specific treatments on probe 
localization. First, we treated cho1Δ carrying pGFP-Lact-C2 with lyso-PS to 
monitor the movement of PS into the cells. Results of these time course 
experiments showed that at 30 minutes, PS localization around the plasma 
membrane could be observed, because the lyso PS was being converted into 
PS, and hence was being transported from the rough ER to the plasma 
membrane. Once at the plasma membrane, the PS remained there until the 180 
minutes, but eventually began to diffuse back into the cytoplasm. Although this 
experiment showed that PS remains at the membrane for at relatively lengthy 
period of time, it is not representative of the biological process whereby PS is 
produced within cells. This experiment depends on the cell taking up extracellular 
lyso-PS from the medium and using it to form PS, instead of producing PS in the 
ER and trafficking it to the membrane. Experiments to assess PS production 
within the cell using fluorescent, click-tagged serine analogs are underway in 
collaborator Michael Best’s laboratory and, if successful, will reflect a more 
accurate view of PS trafficking and dynamics. 
 
Compound Experiments 
Furthermore, we chose to test the effects of membrane-perturbing agents on 
GFP-Lact-C2 localization. In Figure A2.7, cells treated with Pap-A, the PS-
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specific toxin, showed signs of cell death with PS accumulating in the cytoplasm 
in conjunction with loss of cell viability. Cells treated with staurosporine also had 
an expected accumulation of PS in punctuate dots in the cytoplasm, although 
cells remained viable when plated. Cells treated with SB-224289 at both 250 μM 
and 100 μM, showed a similar accumulation of PS in the cytoplasm with no 
concomitant loss of viability. Although the true mechanism of action of SB-
224289 is not currently known, SB-224289 likely causes a disruption in PS 
trafficking by inducing large-scale endocytosis of the plasma membrane. 
 Last, based on the usefulness of the tools developed in this study, we 
wished to translate them into other relevant systems including C. albicans, C. 
glabrata, and E. coli. However, though strains containing GFP-Lact-C2 were 
produced in each of these studies, difficulties were encountered for each, 
prohibiting our ability to utilize these tools in secondary systems. 
 These findings, while not conclusive for our initial experimental goals, 
provide some evidence that PS remains at the membrane for a relatively long 
period (~180 minutes). In addition, although several difficulties were encountered 
in these studies, several strains of excellent quality and importance were 
produced that will be of great use in future studies on PS trafficking and 
membrane dynamics. 
  
250 
 
References 
Achleitner G, Gaigg B, Krasser A et al. Association between the endoplasmic 
reticulum and mitochondria of yeast facilitates interorganelle transport of 
phospholipids through membrane contact. Eur J Biochem 1999;264: 545-
53. 
Andjelic CD, Planelles V, Barrows LR. Characterizing the anti-HIV activity of 
papuamide A. Mar Drugs 2008;6: 528-49. 
Carman GM, Han GS. Regulation of phospholipid synthesis in the yeast 
Saccharomyces cerevisiae. Annu Rev Biochem 2011;80: 859-83. 
Cassilly CD, Farmer AT, Montedonico AE et al. Role of phosphatidylserine 
synthase in shaping the phospholipidome of Candida albicans. FEMS 
Yeast Res 2017;17. 
Cassilly CD, Maddox MM, Cherian PT et al. SB-224289 Antagonizes the 
Antifungal Mechanism of the Marine Depsipeptide Papuamide A. PLoS 
One 2016;11: e0154932. 
Chen YL, Montedonico AE, Kauffman S et al. Phosphatidylserine synthase and 
phosphatidylserine decarboxylase are essential for cell wall integrity and 
virulence in Candida albicans. Mol Microbiol 2010;75: 1112-32. 
Cho KJ, Park JH, Hancock JF. Staurosporine: A new tool for studying 
phosphatidylserine trafficking. Commun Integr Biol 2013;6: e24746. 
Cho KJ, Park JH, Piggott AM et al. Staurosporines disrupt phosphatidylserine 
trafficking and mislocalize Ras proteins. J Biol Chem 2012;287: 43573-84. 
251 
 
Eckert SE, Muhlschlegel FA. Promoter regulation in Candida albicans and 
related species. FEMS Yeast Res 2009;9: 2-15. 
Fairn GD, Hermansson M, Somerharju P et al. Phosphatidylserine is polarized 
and required for proper Cdc42 localization and for development of cell 
polarity. Nat Cell Biol 2011a;13: 1424-30. 
Fairn GD, Schieber NL, Ariotti N et al. High-resolution mapping reveals 
topologically distinct cellular pools of phosphatidylserine. J Cell Biol 
2011b;194: 257-75. 
Gietz RD, Woods RA. Transformation of yeast by lithium acetate/single-stranded 
carrier DNA/polyethylene glycol method. Methods Enzymol 2002;350: 87-
96. 
Hanson BA, Lester RL. The extraction of inositol-containing phospholipids and 
phosphatidylcholine from Saccharomyces cerevisiae and Neurospora 
crassa. J Lipid Res 1980;21: 309-15. 
Kuchler K, Daum G, Paltauf F. Subcellular and submitochondrial localization of 
phospholipid-synthesizing enzymes in Saccharomyces cerevisiae. J 
Bacteriol 1986;165: 901-10. 
Lagace TA, Ridgway ND. The role of phospholipids in the biological activity and 
structure of the endoplasmic reticulum. Biochim Biophys Acta 2013;1833: 
2499-510. 
Lemmon MA. Pleckstrin homology (PH) domains and phosphoinositides. 
Biochem Soc Symp 2007: 81-93. 
252 
 
Levin DE. Cell wall integrity signaling in Saccharomyces cerevisiae. Microbiol 
Mol Biol Rev 2005;69: 262-91. 
Longtine MS, McKenzie A, 3rd, Demarini DJ et al. Additional modules for 
versatile and economical PCR-based gene deletion and modification in 
Saccharomyces cerevisiae. Yeast 1998;14: 953-61. 
Maeda K, Anand K, Chiapparino A et al. Interactome map uncovers 
phosphatidylserine transport by oxysterol-binding proteins. Nature 
2013;501: 257-61. 
Mioka T, Fujimura-Kamada K, Tanaka K. Asymmetric distribution of 
phosphatidylserine is generated in the absence of phospholipid flippases 
in Saccharomyces cerevisiae. Microbiologyopen 2014;3: 803-21. 
Moser von Filseck J, Copic A, Delfosse V et al. INTRACELLULAR TRANSPORT. 
Phosphatidylserine transport by ORP/Osh proteins is driven by 
phosphatidylinositol 4-phosphate. Science 2015;349: 432-6. 
Natarajan P, Wang J, Hua Z et al. Drs2p-coupled aminophospholipid translocase 
activity in yeast Golgi membranes and relationship to in vivo function. Proc 
Natl Acad Sci U S A 2004;101: 10614-9. 
Nishimura K, Fukagawa T, Takisawa H et al. An auxin-based degron system for 
the rapid depletion of proteins in nonplant cells. Nat Methods 2009;6: 917-
22. 
Osman C, Voelker DR, Langer T. Making heads or tails of phospholipids in 
mitochondria. J Cell Biol 2011;192: 7-16. 
253 
 
Pichler H, Gaigg B, Hrastnik C et al. A subfraction of the yeast endoplasmic 
reticulum associates with the plasma membrane and has a high capacity 
to synthesize lipids. Eur J Biochem 2001;268: 2351-61. 
Pomorski T, Lombardi R, Riezman H et al. Drs2p-related P-type ATPases Dnf1p 
and Dnf2p are required for phospholipid translocation across the yeast 
plasma membrane and serve a role in endocytosis. Mol Biol Cell 2003;14: 
1240-54. 
Selkirk JV, Scott C, Ho M et al. SB-224289--a novel selective (human) 5-HT1B 
receptor antagonist with negative intrinsic activity. Br J Pharmacol 
1998;125: 202-8. 
Sleight RG, Pagano RE. Rapid appearance of newly synthesized 
phosphatidylethanolamine at the plasma membrane. J Biol Chem 
1983;258: 9050-8. 
Tamura Y, Onguka O, Itoh K et al. Phosphatidylethanolamine biosynthesis in 
mitochondria: phosphatidylserine (PS) trafficking is independent of a PS 
decarboxylase and intermembrane space proteins UPS1P and UPS2P. J 
Biol Chem 2012;287: 43961-71. 
Vale-Silva LA, Moeckli B, Torelli R et al. Upregulation of the Adhesin Gene EPA1 
Mediated by PDR1 in Candida glabrata Leads to Enhanced Host 
Colonization. mSphere 2016;1. 
Voelker DR. New perspectives on the regulation of intermembrane 
glycerophospholipid traffic. J Lipid Res 2003;44: 441-9. 
254 
 
Yeung T, Gilbert GE, Shi J et al. Membrane phosphatidylserine regulates surface 
charge and protein localization. Science 2008;319: 210-3. 
 
  
255 
 
APPENDIX III 
EXTRACT FROM SAMANEA SAMAN LEAF EXTRACT INHIBITS 
THE TOXICITY OF MARINE DEPSIPEPTIDE PAPUAMIDE A 
  
256 
 
Contributing authors to this work include: Chelsi D. Cassilly,1 John J. Bowling,2  
Marcus M. Maddox,2 Rebecca E. Fong,1 Sabrina V. Williamson,1 Richard E. 
Lee,2 Todd B. Reynolds1 
1. Department of Microbiology, University of Tennessee, Knoxville, TN, USA 
2.  Department of Chemical Biology and Therapeutics, St. Jude Children’s 
Research Hospital, Memphis, TN, USA 
 
This article has not been published elsewhere at this time, nor will it be before 
completion of this ETD. The author contributions are as follows: Conceived and 
designed the experiments: CDC JJB MMM REL TBR. Performed the 
experiments: CDC JBJ MMM REF SVW TBR. Analyzed the data: CDC JJB 
MMM REL TBR. Contributed reagents/materials/analysis tools: TBR JJB REL. 
Wrote the paper: CDC JJB 
 
Introduction 
As reported previously (Cassilly, et al. 2016), a high-throughput screening 
approach has been developed to identify compounds that affect the PS-
accessibility of a PS-binding toxin called Papuamide-A (Pap-A). Pap-A is isolated 
from sea sponges (Theonella spp.) and is known to lyse membranes containing 
PS (Andjelic, et al. 2008, Parsons, et al. 2006, Uzair, et al. 2011). Thus, Pap-A is 
toxic to wild-type C. albicans, but is non-toxic to a Cho1p mutant (cho1∆∆) 
(Cassilly, et al. 2016). Our screening approach utilized Pap-A as a filter which 
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would sort compounds by their ability to protect wild-type C. albicans from a toxic 
dose of Pap-A. We hypothesized that compounds which inhibit PS synthesis or 
PS availability at the plasma membrane, would render Pap-A unable to bind and 
lyse the membranes of those cells, allowing survival of the organism in the 
presence of Pap-A. Compounds that cause this trait would then be possible hits 
for antifungal drug development. 
 It is a well known phenomenon that plants have natural antifungal 
defenses (Cho, et al. 2013a). We thought it likely that some plants could produce 
compounds which might inhibit the fungal Cho1p or affect PS distribution. We 
screened 23,585 plant extract fractions (Natural Products Library from the 
University of Mississippi) for their ability to abrogate the toxic effects of Pap-A 
and identified one plant extract from the Rain Tree that we further characterized. 
The fractions of this extract did not show signs of inhibiting Cho1p, however, we 
identified that this extract has potent ability to inhibit the toxic effects of Pap-A. 
 
Materials and Methods 
Strains Used 
All strains used in this study can be found in (Chen, et al. 2010). The wild-type 
strain from which all mutants were made is SC5314 (Gillum, et al. 1984). This 
study included both cho1∆∆ (YLC337) and cho1∆∆::CHO1 (YLC344) (Chen, et 
al. 2010).  YPD (1% Bacto yeast extract, 2% Bacto peptone, and 2% dextrose 
(Thermo Fisher Scientific, San Jose, CA)) and minimal medium (0.67% Bacto-
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yeast nitrogen base (without amino acids) 2% dextrose) were used to culture all 
strains as indicated (Guthrie 2002) . 
 
Papuamide A resistance assay 
This assay was performed as previously described in (Cassilly, et al. 2016) in a 
96-well plate format. Cultures were grown overnight, shaking, at 30°C and diluted 
to 2 x 104 cells/ml in YPD. Plant extract fractions were diluted to twice the desired 
μg/ml concentration in a volume of 37.5 μl of YPD. Then 37.5 μl of the previously 
diluted cell suspension was added, diluting the final concentration of both cells 
and plant extract by half. Plates were incubated at 37°C for 6 hours, then 75 μl of 
YPD containing depsipeptide (Pap-A at 8 μg/ml) was added to each well, again 
diluting this concentration by half. Plates were incubated overnight at 37°C. 
 The next day Alamar Blue (Invitrogen, Waltham, MA) was added at a 
1:10 dilution and plates were incubated at 37°C for 30 minutes to 2 hours until 
color change was visible.  Fluorescence was then read at excitation 550 nm and 
emission 590 nm on a Cytation3 BioTek plate reader using Gen 5 software. 
 
High throughput screen for Pap-A resistance 
23,585 compounds from the Natural Products Library from the University of 
Mississippi were screened in a total of 93 384-well plates (Nunc). Using a 
BioMek robot with pin tools, 0.173 μl of plant extract fractions at varying 
concentrations were inoculated into 10 μl of YPD in each well (excluding columns 
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1, 2, and 13) from stock plates. Wild-type and cho1∆∆ (positive control strain) 
were grown in liquid YPD in a 30°C shaker overnight and diluted to 104 cells/ml in 
YPD. 10 μl of wild-type were added to each well of the 384 well plates containing 
the test compound using a Wellmate, except column 2 where 10 μl of cho1∆∆ 
was added. Plates were incubated for 6 hours at 37°C, and then 10 μl of YPD 
containing 21 μg/ml Pap-A was added to give a final concentration of 7 μg/ml in 
30 μl of YPD. Plates were then incubated for another 16 hours at 37°C to allow 
selection for Pap-A resistance.  The next day, cell survival was measured by 
adding 10 μl of Alamar Blue (Invitrogen, Waltham, MA) at a 1:3 dilution using a 
Wellmate.  Plates were allowed to incubate again at 37°C for 1 hour.  Plates 
were sealed, then fluorescence was then read at excitation 550 nm and emission 
590 nm on an EnVision plate reader (Perkin Elmer, Waltham, MA).  In each 
plate, three of the columns of wells were used as controls. Column one contained 
50 μM SB-224289 as a positive control (Cassilly, et al. 2016). Column two 
contained cho1ΔΔ plus Pap-A, as a second positive control. Column 13 was a 
negative control containing wild-type cells with no compounds in the presence of 
Pap-A. 
 
Phosphatidylserine Synthase Assay 
This procedure was amended from (Bae-Lee and Carman 1984, Matsuo, et al. 
2007) as described previously in (Cassilly, et al. 2017, Cassilly, et al. 2016). 
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Fractions of S. saman plant extract were added to the reaction mixture at varying 
concentrations to test their ability to inhibit [3H]-PS production. 
 
Ethanolamine Auxotrophy Assay 
Wild-type and cho1∆∆ cultures were grown in YPD overnight shaking at 30°C. 
The next day, cultures were washed with water and diluted to 2x104 cells/ml in 
minimal medium containing 50 mM HEPES buffer. 50 μl of cell suspensions were 
added to wells of a 96-well plate (Costar). Plant extract fractions were diluted into 
minimal medium containing 50 mM HEPES buffer either with or without 1 mM 
ethanolamine (one plate contained ethanolamine, the second did not), and 50 μl 
were added to the wells, diluting the concentration to a final of 25 μg/ml. Wild-
type with no fraction added served as the negative control and cho1∆∆ served as 
the positive control. Plates were incubated at 37°C overnight. The next day, 
Alamar Blue (Invitrogen) was added at a 1:10 dilution and plates were incubated 
for another 2 hours. Following this incubation, fluorescence was read at 
excitation 550 nm and emission 590 nm on a Cytation3 BioTek plate reader 
using Gen 5 software. 
 
β 1,3-glucan Unmasking Microscopy 
β 1,3-glucan unmasking immunofluorescence experiments were performed as 
described in (Davis, et al. 2014a). Wild-type and cho1∆∆ cultures were grown in 
YPD overnight shaking at 30°C. The following day the cells were diluted to an 
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OD600 of 0.1 and Fraction 2-1 or DMSO for a negative control was added to a 
100 μg/ml concentration. This was incubated at 30°C shaking for 1 hour and then 
cells were washed with 1X PBS. Cells were then pelleted and washed in 3% BSA 
rocking for 1 hour at room temperature. Cells were pelleted and then incubated 
with 1:800 anti-(1-3)-glucan antibody (Biosupplies Australia) and incubated on ice 
for 1.5 hours. Afterwards, cells were washed with 1X PBS at least 3 times before 
1:600 goat anti-mouse antibody conjugated to Cy3 (Jackson ImmunoResearch) 
was added in 5% BSA. This was allowed to incubate for 20 minutes on ice before 
washing again with 1X PBS at least 3 times. Cells were resuspended in 1X PBS, 
added to a slide, and imaged on a fluorescent microscope at an exposure of 1 
ms. 
 
GFP-Lact-C2 Microscopy 
Wild-type and cho1∆∆ strains expressing GFP-Lact-C2 were grown in YPD 
overnight shaking at 30°C. The next day, cultures were diluted to 0.2 OD600 in 
YPD and allowed to grow shaking at 30°C for another 3 hours. Following this 
incubation, cultures were diluted again to 0.1 OD600 in 1X PBS and 100 μg/ml 
concentration of plant extract fraction 2-1 or DMSO negative control and 
incubated again shaking at 30°C for 1 hour. Cells were then pelleted, 
resuspended in a small volume of PBS, placed on a glass slide, and imaged via 
fluorescent microscopy. 
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Solid Phase Extraction 
C18 Reverse Phase SPE was peformed to remove tannins and polyphenols, and 
separate the extract into three fractions. First the fraction was applied to the C18 
column and deionized water was passed through to create the first fraction. 
Second 50% methanol was passed through to produce a second fraction. And 
last 100% methanol was passed through the column to create the third fraction. 
 
Statistical analysis 
Graphs were made using GraphPad Prism version 6.04.  Unpaired t-tests were 
used to determine significance between results. RISE (Robust Investigation of 
Screening Experiments) software was used to analyze data from the high 
throughput screen and was used to calculate Z’-scores, identify 95th and 99th 
quantile data, and identify compounds that yielded hits of greater than 90% of 
positive control (cho1∆∆).  
 
Results 
We screened 23,585 plant extract fractions (Natural Products Library from the 
University of Mississippi) for their ability to abrogate the toxic effects of Pap-A 
(Fig. A3.1) (Tu, et al. 2010). From this screen, we identified 79 initial hits, which 
is a 0.3% hit rate with hits considered as fractions that allow greater that 60% of 
the growth of the positive control (cho1∆∆). We then performed a dose-response 
assay to determine both the effective concentration range of the compounds, as  
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Figure A3. 1. Natural Products Library Screened Against Papuamide-A 
23,585 natural product fractions were screened for their ability to protect wild-
type C. albicans (open black circles) against 7 μg/ml Pap-A.  Fluorescence was 
measured as a proxy of growth using Alamar Blue over approximately 1 hour at 
37˚C.  The untreated cho1∆∆ positive control’s growth in the presence of Pap-A 
is represented by green circles. Natural product fractions that allowed wild-type 
cells to display >60% (above the blue line) of the growth of cho1∆∆ control are 
shown in blue circles. Around 95% of the tested natural products allowed growth 
at levels closer to the negative control wells, which contained untreated wild-type 
cells with Pap-A (open red circles).  Horizontal lines indicate the 99th quantile 
(purple) where 99% of the natural product fractions fell, and the 95th quantile 
(yellow) where 95% of the natural product fractions lie.  Vertical lines divide the 
natural product fractions based on the 384-well plate in which they were 
screened which correlate to plate numbers along the bottom.  A full description of 
the screening method can be found in the Materials and Methods.  
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well as the reproducible hits (data not shown). From this dose-response, we 
identified two compounds that reproducibly conferred Pap-A resistance to wild-
type C. albicans, one from the bark extract of the white oak tree Quercus alba 
and the second from leaf extract of the rain tree Samanea saman. The Q. alba 
extract fraction showed an average of 42.3% survival (when compared to 
cho1∆∆) in the presence of Pap-A at a concentration of 18.03 μg/ml (Table A3.1). 
The S. saman extract fraction showed an average of 102% survival (when 
compared to cho1∆∆) in the presence of Pap-A at a concentration of 41.55 μg/ml 
(Table A3.1). 
 There have been several papers published that characterized the white 
oak tree (Keller, et al. 2004, Walters, et al. 2001), whereas the rain tree is an 
understudied plant (Staples 2006). This, in addition to the fact that the rain tree 
extract showed higher levels of protection against Pap-A (Table A3.1), directed 
us to focus our studies on the rain tree extract. As plant extracts are complex 
mixtures of many compounds (Tu, et al. 2010), our goal was to identify which 
compound(s) within this mixture were responsible for the marked Pap-A 
protection. 
Fractionation of S. saman Crude Leaf Extract 
 We obtained crude S. saman leaf extract from the University of Mississippi 
and performed C18 Reverse Phase SPE: hydrophobic separation to remove 
tannins and polyphenols, and separate the extract into three fractions. The first 
fraction (F1) was all compounds dissolved in deionized water, the second (F2) in  
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Table A3. 1. Two Natural Products Show Reproducible Resistance to Pap-A 
Plate Well 
Final Conc 
(ug/ml) % Growth Source 
80004 A18 41.55 111 Samanea|saman|Fabaceae|LeaF|135  
80005 A18 41.55 102 Samanea|saman|Fabaceae|LeaF|135  
80006 A18 41.55 96 Samanea|saman|Fabaceae|LeaF|135  
80004 B09 18.03 32 Quercus|alba|Fagaceae|BarK|139.7  
80005 B09 18.03 83 Quercus|alba|Fagaceae|BarK|139.7  
80006 B09 18.03 12 Quercus|alba|Fagaceae|BarK|139.7  
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Figure A3. 2. Fraction F2 Retains the Highest Concentration of the 
Bioactive Component  
Cells were treated with three fractions of S. saman plant extract for 6 hours and 
then treated with a lethal dose (4 μg/ml) of Pap-A. Protection is seen in all 
fractions at the highest concentration (50 μg/ml). However, as the concentration 
of the extract decreases to 3.125 μg/ml, the only fraction still able to protect wild-
type cells from Pap-A is F2, indicating that the bioactive concentrates to this 
fraction. 
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50% methanol, and the third (F3) was 100% methanol. With these three 
fractions, we performed our Pap-A assay again to determine which fraction 
retained the Pap-A protective activity. This assay revealed that, while all of the 
fractions seem to show some Pap-A protection at high concentrations (50 μg/ml) 
Fraction F2 retained the Pap-A protective activity even at the lowest 
concentrations tested (Fig. A3.2). 
 Our next step was to further fractionate F2 via high-performance liquid 
chromatography (HPLC). For this experiment we used a C18 reverse phase 
column to separate the fraction based on hydrophobicity. This separated F2 into 
seven different portions (F2-1 through F2-7). These seven fractions were then 
again tested for their ability to provide Pap-A resistance in order to allow us to 
narrow the activity to one. Figure A3.3 shows that at the highest concentrations 
of the fractions tested, we see Pap-A protection in all but F2-6 and F2-7. 
However, as the concentration was decreased to 6.25 μg/ml, the Pap-A 
protection activity dropped off to include only F2-1. This indicates that the 
particular compound of interest was present in most fractions in residual 
amounts, but seemed to be most concentrated in F2-1. 
 
S. saman Leaf Extract Fractions Do Not Inhibit Cho1p 
We were interested in determining if any of the fractions generated could inhibit 
Cho1p in an in vitro PS synthase assay (Bae-Lee and Carman 1984, Cassilly, et 
al. 2016, Matsuo, et al. 2007). We performed this assay first with the original  
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Figure A3. 3. Fraction F2-2 Retains the Highest Concentration of the 
Bioactive Component 
Cells were treated with all fractions of S. saman plant extract fraction F2 for 6 
hours and then treated with a lethal dose (4 μg/ml) of Pap-A. Protection is seen 
in all fractions of F2 aside from F2-6 and F2-7 at the highest concentration (400 
μg/ml). However, as the concentration of the extract decreases to 6.25 μg/ml, the 
only fraction still able to protect wild-type cells from Pap-A is F2-1, indicating that 
the bioactive concentrates to this fraction. 
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Figure A3. 4. No S. saman Fractions Inhibit the PS Synthase  
(A) An in vitro PS synthase assay was performed with 100 μg/ml concentrations 
of each plant extract fraction. Activity is represented as counts per minute per 
milligram of protein, quantifying the incorporation of 3H-l-serine incorporated into 
PS. No inhibitory activity is seen when compared with the DMSO negative control 
and the cho1ΔΔ positive control. (B) Ethanolamine auxotrophy tests were 
performed to assess the ability of the plant extract fraction to inhibit Cho1p in 
vivo. Cells were treated with 25 μg/ml concentration of the plant extracts and 
then grown in minimal medium either without or with 1 mM ethanolamine. None 
of the fractions produce ethanolamine auxotrophy in the wildtype when compared 
with the cho1 ΔΔ positive control.  
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 three fractions provided by SPE (F1 and F3) and the seven fractions of F2 at a 
100 μg/ml concentration of each extract fraction, well over the effective 
concentrations shown in our assays. We found that no fraction showed a 
statistically significant decrease in PS synthase activity when compared with a 
non-treated control (Fig. A3.4A). Additionally, we wished to determine if the 
fractions would inhibit Cho1p in vivo. To do this, we used a common trait shown 
by the cho1∆∆ mutant, ethanolamine auxotrophy. Because PS is a precursor for 
the biosynthesis of phosphatidylethanolamine (PE), a vital phospholipid, when 
Cho1p is deleted—or as we suspect, inhibited—the organism will become an 
ethanolamine auxotroph and can only grow if the medium is supplemented with 
exogenous ethanolamine (Chen, et al. 2010). As a result, we used this trait to 
test whether any of the S. saman fractions caused wild-type C. albicans to 
become an ethanolamine auxotroph. We expected to see no growth in minimal 
medium containing no ethanolamine if the fractions inhibited Cho1p, and a return 
of growth in medium containing ethanolamine (indicating that the organism can 
uptake the ethanolamine and circumvent the need for PS to make PE). As in our 
in vitro assay, we found that no S. saman fractions caused the wild-type 
organism to become an ethanolamine auxotroph (Fig. A3.4B). 
 Last, we wish to determine if Fraction F2-1 produced a disruption in the 
cell wall organization, or PS localization, both of which might indicate a disruption 
in PS production or localization (Davis, et al. 2014a). Wild-type cells were treated 
with Fraction F2-1 at a 100 μg/ml concentration and tested for increased β (1,3)- 
271 
 
 
 
 
Figure A3. 5. S. saman Fraction 2-1 Does Not Cause B-1,3 
Glucan Exposure or Disruption of PS Localization 
(A) Microscopy was performed by treating wild-type and cho1 ΔΔ 
cells with DMSO or 100 μg/ml of Fraction F2-1. Cells were then 
washed and incubated with primary antibody for B-1,3, glucan. 
Then treated with secondary antibody Cy3 for imaging as an 
indication of disrupted cell wall structure. (B) Wild-type and cho1 
ΔΔ cells expressing the GFP-Lact-C2 probe were treated with 
DMSO or 100 μg/ml of Fraction F2-1 then assessed via 
microscopy for mislocalization of the probe, indicating PS 
mislocalization. 
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glucan unmasking and GFP-Lact-C2 mislocalization as compared to a cho1ΔΔ 
positive control. Under no circumstances did we see increased β (1,3)-glucan 
unmasking or a changed in the localization of GFP-Lact-C2, indicating that 
Fraction F2-1 does not inhibit PS production or cause a change in cell wall 
organization as we originally hypothesized (Fig. A3.5). These results were 
unexpected based on the reproducible Pap-A protection that Fraction F2-1 
provides to wild-type C. albicans. We expect that it is likely that Pap-A and 
molecules within Fraction F2-1 are interacting, causing Pap-A to be ineffective as 
a toxin against C. albicans. As we previously published for the compound SB-
224289, a serotonin receptor antagonist that showed similar activity to Fraction 
F2-1, this could be potentially useful for applications where toxins, like Pap-A, 
need to be neutralized, but work should be continued to confirm these 
predictions. 
 Despite the unexpected results, we decided to continue in the fractionation 
of this extract in order to characterize some of the molecules that are found 
within the rain tree leaf. HPLC was performed by collaborators at St. Jude, 
however, HPLC fractionation failed to identify a discrete component responsible 
for the observed activity. 
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APPENDIX IV 
CANDIDA ALBICANS PHOSPHATIDYLSERINE SYNTHASE 
PURIFICATION FOR CRYSTALLIZATION 
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Introduction 
We were interested in using the data obtained in Chapter 4 to inform our search 
for PS synthase inhibitors. We utilized the protein model produced using 
Molecular Operating Environment (MOE) software (Fig. 4.6), to perform a 
computational drug screen. The screen was performed using MOE, docking 
compounds within the proposed active site. From this screen of 500 National 
Cancer Institute diversity drug subset (https://cactus.nci.nih.gov/ncidb2.2/) 
defining a hit based on the highest (or more negative) free energy. Following this 
screen, we identified 57 possible PS synthase inhibitors. However, unfortunately 
because of the loose specificity of the screen, this high number of hits was 
unable to be screened via our complex and time-consuming PS synthase 
secondary screen. 
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 The work in this appendix aimed to determine the structure of the 
phosphatidylserine (PS) synthase enzyme within Candida albicans. As described 
in the Introduction, there is a dire need for new antifungals as a result of rising 
cases of fungal infections over the last several decades. This is mostly because 
of the increasing number of people living in an immunocompromised state 
(Mishra, et al. 2007) due to anti-cancer chemotherapeutics, diabetes, and HIV. 
Nearly all the antifungal drugs used to treat life-threatening Candida infections 
target a component of plasma membrane or lipid biosynthesis. The PS synthase, 
Cho1p, plays an important role in this crucial process in C. albicans and 
represents a novel target. 
 Thus, we aimed to determine the 3-dimensional structure of this protein 
via protein crystallography methodology. This work is one of the first key steps 
towards rational drug design to inhibit Cho1p, as well as provide greater 
understanding of enzymes involved in phospholipid biosynthesis. 
 
Methods and Materials 
Strains 
Genomic DNA was isolated from wildtype C. albicans SC5314 and wildtype S. 
cerevisiae Σ (TRY181). Strains were grown using YPD media. 
 For expression studies, S. cerevisiae strain BJS21 was used (Becker Lab) 
or for a vector control, BJ2164. These strains were grown in either YPD or Media 
Lacking Tryptophan (MLT) for transformation selection. 
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MOE Docking Computational Screen 
The homology model from Chapter 4 was used in MOE. First the NCI Diversity 
subset of 500 compounds (https://cactus.nci.nih.gov/ncidb2.2/) was downloaded 
into MOE. Compounds were docked systematically based on entropy (rigidity in 
binding) and enthalpy (ability to make H-bonds). The parameters “S” and 
“LONDON” were used within MOE to assess free energy. Those compounds with 
the most negative free energy were selected as hits. This work was done with the 
assistance of the Baudry Lab on computer “Napoleon.” More information about 
computational screens and compound docking can be found (Baudry, et al. 
2003) and on the MOE tutorials (https://www.chemcomp.com/MOE-
Molecular_Operating_Environment.htm). 
. 
Genetics 
 In order to tag CaCHO1 and ScCHO1, we utilized the plasmid pBEC2 (7.8 
Kb) which contained STE2 gene with a 3X FLAG and 6x His tag after a PGDP1 
which is a high expressing promoter. This plasmid also contained TRP1 for use 
in strains with tryptophan auxotrophy. This plasmid was digested with AatII and 
HpaII to release a 400 bp fragment of STE2. The plasmid was then CIP treated 
for 3 hr to remove phosphates at the end of the fragment. The fragment was then 
gel extracted (Qiagen) to purify the digested plasmid from the STE2 fragment. 
 Next, using primer CCO74 which has 30 bp homology with PGDP1 and 20 
bp homology with CaCHO1 beginning, and CCO75 which has 30 bp homology 
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with the 3X FLAG tag and 20 bp homology with CaCHO1 end, we amplified 
CaCHO1 which was approximately 800 bp in size. This fragment and the purified 
plasmid (~7.5 Kb) were ligated in vivo when transformed together into S. 
cerevisiae strain BJS21 using the LiOAc transformation procedure described in 
(Gietz and Woods 2002). Transformants were selected on media lacking 
tryptophan (MLT) for strains capable of growing in the absence of tryptophan. 
 Plasmids were then isolated from 6 transformants using the ZYMO yeast 
plasmid extraction kit according to the manufacturer’s protocol. Isolated plasmids 
were then transformed into DH5-α E. coli using ampicillin selection. Following 
transformation, the plasmids were miniprepped (Qiagen) and then sequenced 
using F1424GDP (Becker Lab) primer with homology to pBEC2. The resulting 
plasmid was called pCDC13. 
 In order to address the CTG-codon issue between S. cerevisiae and C. 
albicans, site-directed mutagenesis primers were produced, CCO78 and CCO79. 
SDM was performed as described in Chapter 4 to make the mutation L246S. 
Because CCO78 and CCO79 were not successful (there were repeats 
introduced because the sequences contained a highly repetitive sequence in the 
gene) new primers were made, CCO84 and CCO87. Further, a spurious 
mutation was identified as T162. Because of the sensitivity of the project and the 
importance of each amino acid, primers CCO113 and CCO114 were ordered to 
correct the spurious mutation to T162A (correct sequence matches to CHO1 
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allele A in the Candida Genome Database). The resulting plasmid, pCDC16, was 
transformed into BJS21 to produce CDCS43.  
 For tagging ScCHO1, we performed a PCR to amplify ScCHO1using 
primer CCO85 and CCO86 with the result of an 800 bp PCR product. In vivo 
ligation of this PCR product and the cut plasmid pBEC2 (from above) was 
performed in BJS21 using tryptophan auxotrophy. 6 transformants were selected 
and plasmids were isolated, transformed into E. coli, miniprepped, and then 
sequenced using F1424GDP (Becker Lab) primer. Mutations (particularly 
premature stop codons) were present and thus a new reverse primer was 
created, CCO98, and used. This new primer produced correct plasmids, although 
the selected plasmid contained a spurious mutation, L236. Because of the 
sensitivity of the project and the importance of each amino acid, primers CCO115 
and CCO116 were ordered to correct the spurious mutation to L236F. Once 
successful, the plasmid became known as pCDC20 and the strain CDCS47. 
 Site directed mutagenesis of all spurious mutations and hypothesized 
phosphorylation sites was performed as described in Chapter 4. To produce the 
S46AS47A mutation in ScCHO1, we produced primers CCO124 and CCO125. 
For the S46DS47D in ScCHO1, we produced primers CCO126 and CCO127. For 
the S43AS44A mutation in CaCHO1, we produced primers CCO132 and 
CCO133. Last, for the S43DS44D mutation in CaCHO1, we produced primers 
CCO134 and CCO135. One plasmid was produced, pCDC26, containing 
ScCHO1S46S47D-FLAGx3-Hisx6. 
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 Last, a vector control strain was made containing the empty vector, 
p424GDP which contained Ampicillin resistance and TRP1. p424GDP was 
transformed into BJS21 to produce CDCS40. For primer, plasmid, and strain 
lists, see Tables A4.1, A4.2, and A4.3, respectively. 
 
Western Blots 
Protein was isolated from CDCS43 as described in Chapter 4 and a western blot 
was performed using BJS21 as a positive control and wildtype C. albicans as a 
negative control. For detection, a rat anti-FLAG primary antibody (637301 
BioLegend) was used, followed by a goat anti-rat secondary antibody (926-68076 
LI-COR). The western blot showed adequate expression of CaCho1p-Flagx3-
Hisx6 and ScCho1p-Flagx3-Hisx6. 
 
Phosphatase Treatment 
Protein samples were treated with phosphatase as follows. 40 μg of protein was 
treated with 1 μl. of λ-phosphatase, 3 μl. of phosphatase buffer, 3 μl. of Mn buffer 
in a total volume of 30 μl. Samples were incubated at 30 C for 1 hour. Following 
incubation, 1 μl of Laemmli Dye was added to each tube and the entire reaction 
was boiled and loaded on an SDS PAGE. The western blot was then performed 
as described above and in Chapter 4. 
  
282 
 
Table A4. 1. Primers Used in this Study 
Primer  Sequence  Source  
CCO74 
gtcttttttttagttttaaaacaccaagaacttagtttcgaCGGATCTAGAACAT
GTCAGACTCATCAGCT 
This 
study 
CDC75 
GCTGCTGCCGCTGCCGCGCGGCACACCGGTCTTGTCAT
CGTCGTCCTTGTAGTCTGGTTTAGGAATTTTTAAAGAT 
This 
study 
F1424GDP GTATATAAAGACGGTAGGTATTG 
Becker 
Lab 
CCO78 GGAATAGTTTTCCAAGATACTTCATTTGAATTCCATTTGG 
This 
study 
CCO79 CCAAATGGAATTCAAATGAAGTATCTTGGAAAACTATTCC 
This 
study  
CCO84  
GACAACTTACCATTTGGAATAGTTTTCCAAGATACTTCAT
TTGAATTCCATTTGGTCACAATAG 
This 
study  
CCO87 
CTATTGTGACCAAATGGAATTCAAATGAAGTATCTTGGAA
AACTATTCCAAATGGTAAGTTGTC 
This 
study  
CCO115  GTGTCAGAAAGGGTTTCATTtTTGATAACATCCCATTCGG 
This 
study 
CCO116 
CCGAATGGGATGTTATCAAaAATGAAACCCTTTCTGACA
C 
This 
study  
CCO85 
gtcttttttttagttttaaaacaccaagaacttagtttcgaCGGATCTAGAACAT
GGTTGAATCAGATGAA 
This 
study 
CCO86 
GCTGCTGCCGCTGCCGCGCGGCACACCGGTCTTGTCAT
CGTCGTCCTTGTAGTCGAGCTTGAAAATTCCAAAGCCA 
This 
study  
CCO98 
GCTGCTGCCGCTGCCGCGCGGCACACCGGTCTTGTCAT
CGTCGTCCTTGTAGTCTGGCTTTGGAATTTTCAAG 
This 
study  
CCO113 GGGTATCTCCAGCAACAATTgCCTTTGCTATTGGATTCAG 
This 
study  
CCO114 
CTGAATCCAATAGCAAAGGCAATTGTTGCTGGAGATACC
C 
This 
study  
CCO124 
GAAGTTGGTGGCACATTAAGCAGAAGAGCCgCAgcTATA
TTTTCTATAAATACAACTCCATTGG 
This 
study 
CCO125 
CCAATGGAGTTGTATTTATAGAAAATATAGCTGCGGCTC
TTCTGCTTAATGTGCCACCAACTTC 
This 
study 
CCO126 
GAAGTTGGTGGCACATTAAGCAGAAGAGCCgatgaTATAT
TTTCTATAAATACAACTCCATTGG 
This 
study 
CCO127 
CCAATGGAGTTGTATTTATAGAAAATATATCATCGGCTCT
TCTGCTTAATGTGCCACCAACTTC 
This 
study 
CCO132 
GCCAACCCACCTTTATTGAGAAGATCAgCTgCATTATTCT
CCTTATCCTCGAAAGATGACTTG 
This 
study 
CCO133 
CAAGTCATCTTTCGAGGATAAGGAGAATAATGCAGCTGA
TCTTCTCAATAAAGGTGGGTTGGC 
This 
study 
CCO134 
GCCAACCCACCTTTATTGAGAAGATCAgaTgatTTATTCTC
CTTATCCTCGAAAGATGACTTG 
This 
study 
CCO135 
CAAGTCATCTTTCGAGGATAAGGAGAATAAATCATCTGA
TCTTCTCAATAAAGGTGGGTTGGC 
This 
study 
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Table A4. 2. Plasmids Used in this Study 
Plasmid  Inserts  Source  
pBEC2 
Ste2p-FLAGx3-Hisx6, TRP1, Cen/Ars, 
Amp Becker Lab 
p424GDP Amp, TRP1 Becker Lab 
pCDC13 
CaCHO1-FLAGx3-Hisx6, TRP1, Cen/Ars, 
Amp This study 
pCDC16 
CHO1L246S-FLAGx3-Hisx6, TRP1, 
Cen/Ars, Amp This study 
pCDC20 
ScCHO1-FLAGx3-Hisx6, TRP1, Cen/Ars, 
Amp This study 
pCDC26 
ScCHO1S46S47D-FLAGx3-Hisx6, TRP1, 
Cen/Ars, Amp This study 
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Table A4. 3. Strains Used or Produced in this Study 
Strain  Organism  Genotype  Source  
Σ (TRY 181)  S. cerevisiae  ura3Δ his3Δ  Lab Strain  
SC5314 
(Ca157) C. albicans   Lab Strain  
Ca159 C. albicans cho1ΔΔ 
Chen et al., 
2010 
BJ2168 S. cerevisiae 
 MATa, prc1-407 prb1-1122 
pep4-3 leu2 trp1 ura3-52 Becker Lab 
BJS21  S. cerevisiae 
 MATa, prc1-407 prb1-1122 
pep4-3 leu2 trp1 ura3-52 
ste2::KanR Becker Lab 
CDCS40 S. cerevisiae 
 MATa, prc1-407 prb1-1122 
pep4-3 leu2 trp1 ura3-52 
ste2::KanR p424GDP This Study 
CDCS43 S. cerevisiae pCDC16 This Study 
CDCS47 S. cerevisiae pCDC20 This Study 
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Results 
The preliminary steps involved in this project involved generating a “tagged” 
version of Cho1p that can be expressed at high volumes and isolated via affinity 
chromatography for further purification and characterization. 6xHis tags are ideal 
for this because they are easily bound to Nickel columns for high  
quality purification (Monk, et al. 2014). In order to do this, we utilized the plasmid 
pBEC2 which contained STE2 gene with a triple FLAG tag and 6 His tag after a 
PGDP1 which is a high expressing promoter. The resulting plasmid, pCDC16, 
contained CaCHO1-Flagx3-Hisx6 under the PGDP1 promoter. This plasmid was 
transformed into BJS21 S. cerevisiae to produce CDCS43. Expression of 
CaCHO1-Flagx3-Hisx6 was confirmed via western blot (Fig. A4.1). 
 In addition to CaCHO1, we were interested in tagging ScCHO1 as well to 
perform the crystallization of both proteins in tandem. This, we hypothesized, 
would provide us with higher chances of success. Thus, we produced the 
plasmid pCDC20 which contained ScCHO1-Flagx3-Hisx6 under the PGDP1 
promoter. This was transformed into BJs21 to produce the strain CDCS47. 
Following this, protein from CDCS47 was isolated and a western blot was 
performed to confirm expression using the same parameters as for CDCS43 
(Fig. A4.1). 
 Interestingly, we saw the presence of a doublet band around 34 and 36 
KDa in both CaCHO1-Flagx3-Hisx6 and ScCHO1-Flagx3-Hisx6. Previous work 
(as described in Chapter 4) demonstrated that Cho1p in S. cerevisiae is  
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Figure A4. 1. Expression of CaCho1p-Flagx3-Hisx6 and ScCho1p-Flagx3-
Hisx6 
Western blot analysis using an anti-FLAG antibody shows bands for CaCho1p-
Flagx3-Hisx6 and ScCho1p-Flagx3-Hisx6 around ~34 KDa. Ste2p-Flagx3-
Hisx6 is shown as a positive control and either wild-type C. albicans or a 
BJS21 strain carrying a vector control plasmid as negative controls. The ladder 
along the right side shows the band sizes in KDa. 
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phosphorylated by protein kinase C (Choi, et al. 2010, Kinney and Carman 
1988). In order to determine if this was the reason for the doublet band we 
observed, we treated protein samples with λ-phosphatase. Indeed, we saw a 
disappearance of the doublet band in ScCho1p-Flagx3-Hisx6 when treated with 
λ-phosphatase (Fig. A4.2A). Unfortunately, these results were inconsistent for  
CaCho1p-Flagx3-Hisx6 which showed only a slight disappearance of the band 
sometimes and other times protein samples of CaCho1p-Flagx3-Hisx6 untreated 
with λ-phosphatase, but incubated at 30°C for 1 hour showed a loss of the 
doublet band. This variability may indicate that the phosphorylation of CaCho1p-
Flagx3-Hisx6 could be very transient (Fig. A4.2B). 
 Because having a mixed population of phosphorylated and 
unphosphorylated protein could cause serious issues with a crystallization 
procedure, we made an effort to identify possible phosphorylation sites in both 
CaCHO1 and ScCHO1. Based on previous studies in S. cerevisiae (Choi, et al. 
2010), two serine residues were identified as phosphorylation sites, S46 and 
S47. Homologous serine residues were identified in CaCHO1, S43 and S44. 
Thus, we decided to mutate these residues to alanine and aspartic acid. Alanine 
would served to completely abolish the phosphorylation site, while aspartic acid 
would be a mimic of a phosphate group. Although SDM procedures were carried 
out for all primer combinations in pCDC14 and pCDC20 respectively, due to time 
constraint, the project was never completed. 
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Figure A4. 2. Phosphatase Treatment of ScCho1p-Flagx3-Hisx6 and 
CaCho1p-Flagx3-Hisx6 
Protein samples were either 1) treated with λ-phosphatase for 30 minutes at 
30°C, 2) incubated without the enzyme for 30 minutes  at 30°C,  or 3) untreated, 
then analyzed via western blot using an anti-FLAG antibody. (A) ScCho1p-
Flagx3-Hisx6 and (B) CaCho1p-Flagx3-Hisx6. In A) the ~36 KDa band 
disappears, leaving only the dephosphorylated 34 KDa band. In B) there is a 
slight disappearance of the 36KDa band, but it is not as stark as the difference in 
ScCho1p-Flagx3-Hisx6. The ladder along the right side shows the band sizes in 
KDa. 
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